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ABSTRACT 
 
An efficient approach to the hydrobenzofuro[3,2-b]chromenone core of 
sanggenon-type natural products has been developed. The key transformation involves a 
protecting group-free double rearrangement of a bis-allyloxyflavone ether substrate. A 
sequence involving asymmetric 3-allyl rearrangement followed by aromatic Claisen 
rearrangement has been established for the asymmetric synthesis of the 
hydrobenzofuro[3,2-b]chromenone core structure. This methodology has been 
successfully applied to asymmetric syntheses of both sanggenol F and sanggenon A.  
Efficient chiral, racemic syntheses for sanggenons C and O have been achieved. 
The key transformation entails a biomimetic Diels-Alder cycloaddition between a 
flavonoid diene and a 2′-hydroxychalcone. The flavonoid diene was produced from a 
protected flavonoid chromene via isomerization.  
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Metal-catalyzed alkynyl Claisen (Saucy-Marbet) rearrangements of 3-alkynyl 
flavone ethers have been evaluated, and a 1,2-acyl migration cascade which afforded 
novel furanyl benzofuranone scaffolds was discovered. Mechanistic studies have revealed 
that the rearrangement is likely initiated by 5-endo enyne cyclization to a platinum-
containing spiro-oxocarbenium intermediate, which may be intercepted by methanol to 
produce a spirodihydrofuran or further rearranged to afford allenyl chromanediones and 
benzofuranones at higher reaction temperature. Lewis acid-catalyzed [1,3]-
rearrangements of 3-aryl substituted flavone ethers have also been developed. 
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1. Chapter 1 
 
 
Sanggenon-type Natural Products  
 
 
1.1.  Introduction to sanggenon-type natural products.  
1.1.1. Isolation and structure elucidation.   
The family of modified flavanone natural products bearing a densely 
functionalized hydroxy-benzofuro[3,2-b]chromenone ring system was first isolated from 
the extracts of the Chinese traditional herbal medicine “Sang-bai-pi”, the root bark of 
Morus sp. (Moraceae), by Nomura and coworkers in the 1980s. These cis-3-hydroxy-2-
prenylflavanone derivatives bear an ether linkage between the 2′- and 3-positions forming 
a 5,6-fused ring system (highlighted in red, Figure 1.1). More complex members of this 
family contain a tetra-substituted cyclohexene ring and are believed to be Diels-Alder 
type adducts with a molecule of highly oxygenated 2′-hydroxychalcone, e.g. sanggenon C 
(4),
1,2
 D(6),
3
 O(5),
4,5
 and cathayanon A(10), B(11),
6
 E(9)
7
. The polycyclic ketal-
2 
 
 
 
containing cathayanins B (7) and C (8)
8
 are further ketalization products of sanggenons C 
and O respectively. 
Figure 1.1 Representative sanggenon and cathayanon natural products. 
 
The relative stereochemical assignments of the cyclohexene ring of these natural 
products were primarily based on the magnitude of the J1 coupling constants found in the 
1
H NMR spectra. A number of closely related Diels-Alder type natural products and 
3 
 
 
 
model adducts have been extensively studied.
9-12
 As shown in Figure 1.2, the “all-trans” 
or exo-adducts exhibit J14H-20H ≈ J19H-20H ≈ 11 Hz, while the “cis-trans” or endo-adducts 
exhibit a smaller J14H-20H ≈ 5 Hz and a variable J19H-20H in the range of 4-11 Hz. By 
comparison with the known natural products mulberrofuran C (12) and kuwanon G (13), 
it has been determined that sanggenons C (4) and O (5) are endo-adducts and sanggenon 
D (6) an exo-adduct (Figure 1.3). 
Figure 1.2 Relative stereochemical assignments based on J1 coupling constants. 
 
  
4 
 
 
 
Figure 1.3 Relative stereochemical assignments for select natural products. 
 
Most sanggenon-type natural products isolated from Morus alba root bark exhibit 
large optical rotations due to several stereogenic centers present adjacent to the 
chromophores in the molecules. The absolute stereochemistry of the cyclohexene ring in 
these natural products was elucidated by comparison to that of mulberrofurans C (12) and 
G (14). The Diels-Alder adduct mulberrofuran C (12) was converted to mulberrofuran G 
(14) via ketalization in acidic media under UV irradiation. Though the exact mechanism 
is unclear, it is possible that protonation of the triplet state of the carbonyl group relieves 
configurational strain. This leads to carbocation intermediate 12′ which is susceptible to 
nucleophilic addition of the adjacent phenols (Scheme 1.1b).
13
 Mulberrofuran G (14) was 
subsequently methylated to yield pentamethyl ether 15. Bromination with NBS and 
oxidation with DDQ afforded bromide 16 (Scheme 1.1a). Structures of both 15
14
 and 
16
15
 have been confirmed by X-ray crystallography and the absolute stereochemistry at 
5 
 
 
 
C-8″ was determined to be R. The cis-trans configuration of the cyclohexene ring 
allowed for the determination of the absolute stereochemistry of mulberrofuran C (12) as 
(3″S,4″R,5″S).  
Scheme 1.1 Determination of the absolute configuration of mulberrofuran C (10). 
 
The elucidation of the absolute stereochemistry of sanggenon C (4)
2
 began with 
the circular dichroism (CD) spectra of cyclized epimers 7 and 8 (Figure 1.4). The 
ketalization of sanggenon C (4) was achieved under mild acidic conditions to afford 
cathayanin B (7). Epimerization of 4 at C-2 and C-3 was achieved under basic conditions 
to provide sanggenon O (5) (vide infra, cf. Scheme 1.2), which was then cyclized with 
6 
 
 
 
acid to give cathayanin C (8). The CD spectrum of a 1:1 mixture of 7 and 8 (the 
contribution of the stereogenic centers at C-2 and C-3 disappeared) showed positive 
Cotton effects at 220, 237, 295(sh), 309 and 325(infl.), and negative Cotton effects at 
260(sh) and 276 nm. The CD spectrum of 7 + 8 is in agreement with that of 
mulberrofuran G (14). The absolute stereochemistry of the cyclohexene ring in 
sanggenon C (4) was therefore determined to be (14S,20R,19S). The relative 
configuration of the 2-prenyl and 3-hydroxyl groups was determined to be cis, based on 
the fact that the acetylation of the 3-hydroxyl group (4a→4b and 5a→5b) caused 
consistent changes in H2-9 chemical shifts, possibly due to the anisotropic effect of the 3-
O-acetyl group.
16
 Nuclear Overhauser Effect (nOe) measurements in both isomers 7 and 
8 made it possible to confirm the absolute stereochemistry at C-2 and C-3 as (2R,3S) in 
sanggenon C (4). Figure 1.4 shows that cross peaks with nOes were observed between 
H-19 and H3-13, and between H-18β and H3-12 in 7, cross peaks with nOes were also 
observed between H-27 and H3-13, and between H-27 and H3-12 in 8. The absolute 
stereochemistry of sanggenon C was therefore determined to be (2R,3S,14S,20R,19S) as 
shown in structure 4 (Figure 1.4).  
Similarly, the absolute stereochemistry of sanggenon O (5) was established as 
(2S,3R,14S,20R,19S). The absolute stereochemistries of sanggenol F (1)
2,17
 and 
sanggenon A (2)
18
 were elucidated to be (2R,3S) by comparison of their CD spectra with 
the differential CD spectrum between 7 and a 1:1 mixture of 7 and 8. No information 
about the absolute stereochemistry of sanggenon D (6) has been reported to date. 
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Figure 1.4 Elucidation of the absolute configuration of sanggenon C (4). 
 
The Lin group reported the isolation of Diels-Alder adducts cathayanons A (10) 
and B (11) from the root bark of Morus cathayana along with sanggenons C (4) and O 
(5).
6
 The relative and absolute stereochemistry of cathayanon A were confirmed by X ray 
crystallography and CD spectrum analysis, respectively. It was determined that 
cathayanon A (10) was an endo-adduct with the absolute stereochemistry 
(2S,3R,14S,20R,19S) (Figure 1.5), and cathayanon B was an exo-adduct with the 
absolute stereochemistry (2S,3R,14R,20R,19S) (cf. Figure 1.1). 
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Figure 1.5 Structure and X ray analysis of cathayanon A (10). 
     
The hemiacetal core structure in the sanggenon family of natural products is acid- 
and base-sensitive and prone to ring-opening and racemization via Wessely-Moser 
rearrangement. For example, alkaline treatment of sanggenon A (2) results in an 
equilibrium mixture of (±)-sanggenon A (2) and (±)-sanggenon M (3) in 2:5 ratio 
(Scheme 1.2).
18
 Racemization at C-2 and C-3 may proceed through hemiacetal opening 
followed by C-2 and C-3 ether bond cleavage to afford 1,2-diketone intermediate 17a or 
17b, and after subsequent bond rotation around C4-C5″ and hemiacetal formation, may 
yield the regioisomer (±)-sanggenon M (3). 
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Scheme 1.2 Wessley-Moser rearrangement under basic and acidic conditions. 
 
 
1.1.2.  Biological activity  
The Chinese herbal medicine “Sang-bai-pi (Morus Alba)” is traditionally used as 
an expectorant, detumescent, and diuretic for treating cough, asthma, dysuria and various 
respiratory and urinary inflammation. The sanggenon family of natural products exhibits 
promising biological activities including cytotoxicity, as well as hypertensive, anti-viral 
and anti-inflammatory properties. For example, Nomura and coworkers have shown that 
sanggenons A (2), C (4), D (7) and M (3) selectively target human oral squamous cell 
carcinoma (HSG-2) and human salivary gland tumor (HSG) over normal human gingival 
fibroblasts (HGF). Among these, sanggenons M (3) and C (4) proved most potent with 50% 
cytotoxic concentration (CC50) values in the range of 13-23 µM for HSC-2 and HSG cell 
lines.
19
 The Diels-Alder adduct sanggenon C (4) was more extensively studied recently, 
and was shown to suppress proinflammatory cytokine TNF-α induced activation of NF-
10 
 
 
 
κB at a potency of 1-10 µM. NF-κB is a nuclear transcription factor that regulates the 
expression of over 200 genes, including those associated with inflammatory diseases.
15
 
Sanggenon C (4) is also a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), a 
subtype of phosphatase that dephosphorylates insulin receptor (IR) which suggests 
potential for treatment of Type 2 diabetes due to its role in insulin signaling and 
metabolism.
20
 Moreover, sanggenon C (4) decreases tumor cell viability by means of 
proteasome inhibition (IC50 ~ 15 µM) and induces cell cycle arrest at the G0/G1 phase 
which eventually leads to cell death in several isolated cancer cells including murine 
hepatoma H22 and leukemic P388 cancer cell lines.
21
 Two endo-cycloadducts 
sanggenons C (4) and O (5) (epimers at C-2 and C-3) have been shown to suppress nitric 
oxide synthases (iNOS) protein expression and subsequent nitric monoxide (NO) 
production in a dose-dependent manner, a pathway known to be involved in various 
inflammatory conditions.
22
 In addition, sanggenons C (4), D (6), E (18) and O (5) exhibit 
strong inhibition towards cyclooxygenase COX-1 (with IC50 values ranging between 10-
14 µM) and COX-2 (with IC50 values ranging between 40-50 µM). Studies with virtual 
screening (VS) techniques have shown that structural features of these Diels-Alder 
adducts are necessary for the adequate inhibitory effects of sanggenons on both COX 
isoenzymes.
23
 Furthermore, after HPLC-based activity profiling of 982 plant and fungal 
extracts, sanggenons C (4) and D (6) were identified as positive γ-aminobutyric acid type 
A receptor (GABAA) modulators, displaying potencies with EC50 values ranging from 13 
to 17 µM, and with maximal IGABA potentiation ranging from 716% to 730%. Therefore, 
sanggenons and related compounds may be considered for treatment of anxiety and sleep 
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disorders as well as epilepsy.
24
  
 
1.1.3. Related Diels-Alder cycloadducts and their biogenesis. 
The cyclohexenyl functionality in the sanggenon family is also commonly found 
in a number of related natural products isolated from the roots of the mulberry tree and 
ginger-family plants. These include Diels-Alder type adducts of flavonoid and aromatic 
dienes with 2′-hydroxychalcone, e.g. kuwanons G (19)9-11 and H (20),25 australisine A 
(21)
26
 and sorocenol B (22),
27
 as well as the dimeric chalcone adducts brosimones A 
(24)
28
 and B (25)
29
 (Figure 1.6). 
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Figure 1.6 Related prenylflavonoid Diels-Alder cycloadducts. 
 
Most sanggenon-type natural products and these related phenolic compounds 
isolated from the mulberry tree are often regarded as enzymatic [4+2] cycloadducts.
30-32
 
For example, kuwanon G (19) is likely derived from cycloaddition of the α,β-unsaturated 
bond of chalcone 26 as the dienophile and the isoprenyl portion of dehydroprenylphenol 
27 as the diene. The diene is thought to further originate from enzymatic dehydrogenation 
of a prenyl group (Figure 1.7). Interestingly, the prenylated compound kuwanon C (28) 
and the 2,2-dimethylchromenyl morusin (29) are co-isolated from the same plant, thereby 
supporting the proposed biosynthetic pathway. 
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Figure 1.7 Proposed biosynthesis of kuwanon G (19). 
 
In a representative study of the biosynthetic pathways for kuwanon J (35) and 
chalcomoracin (39) using 
13
C-labeled feeding experiments, selection of callus cultures 
from Morus alba afforded highly productive cell lines to which sodium [1-
13
C]-, [2-
13
C]-, 
and [1,2-
13
C2]acetates were administered (Figure 1.8).
33
 The 
13
C-labeling patterns of the 
resulting Diels-Alder adducts 35 and 39 suggest that the chalcone 31 as well as 
benzofuran skeleton 36 originate from Claisen-type condensation of cinnamoyl 
polyketide 30 and that the tricarboxylic acid (TCA) cycle participates in the biosynthesis 
of isoprenyl units. Indeed, the presence of 
13
C-labeling at the third acetate unit (C-25″ 
and C-7″) is an indication of prenyl group isomerization (via butadienyl intermediates 
41a and 41b), and diene formation at the isoprenyl units by means of dehydrogenation.
34
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Figure 1.8 
13
C-labeling pattern in kuwanon J (35) and chalcomoracin (39). 
 
Administration of O-methylated chalcone 43, which was not found as a natural 
metabolite, to the M. alba cell cultures, yielded prenylated chalcone 44 along with Diels-
15 
 
 
 
Alder adducts 45 through 48 (Figure 1.9).
35
 The structure of 44 indicates that prenylation 
occurs after aromatization of the cinnamoyl polyketide. In addition, when chalcone 44 
was administered to the cell culture, the metabolites 45 through 48 were isolated, strongly 
suggesting that one molecule of the prenylated chalcone acts as a dienophile, while 
another molecule of the prenylated chalcone serves as a diene after dehydrogenation of 
the prenyl group. In fact, cycloadducts 45 through 48 are optically active and possess the 
same absolute stereochemistry as kuwanon J (35) and chalcomoracin (39) indicating that 
the Diels-Alder cycloaddition reaction is under enzymatic control.
35,36
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Figure 1.9 Administration of O-methylchalcone 43 precursors to Morus alba cell 
culture. 
 
 
1.2. Selected biomimetic syntheses of Diels-Alder type natural products. 
Even though to date, the existence for a “Diels-Alderase” remains elusive, 
indirect evidence exists for enzyme catalyzed-Diels-Alder reactions in nature, and the 
catalysis of Diels-Alder cycloadditions has been realized with biomolecules such as 
antibodies and metal-binding RNA fragments.
36
 Biomimetic total syntheses invoking 
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Diels-Alder cycloadditions as key steps have showcased the capability and elegance of 
such transformations in constructing structural complexity with efficiency.
37
  
In the biomimetic bisorbibutenolide synthesis by Nicolaou and coworkers,
38,39
 the 
homodimer bisorbicillinol (52) was constructed via Diels-Alder cycloaddition of two 
rapidly equilibrating quinols 50 and 51 derived from deacetylation of chiral monomer 49. 
Base catalyzed-ring contraction of the cyclohexenone moiety in 52 fostered the desired 
butenolide ring structure in bisorbibutenolide (55) in excellent yield. Significantly, 
isolation of the quinol monomer sorbicillinol 50 from natural sources further 
substantiated this proposed biosynthetic hypothesis.
40
 
Scheme 1.3 Biomimetic synthesis of bisorbicillinol (52) and bisorbibutenolide (55). 
 
An elegant total synthesis of (-)-longithorone A (61) by Shair and coworkers
41,42
 
was based on a biosynthetic hypothesis first proposed by Schmitz and co-workers.
43,44
 In 
the sequence, the intermolecular Diels-Alder cycloaddition of two [12]cyclophanes 56 
and 57 was followed by oxidation to unveil quinone species 60, a compound which was 
18 
 
 
 
found to be suitable for the designed intramolecular transannular Diels-Alder reaction to 
fashion three new rings concurrently and complete the synthesis of longithorone A (61) 
in high yield.  
Scheme 1.4 Biomimetic synthesis of (-)-longithorone A (61). 
 
Sorensen’s total synthesis of (+)-FR18287745,46 showcased the remarkable utility 
of a Diels-Alder cycloaddition cascade in terms of both atom economy and versatility of 
the process. At 40 °C, the key macrocyclic precursor 62 underwent an unprecedented 
cascade of intramolecular transannular Diels-Alder cycloadditions to construct five rings 
and seven consecutive stereogenic centers to afford 64 as a single diastereomer. 
Pentacycle 64 was then transformed to (+)-FR182877 65 after deprotection and 
transesterification. 
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Scheme 1.5 Biomimetic synthesis of (+)-FR182877. 
 
 
1.3. Previous synthetic approaches to the flavonoid Diels-Alder natural 
products. 
In a detailed investigation of natural products kuwanons G (19) and H (20), 
Nomura and coworkers obtained crystallographic data for two model cycloadducts 68 
and 69 through thermal [4+2] cycloaddition between trans-chalcone 66 and butadiene 67 
in toluene (Scheme 1.6).
10
 Similarly, chalcone 71 and flavonoid diene 72, obtained by 
pyrolysis of the octamethyl ether of kuwanon G 70, were heated in toluene at 160°C to 
afford the exo-adduct racemic kuwanon G octamethyl ether 73 (35% yield) and endo-
adduct 74 (32% yield). These model Diels-Alder cycloadditions are key experiments for 
the elucidation of the relative stereochemistry within this family of natural products. 
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Scheme 1.6 Model thermal Diels-Alder cycloaddition. 
 
The Rizzacasa group achieved the racemic synthesis of permethyl ether of 
mulberrofuran C 82 and chalcomoracin (not shown).
47
 As shown in Scheme 1.7, 
Sonogashira cross coupling between iodide 75 and alkyne 76 afforded iodo compound 77. 
Saponification to remove the acetate and subsequent cyclization with TBAF yielded 
benzofuran 78, followed by Suzuki-Miyaura coupling with pinacolboronate 79 to yield 
trans diene 80. Thermal Diels-Alder cycloaddition in toluene at 180 °C between 2′-
hydroxychalcone 81 and benzofuran 80 produced endo- and exo-cycloadducts 82 and 83 
as a 1:1 mixture with a 40% combined yield.  
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Scheme 1.7 Synthesis of mulberrofuran C methyl ethers. 
 
Rahman and coworkers recently reported the racemic synthesis of methyl ethers 
of kuwanon V 94 and dorsterone 94 (Scheme 1.8).
48
 Diene 87 was derived from a Heck 
reaction of iodochalcone 84 with butenol 85, followed by acylation and subsequent 
elimination to produce chalcone 86. Dienophile 90 was synthesized through prenylation 
of chalcone 88 followed by [1,3]-sigmatropic rearrangement of the resulting prenyl ether 
89. For the key Diels-Alder cycloaddition, both strong heating conditions and 
AgOTf/Bu4NBH4 as a catalyst
49
 at lower temperatures afforded an approximately 50% 
yield and 3:2 endo/exo selectivity. 
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Scheme 1.8 Synthesis of (±)-kuwanon V and (±)-dorsterone methyl ethers via Diels–
Alder cycloaddition. 
 
The Porco laboratory at Boston University has developed two highly efficient 
catalytic systems for Diels-Alder cycloadditions between substituted dienes and 2′-
hydroxychalcones. These include a combination catalyst of CoI2, ZnI2 and borohydride, 
as well as a silver nanoparticle (AgNP) catalyst. Application of these fascinating Diels-
Alder cycloaddition catalysts have resulted in the total synthesis of nicolaioidesin C 
(104),
50
 panduratin A (23),
49
 sorocenol B (22),
51
  and brosimones A (24)
28
 and B (25).
29
  
In the electron transfer-initiated Diels-Alder cycloaddition of relatively electron-
rich 2′-hydroxychalcone (95) and diene (97) catalyzed by a combination of CoI2/1,10-
phenanthroline/ZnI2/Bu4NBH4 (10/10/60/10 mol%),
50
 Lewis acid ZnI2 is thought to 
23 
 
 
 
coordinate to the chalcone oxygens and render it susceptible to single electron transfer 
(SET) from an electron donor such as Co(I) or BH4
-
 (Scheme 1.9). The resulting 
chalcone radical anion 96 may undergo a stepwise regioselective addition and ring-
closing cyclization with diene 97 to afford ketal intermediate 99, which after subsequent 
electron transfer is thought to produce cycloadduct 100. In this way nicolaioidesin C 
(104)
52
 was constructed employing chalcone 101 as the dienophile and myrcene (102) as 
diene. 
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Scheme 1.9 Electron-transfer initiated Diels-Alder cycloaddition of 2′-
hydroxychalcones. 
 
The silver nanoparticle (AgNP) catalytic system was discovered in a screening of 
various Lewis acids (Scheme 1.10):
49,53
 a black precipitate was formed when a 3:1 ratio 
of AgBF4 and Bu4NBH4 was mixed in CH2Cl2. The clear supernatant showed strong 
Tyndall effects, suggesting the presence of particles on the nanometer scale, which led to 
25 
 
 
 
the discovery and development of AgNP as highly efficient catalysts for Diels-Alder 
cycloadditions of 2′-hydroxychalones and dienes, with a turnover number (TON) of 
approximately 3×10
2
. It is believed that the mild oxidant AgBF4 is reduced by 
borohydride to a Ag(0) species which aggregates in situ to form silver nanoparticles with 
an average size of 2.5 nm. The nanoparticle can be adsorbed onto silica gel and used as a 
storable catalyst. Mechanistically, the catalytic cycle is thought to begin with the 
adsorption of 2′-hydroxychalcone onto the AgNP surface. Proton removal and single 
electron transfer (SET) form a AgNP-stabilized phenoxyl radical 105a which would be in 
resonance with carbon-centered radical 105b. The species may undergo a concerted [4+2] 
cycloaddition with diene 97 to generate 106, which after back electron transfer (BET), 
protonation, and desorption from the AgNP provides cycloadduct 100. In this sequence, 
the AgNP may essentially serve as an “electron shuttle” to activate the 2′-
hydroxychalcone by lowering its LUMO towards the Diels-Alder cycloaddition. 
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Scheme 1.10 Silver nanoparticle-catalyzed Diels-Alder cycloaddition. 
 
 
In the total synthesis of brosimones A (24) and B (25), platinum on activated 
carbon (Pt/C) and AgNP catalyzed the dehydrogenative Diels-Alder (DHDA) 
cycloaddition of prenylated chalcone 108 to afford cycloadducts exo-110 and endo-111 
(not shown) in 1.2:1 ratio and 64% combined yield with cyclopentene as a H2 scavenger 
(Scheme 1.11). Brosimone B (25)
29
 was generated in 85% yield after benzyl group 
deprotection of the exo-adduct 110. Exo-110 also underwent intramolecular DHDA when 
treated with DDQ and AgNP at elevated temperature to provide caged structure exo-exo-
112, which under similar benzyl deprotection afforded [3.3]cyclophane brosimone A (24). 
28
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Scheme 1.11 Total syntheses of brosimones A (24) and B (25). 
 
 
1.4. Conclusion 
The sanggenons are an intriguing family of natural products owing to their 
complex chemical structures, potent biological activities, and interesting biosynthetic 
origins. To the best of our knowledge, as yet there are no examples of synthetic efforts 
toward sanggenon-type natural products. The sensitive functionalities including the 
benzofurochromenone structure and cyclohexene rings in these natural products present 
challenges and opportunities for reaction development, and render this family of natural 
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products excellent synthetic targets. In this thesis, I will describe our efforts in 
developing an asymmetric rearrangement of 3-allyloxyflavone ethers and its application 
to the total syntheses of sanggenol F and sanggenon A (Chapter 2), biomimetic syntheses 
of sanggenons C and O employing a silver nanoparticle-catalyzed Diels-Alder 
cycloaddition of a flavonoid diene and 2′-hydroxychalcone (Chapter 3), and development 
of the alkynyl Claisen rearrangement of 3-alkynyl flavone ethers, as well as the 1,3-
rearrangement of 3-aryl substituted flavone ethers, as part of a diversity oriented 
methodology development project (Chapter 4). 
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 Chapter 2 2.
 
 
Syntheses of Sanggenol F and Sanggenon A 
 
 
2.1. Retrosynthetic plans. 
 Retrosynthetic analysis for sanggenol F and sanggenon A. 2.1.1.
Sanggenon-type natural products are intriguing synthetic targets due to their 
complex chemical structures. Although chemical syntheses of related Diels-Alder type 
natural products including sorocenol B (22),
51
 and brosimones A (24)
28
 and B (25)
29
 have 
been achieved, there are no reported syntheses to access the benzofuro[3,2-b]chromenone 
ring system found in the sanggenons, nor are there reports of Diels-Alder cycloadditions 
of complex flavonoid dienes. In our retrosynthetic analysis, we envisioned that 
sanggenon A (2) may be derived from sanggenol F (1) via selective oxidation of the 
benzylic prenyl group. The sanggenol F core structure may arise from cyclization of 3,4-
chromanedione 113 with the adjacent 2′-hydroxyl group followed by cross metathesis 
30 
 
 
 
(Scheme 2.1). For the construction of the 3,4-chromanedione motif, we considered 
metal-catalyzed asymmetric double Claisen rearrangement of bis-allyloxyflavone ether 
114, a compound which may be derived from the commercially available flavanol morin 
(115) via a protection and O-allylation sequence. 
Scheme 2.1 Retrosynthetic analysis for sanggenol F and sanggenon A. 
 
 
 Literature examples of asymmetric Claisen rearrangements. 2.1.2.
Since its discovery in 1912, the Claisen rearrangement has been a very powerful 
reaction in organic synthesis. It is very effective in the selective construction of 
contiguous quaternary stereogenic centers, in which bond formation between sterically 
congested carbon atoms is particularly difficult.
54
 Claisen rearrangements usually proceed 
in high diastereoselectivity due to a highly organized chair-like transition state, as well as 
the concerted nature of C-O bond breaking and C-C bond forming events. Because of the 
great potential for the application of Claisen rearrangements in the synthesis of complex 
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scaffolds, there have been many studies on asymmetric Claisen rearrangement using both 
chiral Lewis acid catalysis and hydrogen-bond donating organocatalysis.  
Early reports of asymmetric Claisen rearrangements involve Lewis acid/chiral 
ligand complexes of aluminum,
55-57
 boron,
58-60
 magnesium,
61
 copper,
62-64
 scandium,
65
 
palladium,
66,67
 and ruthenium.
68
 However many of these catalytic systems were found to 
require stoichiometric amounts of catalysts and to also suffer from strong product 
inhibition and/or competing background reactions. The first truly catalytic asymmetric 
Claisen rearrangement was reported by Hiersemann and coworkers (Scheme 2.2),
62,64
 in 
which the use of a copper/bis(oxazoline) complex 117 catalyzed the rearrangement of 
activated allyl vinyl ethers 116 with excellent diastereoselectivity and enantioselectivity. 
In the proposed highly polarized, but concerted pericyclic transition state (119, Scheme 
2.2), both the substrate and the C2-symmetric ligand chelate to the copper center in a 
square planar manner. The bulky tert-butyl groups on the ligand promote rearrangement 
from the bottom face to minimize steric interactions. 
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Scheme 2.2 Cu/Box-catalyzed Claisen rearrangement of allyl vinyl ethers. 
 
The rate of the Claisen rearrangement is enhanced by electron withdrawing 
groups at position 2, electron donating groups at position 4 and 6, and in hydrogen bond-
donating solvents. The latter serves to stabilize charge separation in the transition state.
69
 
These observations have inspired the design of hydrogen-bond donating catalysts by 
Curran,
70
 Hiersemann,
71
 Jacobsen,
72-74
 and Kozlowski.
75
 The C2-symmetrical guanidinium 
BArF catalyst 120 developed by the Jacobsen group was found to be highly 
enantioselective in the rearrangement of allyl vinyl ethers 121 and 123 in non-polar 
solvents (Scheme 2.3).
72-74
 Computational studies showed that the transition state was 
stabilized via hydrogen bonding between the catalyst and both the ether and ester 
carbonyl oxygens. In the case of 123, the guanidinium ion lowers the activation barrier 
for the rearrangement by 5.3 kcal∙mol-1, and substrate 123 binds more readily to the 
catalyst than does product 124 (1.4 kcal∙mol-1 lower in energy).73 In the organocatalyzed 
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racemic Claisen rearrangement of allyl vinyl ether 126, Kozlowski and coworkers 
investigated the optimal orientation (bond angle) and distance (bond length) of the 
expected hydrogen bonding between the catalyst and the ether oxygen in the transition 
state (Scheme 2.4).
75
 By computational studies and crystal database mining, 
bisamidinium catalyst 125 was designed, and found to promote a 55-95 fold rate 
acceleration in the rearrangement of 126. 
Scheme 2.3 Enantioselective Claisen rearrangement with hydrogen-bond donor 
catalyst 120. 
 
Scheme 2.4 Bisamidinium-catalyzed achiral Claisen rearrangement. 
 
The Nelson group
68
 reported the first example of a ruthenium-catalyzed 
asymmetric Claisen rearrangement of unactivated allyl vinyl ethers 129 (Scheme 2.5). 
Though the reaction mechanism is still under investigation, possible ruthenium insertion 
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into the C-O bond may be followed by enolate-allyl cation recombination to yield trans-
aldehyde 130, a stereochemical course which is complimentary to the syn-
diastereoselectivity observed in thermal [3,3] rearrangements. The use of pyridine-based 
ligand 132 with the ruthenium catalyst prevents the competing [1,3] rearrangement 
pathway (129→131) in addition to control controlling the stereoselectivity. 
Scheme 2.5 Catalytic asymmetric Claisen rearrangement of unactivated allyl vinyl 
ethers. 
 
In the Meerwein-Eschenmoser Claisen rearrangement of allyloxy-indole 133 
reported by the Kozlowski and coworkers,
66,67
 palladium (II) catalysts were investigated 
because of their relatively higher affinity to substrates over products. In combination with 
BINAP ligand 137 or PHOX ligand 138, the cationic palladium (II) catalyst Pd(SbF6)2 
effectively catalyzed the [3,3] rearrangement of 133 to afford highly enantioenriched 
oxindoles 134 (Scheme 2.6a). Mechanistic studies showed that palladium may serve as a 
Lewis acid in bidentate coordination with the substrate, rather than forming a π–allyl 
intermediate. The same catalyst system was also used in the first example of an 
asymmetric Saucy-Marbet (alkynyl-Claisen) rearrangement of 135 to provide allenyl 
oxindole 136 (Scheme 2.6b).
67,76
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Scheme 2.6 Catalytic enantioselective Meerwein-Eschenmoser Claisen 
rearrangement. 
     
As will be discussed in detail in this chapter, we have developed an asymmetric 
double rearrangement of bis-allyloxyflavone ether 114 (cf. Scheme 2.1) in order to 
construct the hydroxyl-benzofuro[3,2-b]chromenone core of the sanggenon natural 
product family. To the best of our knowledge, the use of Claisen rearrangements in 
complex flavanone construction has not been reported before. 
 
2.2. Methodology development. 
 Enantioselective rearrangement of 3-allyloxyflavone ethers. 2.2.1.
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The Porco laboratory has been interested in the asymmetric Claisen 
rearrangement of allyloxyflavones 139 as the transformation enables enantioselective 
access to the benzofuro[3,2-b]chromenone core of the sanggenon natural product family. 
Dr. Jean-Charles Marie from the CMLD-BU initially developed a highly efficient and 
enantioselective rearrangement using a chiral Lewis acid scandium triflate/Ph-PyBox 
complex 140 (Scheme 2.7a).
65
 Electron donating and withdrawing groups on the phenyl 
groups in 139 were well tolerated. Scandium (III) is believed to chelate to both ligand and 
substrate as illustrated in the calculated MM2/MM3 transition state (Scheme 2.7b). The 
rearrangement takes place from the Re face to yield the S-enantiomer due to the steric 
hindrance of the phenyl groups on the ligand. 
Scheme 2.7 Enantioselective formation of chromanediones via asymmetric Claisen 
rearrangement of allyloxyflavones. 
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My studies began with evaluating two model substrates (142 and 151) for the 
application of this methodology to the synthesis of the sanggenon natural products. 
Lanthanide triflates of differing ionic radii
77
 were screened in conjunction with (R)-Ph-
PyBox ligand 143 (Table 2.1). The asymmetric rearrangement was performed with 30 
mol% of metal triflate/PyBox complex in DCE at 35 °C. The 3,4-chromanedione product 
144 was condensed with 1,2-phenylenediamine to afford quinoxaline 146 for purification 
and ee measurement purposes. The enantioselectivity of the rearrangement was found to 
be dependent on the ionic radii of the lanthanide metal center. The ee decreases with 
decreasing ionic radii in the lanthanide series. Thus, La(OTf)3 with a relatively large ionic 
radius of 103.2 pm afforded 146 in 90% ee (entry 1), and Yb(OTf)3 with a smaller ionic 
radius of 86.8 pm afforded 146 in 11% ee (entry 6). Moreover, an ee of 96% was 
achieved with Sc(OTf)3, which gave the antipode in comparison to La(OTf)3 (entry 7).  
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Table 2.1 Lewis acid-catalyzed Claisen rearrangement of allyloxyflavone ether 142. 
 
entry
a
 M(OTf)3 ionic radii (pm) 
conversion of 144
 
 
(isolated yield of 146)
b
 
ee
c
 of 146 
1 La(OTf)3 103.2 100% (73%) 90% (R)* 
2 Nd(OTf)3 98.3 100% (90%) 87% (R)* 
3 Sm(OTf)3 95.8 100% 85% (R)* 
4 Gd(OTf)3 93.5 100% (85%) 85% (R)* 
5 Er(OTf)3 89.0 100% 40% (R)* 
6 Yb(OTf)3 86.8 100% (62%) 11% (R)* 
7 Sc(OTf)3 74.5 70% (40%) 96% (S)* 
a
 Unless otherwise specified, all reactions were carried out with 0.10 mmol of 
142 and 30 mol% of metal triflate/(R)-PyBox complex at 0.07 M in DCE at 
35 °C. The reactions were complete in 12 h and reaction mixture was treated with 
1,2-phenylenediamine to yield 146. 
b
 Conversion to 144 was determined by crude 
1
HNMR analysis. 
c
 ee determined on purified 146 by chiral HPLC analysis on a 
ChiraPak AD-H column.  
 
A similar trend in enantioselectivity was reported by Desimoni and coworkers in a 
study of Diels-Alder reactions between acryloyloxazolidinone 147 and cyclopentadiene 
148:
78
 (R)-PhPyBox complexes of scandium and lanthanum triflate resulted in the S and 
R enantiomers of the cycloadducts respectively (Scheme 2.8). The reversed asymmetric 
induction can be rationalized by two different reaction intermediate conformations with 
Sc(OTf)3 (Figure 2.1a) and La(OTf)3 (Figure 2.1b), which favor addition to the opposite 
faces of the coordinated dienophile. 
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Scheme 2.8 Enantioselective Diels-Alder reaction catalyzed by lanthanide triflates. 
 
Figure 2.1 Proposed reaction intermediates for the Diels-Alder reaction between 147 
and 148 catalyzed by (R)-PhPyBox complex of (a) Sc(OTf)3 and (b) La(OTf)3. 
 
The reversed enantioselectivity for rearrangements of allyloxyflavone ethers using 
Sc(III) and La(III) complexes may be explained by the different conformations of the 
Lewis acid/ligand/substrate complex as a result of different radii and coordination 
numbers of the metal center. For example, the scandium (III) complex (coordination 
number 7) likely possesses a pentagonal bipyramidal geometry
79
 in which the tridentate 
PyBox ligand occupies the equatorial plane, and substrate oxygens reside in the apical 
and equatorial positions. The rearrangement occurs from the Re face (Figure 2.2a). On 
the other hand, the bulkier lanthanum(III) may result in a complex (coordination number 
9) as shown in Figure 2.2b in which the rearrangement occurs from the Si face. The other 
(a) (b) 
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medium sized lanthanides may form both complexes a and b (Figure 2.2), and the 
population distributions between these two complexes may vary with the ionic radii as 
well the coordination number of the metal centers.
78
 
Figure 2.2 Calculated transition state of (a) Sc(OTf)3/(R)-Ph-PyBOX- and (b) 
La(OTf)3/(R)-Ph-PyBOX-catalyzed rearrangement of 142. 
          
          
The metal/PyBox complexes were derived from the crystal structures of Sc[(S,S)-Ph-
PyBox(H2O)](OTf)3 complex
79
 and La(S,S-diPh-PyBox)(H2O)4(OTf)2 complex.
80
 
Transition state geometry of 142 was calculated using Spartan 11 (Semi-empirical, AM1). 
The two models were manually docked using ChemBio3D. Green balls represent triflate 
or solvent molecules. 
a b 
a) b) 
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The two optimal metal catalysts scandium and lanthanum were then employed in 
the rearrangement of various 2′-substituted substrates for the construction of the desired 
hydrobenzofuro[3,2-b]chromenone core structure (Table 2.2). Among the substrates 
evaluated, the Sc/PyBox complex was found to exhibit better reactivity and 
enantioselectivity for most of the substrates in comparison to the La/PyBox system. In the 
case of 2′-hydroxy substrate 151b, the resulting chromanedione was trapped in situ by the 
2′-hydroxyl group to afford the hydrobenzofuro[3,2-b]chromenone core structure 154 
directly (entry 3). The low yield of this tandem sequence may be due to product 
inhibition of the Sc/PyBOx complex by compound 154. In the cases of substrates with 
bulky OTES or OMOM groups protecting groups, the desired core structure was obtained 
in high ee and yield after mild deprotection (entries 4, 5).  
Table 2.2 Asymmetric Claisen rearrangement of 2-substituted allyloxyflavones. 
 
entry
a
 substrate 
substitution 
R
1
, R
2
 
Sc(OTf)3 La(OTf)3 
conversion of 152 
(isolated yield)
e
 
ee
f
 
conversion of 152 
(isolated yield)
e
 
ee
f
 
1
b
 151a H, H (78%) 86% (19%) −73% 
2
b
 142 5-OMe, H 70% (40%) 96% 100% −90% 
3 151b H, 2′-OH 41% 76% 22% --- 
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4
c
 151c H, 2′-OTES 100% (93%) 97% Trace --- 
5
d
 151d H, 2′-OMOM 45% 97% 20% --- 
6
b
 151e H, 2′-OMe 95% 94% 36% −17% 
a
 Unless otherwise specified, all reactions were conducted with 0.10 mmol of 151 and 30 mol% 
of lanthanide triflate/(R)-PyBox complex at 0.07 M in DCE at 40 °C. The reactions were 
complete in 12 to 36 h. 
b
 Reaction mixture was treated with 1,2-phenylenediamine to afford 153. 
c
 Reaction mixture was treated with HF∙pyridine in CH2Cl2 to afford 154. 
d
 Reaction mixture 
was treated with p-TsOH∙H2O in CH2Cl2 to afford 154. 
e
 Conversion was determined on 152 by 
crude 
1
H NMR analysis. Isolated yield was determined on purified 153 or 154. 
f
 ee determined 
on purified 153 or 154 by chiral HPLC analysis on a ChiraPak AD-H column. 
 
 Mechanistic studies. 2.2.2.
Scheme 2.9 Deuterium-labeling and crossover experiments. 
 
Deuterium-labeling and crossover experiments were conducted by Dr. J.-C. Marie 
to investigate the mechanism of the rearrangement. In the Claisen rearrangement of 
substrate 155, the deuterium labels at the methylene position of the allyl group in 155 
were found at the terminal position of the olefin in 157 (Scheme 2.9a). In the crossover 
experiments, a mixture of closely-related allyloxyflavone ethers 158 and 159 under 
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standard achiral rearrangement conditions yielded a mixture of the quinoxalines 160 and 
161, with no crossover products observed (Scheme 2.9b). These results are consistent 
with an intramolecular, formal [3,3] sigmatropic rearrangement of the allyloxyflavone 
ether substrates. Alternatively, the reaction may form a resonance structure 
benzopyrylium 162 (Figure 2.3), derived from delocalization of positive charge and 
aromatization upon chelation to Lewis acid. Benzopyrylium 162 may undergo a [2,3] 
sigmatropic rearrangement
81,82
 to afford oxonium ion 163. Oxonium ion 163 may 
undergo a stereospecific [1,2]-allyl shift
83
 to generate the same product 156, with the 
deuterium atom residing on the terminal position of the olefin.  
Figure 2.3 Mechanistic alternative for the asymmetric rearrangement. 
 
To examine the possibility of this latter pathway, we probed for the presence of 
the proposed benzopyrylium intermediate 162 by fluorescence and 
13
C NMR 
spectroscopy of a closely related substrate 166. Specifically, 4-siloxy-1-benzopyrylium 
salt 164 was prepared by treatment of 166 with TBSOTf,
84
 and its fluorescence emission 
was characteristic of benzopyrilium ions (450 nm upon excitation at 410 nm, Figure 2.4). 
A similar fluorescence emission at 450 nm was observed for the Sc(OTf)3/3-
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methoxyflavone complex 165, formed by addition of Sc(OTf)3 to 166 (excitation at 400 
nm). In contrast, 3-methoxyflavone 166 and Sc(OTf)3 alone did not show the same 
fluorescence profile when irradiated.  
Figure 2.4 Overlay of fluorescence spectra of 164, 165, 166, and Sc(OTf)3 (3.0×10-4 
M in CH2Cl2).    
 
Both the 13C NMR spectra of benzopyrylium salt 164 and scandium complex 165 
(Figure 2.5) showed comparable downfield shifts for C-2 (3-methoxyflavone 166: 156 
ppm; 164: 162 ppm; 165: 165 ppm) and C-4. This may be due to the decreased electron 
density at C-2, as well as increased aromaticity as a result of electron delocalization.85,86 
Furthermore in Figure 2.6, 1 equivalent of Sc(OTf)3 was gradually titrated into a CD3CN 
solution of 166. The 13C NMR spectra showed gradual shift for carbon peaks in close 
vicinity to the pyrylium ring (e.g. C-4, C-2, C-3, C-7, C-1′ and C-4a).  
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Figure 2.5 
13
C NMR spectra of a) 166, b) 164, c) 165 in CD2Cl2.  
ppm (t1)
120130140150160170180190
f  
To the sample of 165 was added HFIP (4% by volume) for better solubility. 
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Figure 2.6 NMR spectra of the titration of 1 equivalent of Sc(OTf)3 to 166 in CD3CN.  
ppm (t1)
110120130140150160170180
f
3MF + 0 eq Sc in CD3CN
+ 0.15 eq
+ 0.30 eq
+ 0.50 eq
+ 1.0 eq
 
From the top, 
13
C NMR spectra of a) 166, b) 166 with 15 mol% of Sc(OTf)3, c) 166 with 30 mol% 
of Sc(OTf)3, d) 166 with 50 mol% of Sc(OTf)3, e) 166 with 1.0 equiv of Sc(OTf)3.   
 
The fluorescence and 
13
C NMR spectra support the possible involvement of the 
benzopyrylium intermediate 162 in the asymmetric rearrangement of 3-allyloxyflavones, 
although these observations are not sufficient to confirm that benzopyrylium salt 162 is a 
reactive intermediate. To distinguish between the two mechanisms, further mechanistic 
studies will be carried out in future experiments. 
For pathway involving the [2,3]/[1,2] mechanism, the rate-determining [2,3]-
rearrangement step likely goes through a formally charged benzopyrylium species 162 (cf. 
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Figure 2.3). In the [3,3] sigmatropic pathway, the rate-determining step undergoes a 
partially charged or overall neutral intermediate. The electronic effects of different 
substitutions on the flavone B ring on the reaction rate constant k will be investigated. 
Various 3-allyloxyflavones with different substitutions at 4′-position will be evaluated 
with scandium(III)/PyBOX conditions. We anticipate a zero slope of log(kX/kH) versus 
substituent constant σ for the [3,3] sigmatropic pathway and a strongly negative slope for 
a [2,3]/[1,2] process or an ionic [3,3] process.  
Scheme 2.10 Proposed Hammett correlation studies. 
 
13
C kinetic isotope effects may also be investigated. As the reaction proceeds, the 
starting materials are fractionatively enriched in isotopically slower-reacting components. 
The kinetic isotope effect (KIE) may be calculated  according to: 
         
       
             
                                                   
Here, R/R0 represents the proportion of isotopic component in recovered starting 
material to original starting material, and F represents the reaction conversion. The 
determination of multiple small kinetic isotope effects at natural abundance described by 
Singleton and coworkers will be utilized.
87
 Rearrangement of 151a may be taken to 99% 
conversion and starting material may be recovered by silica gel chromatography and R/R0 
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may be measured by 
13
C NMR integration. KIE may be calculated according to equation 
1. We expect a concerted [3,3] mechanism if a large KIE is observed at C-2, and a 
[2,3]/[1,2] pathway if large KIE is observed at C-3 (cf. Figure 2.3). 
Scheme 2.11 Proposed kinetic isotope effect studies. 
 
Additional evidence to support a [2,3] sigmatropic rearrangement pathway may 
be obtained through evaluation of the Lewis acid-catalyzed rearrangement of silyl enol 
ether 151f. Under Lewis base catalysis, 151f undergoes mainly a [2,3]-Wittig 
rearrangement to yield 152f, and under thermolysis conditions 151f undergoes 
predominantly the [3,3]-Claisen rearrangement to yield 153f (Scheme 2.12a).
88,89
 This 
observation suggests the activation of the silyl enolate may dictate the reaction pathway. 
Formation of 152f or 152g upon treatment of 151f or 151g with scandium triflate/PyBOX 
may support the [2,3]/[1,2]-shift mechanism. Alternatively, formation of 153f or 153g 
may support the [3,3]-Claisen rearrangement pathway (Scheme 2.12b). 
Scheme 2.12 Proposed rearrangements of allyloxy silyl enol ether. 
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2.3. Total syntheses of (±)-sanggenol F and (±)-sanggenon A 
As described in the retrosynthetic analysis (Scheme 2.1), the sanggenon core 
structure may be derived from bis-allyloxyflavone ether 114. The two precedented routes 
for the requisite 3-hydroxyflavone synthesis proved to be ineffective in obtaining the 
requisite 3-hydroxyflavone starting material 167. Algar-Flynn-Olyamada (AFO) 
reaction
90
 of 2′-hydroxychalcone 168 with a 5-substitution favors a 5-exo cyclization to 
yield the aurone isomer 169 (Scheme 2.13a). The alternative Baker-Venkataraman 
rearrangement
91
 of ortho-acyl benzoate 170 is more convergent but requires nine steps 
from commercially available starting materials (Scheme 2.13b). Therefore, we decided to 
prepare the key intermediate bis-allyloxyflavone ether 114 via selective protection and 
allylation of the commercially available pentahydroxyflavanol morin (115, Scheme 2.1). 
To prevent racemization of the sanggenon core structure via Wessley-Moser 
rearrangement under strongly acidic or basic conditions (cf. Chapter 1, Scheme 1.2), we 
considered that a protecting group-free double rearrangement could be performed directly 
on bis-allyloxyflavone ether substrate 114 (R = H).  
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Scheme 2.13 Various strategies for the synthesis of bis-allyloxyflavone ethers. 
 
The synthesis of the requisite bis-allyloxyflavone ether 176 (same as 114, R = H) 
commenced with tetra-MOM group protection of morin (115) and subsequent 5-allylation 
to afford tetra-MOM protected intermediate 172 (Scheme 2.14). Selective 3-MOM 
deprotection proceeded with NaI and a catalytic amount of aqueous HCl.
92
 Proton may 
chelate between the 4-carbonyl group and O-3 in 173 and activate the 3-MOM group for 
selective MOM deprotection. Finally, 3-allylation and global MOM deprotection 
afforded the desired bis-allyloxyflavone ether 176.  
Scheme 2.14 Synthesis of bis-allyloxyflavone ether 176. 
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A number of rare earth triflates were evaluated in the achiral, double 
rearrangement of bis-allyloxyflavone ether 176 (Table 2.3). Among them, Yb(OTf)3 with 
stronger Lewis acidity was found to produce the double rearrangement product 177 in 72% 
yield. Other lanthanide triflates were found to afford double rearrangement product 177, 
along with single rearrangement products 178 and 179 in varying ratios. In theory, there 
are two possible chelation sites in the substrate: between O-3 and O-4 and between O-5 
and O-4 (Scheme 2.15).
93
 The distances between O-3 and O-4 and between O-5 and O-4 
were calculated to be 2.80 Å and 2.55 Å respectively (Scheme 2.15d). Selective binding 
to either or both chelation sites may occur depending on the ionic radius of the Lewis 
acid to enable 3-allyl rearrangement (Scheme 2.15a) and/or 5-allyl rearrangement 
(Scheme 2.15b). Different modes of chelation by rare earth metal triflates may explain 
the product distributions observed in Table 2.3. For example, La(OTf)3 with a larger 
ionic radius may preferentially chelate between O-3 and O-4, which has a larger binding 
pocket to afford 3-allyl rearrangement product 178 as the major product.  
Table 2.3 Lewis acid-catalyzed double rearrangement of bis-allyloxyflavone ether 
176. 
 
entry
a
 M(OTf)x ionic radii (pm) 
product distribution 
(177:178:176)
b
 
yield% 
(177, 178, 176) 
1 Zn(OTf)2 74.0 28:72:0 24%, 62%, 0% 
2 Sc(OTf)3 74.5 nd
c
 57%, 34%, 5%, 0%
d 
3 Yb(OTf)3 86.8 100:0:0 72%, 0%, 0% 
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4 Y(OTf)3 90.0 nd 60%, 36%, 0% 
5 Gd(OTf)3 93.8 nd 48%, 40%, 0% 
6 Nd(OTf)3 98.3 nd 38%, 62%, 0% 
7 La(OTf)3 103.2 0:81:2:17 0%, 70%, 24% 
a
 Unless otherwise specified, all reactions were carried out with 0.013 mmol of 176 and 
30 mol% of lanthanide triflate at 0.03 M in CH2Cl2/HFIP at 40 °C. 
b
 Product distribution 
of 176, 177, 178 was determined by crude 
1
H NMR analysis. Isolated yield determined 
using purified 176, 177, and 178. 
c
 Product distribution not determined. 
d
 Reaction 
yielded a mixture of 176, 177, 178, and 179. Yield% represents yields of products 177, 
178, 179, and 176 respectively. 
 
Scheme 2.15 Possible reactions of bis-allyloxyflavone ether 176.  
 
Spartan 11. Conformer distribution 
Semi-empirical, AM1 
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Based on the catalyst screening results, the double rearrangement was performed 
with Yb(OTf)3 in CH2Cl2 and HFIP (1,1,1,3,3,3-hexafluoroisopropanol) to yield the 
desired tetrahydroxyl core structure 177 in 50% yield (Scheme 2.16). In an attempt to 
install the prenyl group, cross-metathesis was performed directly on 177 to provide 
sanggenol F (1) in 65% yield. To purify the product 177 from chelating metal catalysts, a 
global silylation/cross metathesis/desilylation sequence was employed. In this sequence, 
the tetra-silyl protected sanggenol F was found to be very non-polar and could be easily 
separated from the metal catalyst via silica gel chromatography. Sanggenon A (2) was 
obtained after DDQ oxidation
94-96
 in 30% yield. In this linear route, sanggenol F (1) was 
synthesized in 7 steps and in 11% overall yield from morin (115). 
Scheme 2.16 Total synthesis of (±)-sanggenol F and (±)-sanggenon A. 
 
To demonstrate the advantage of the protecting group-free double rearrangement, 
the MOM-protected bis-allyloxyflavone ether 175 was also evaluated. Using Eu(fod)3
97
 
under microwave conditions resulted the desired double rearrangement and subsequent 
MOM group transfer to afford the sanggenol core 180 in 50% yield. However, 
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deprotection of the MOM groups under various acidic conditions afforded a mixture of 
regioisomers, so this route was not further pursued. In contrast, conditions used in 
Scheme 2.16 were mild enough to prevent the Wessley-Moser rearrangement, and are 
therefore compatible with the synthesis. 
Scheme 2.17 Double rearrangement of bis-allyloxyflavone ether 175. 
 
 
2.4. Asymmetric syntheses of sanggenol F and sanggenon A. 
 Enantioselective double rearrangement of bis-allyloxyflavone ethers. 2.4.1.
For the enantioselective double rearrangement of 176, various reaction conditions 
were examined. A preliminary survey showed that Sc(OTf)3/Ph-Pybox catalyst produced 
a mixture of double rearrangement product 177 (27% ee), 3-allyl rearrangement product 
178 (72% ee), and 5-allyl rearrangement product (5SR) 179 (Scheme 2.18). Two control 
experiments were performed in order to understand the large difference in ee between the 
single rearrangement product 178 and double rearrangement product 177 (Scheme 2.19). 
Firstly, the enantiomerically-enriched 3-allyl rearrangement product 178 (71% ee) was 
subjected to achiral rearrangement conditions. No significant decrease of ee was observed 
for the resultant double rearrangement product 177 (68% ee) or the recovered starting 
material 178 (71% ee) (Scheme 2.19a). In a second control experiment, the asymmetric 
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rearrangement of the 5-allyl rearrangement product 179 with Sc(OTf)3/Ph-Pybox showed 
poor enantioselectivity in producing 177 (16% ee). The presence of the extra 5-hydroxyl 
chelation site may result in a different arrangement of substrate/catalyst/ligand complex 
which may attribute to the observed poor enantioselectivity (Scheme 2.19b). 
Scheme 2.18 Enantioselective double rearrangement of 176. 
 
Scheme 2.19 The asymmetric rearrangements of substrates 178 and 179. 
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There are two possible pathways to access the double rearrangement product 177 
(Scheme 2.20), depending on whether the enantioselective 3-allyl rearrangement takes 
place prior (pathway a) or after (pathway b) the 5-allyl rearrangement. Our experiments 
suggest that pathway b may result in the production of 177 in low ee. Fortunately, it is 
possible to guide the reaction pathway through 178 and terminate the reaction at the 
single rearrangement stage by lowering the reaction temperature to room temperature and 
isolating the 3-allyl rearrangement product 178. Subsequent aromatic Claisen 
rearrangement of 178 afforded the sanggenol F core structure 177 in an overall moderate 
to highly enantioselective sequence. 
Scheme 2.20 Two possible pathways towards double rearrangement product 177. 
 
To optimize the enantioselective 3-allyl rearrangement, a series of lanthanide 
triflates were further screened in conjunction with (R)-Ph-PyBOX 143 (Table 2.4). 
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Unlike the strong correlation observed between the ionic radii and the ee observed in the 
previous model study (cf. Table 2.1), most catalysts showed low induction (< 10% ee), 
with the exception of Sc(OTf)3, which selectively catalyzed the desired 3-allyl 
rearrangement of 176 to afford rearranged product 178 in 67% yield and in 72% ee.  
Table 2.4 Lewis acid screen for the enantioselective 3-allyl rearrangement of bis-
allyloxyflavone ether 176. 
 
entry
a
 M(OTf)n 
ionic radii 
(pm) 
product distribution 
(177:178:176)
b
 
yield % of 178 ee% of 178
d
 
1 La(OTf)3 103.2 nd
c
 nd
c 
6% 
2 Bi(OTf)3 103.0 0:85:15 nd 4% 
3 Ce(OTf)3 101.0 100:0:0 nd 5% 
4 Pr(OTf)3 99.0 0:22:78 nd 0% 
5 Nd(OTf)3 98.3 6:94:0 nd 0% 
6 Eu(OTf)3 94.7 0:97:3 nd 0% 
7 Dy(OTf)3 91.2 31:69:0 nd 0% 
8 Ho(OTf)3 90.1 29:71:0 nd 6% 
9 Y(OTf)3 90.0 33:67:0 nd 0% 
10 Ce(OTf)4 87.0 100:0:0 nd 6% 
11 Yb(OTf)3 86.8 nd
c
 nd 0% 
12 In(OTf)3 80.0 0:87:13 nd 6% 
13 Sc(OTf)3 74.5 2:87:11:0
e 
67% 72% 
14 Zn(OTf)2 74.0 nd
c
 nd 0% 
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a
 Unless otherwise specified, all reactions were carried out with 0.013 mmol of 176 and 30 mol% 
of lanthanide triflate/143 complex at 0.03 M in CH2Cl2/HFIP at 40 °C. The reactions were 
complete in 12 h. 
b
 Product distribution of 176, 177, and 178 was determined by integration of 
UPLC trace (ELSD channel). 
c
 Not determined. 
 d
 ee determined on purified 178 by chiral 
HPLC analysis on a ChiraPak AD-H column. 
e
 Product distribution of  177:178:179:176. 
 
The 3-allyl rearrangement in the presence of Sc(OTf)3/143 complex was further 
investigated by varying other reaction parameters such as solvent, counterion and 
additives (Table 2.5). In the case of reactions in nonpolar solvents (entries 3-6 and 8), 
HFIP (polar, non-coordinating)
98-101
 was used as co-solvent to solubilize the polar starting 
material. Polar solvents such as dioxane/H2O mixture and CH3CN
102
 (entries 1, 2) 
resulted in the production of chiral, racemic product, while non-polar solvents such as 
toluene, benzene, ether, and CH2Cl2 (entries 4, 5, 6 and 8) with various portions of HFIP 
provided the rearrangement product in high enantioselectivity. It is precedented that in 
the Diels-Alder cycloaddition catalyzed by Cu(OTf)2/Box complex with AgSbF6 as 
additive resulted in higher asymmetric induction.
103
 However in our case, 
Sc(OTf)3/PyBox with various equivalents of AgSbF6 did not improve the ee (Table 2.6, 
entries 1-3). Other additives such as LiClO4,
104
 pyruvic acid, and benzoic acid
105
 (entries 
5-7) showed no beneficial results in terms of the enantioselectivity of the rearrangement. 
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Table 2.5 Solvent screen for the enantioselective 3-allyl rearrangement of bis-
allyloxyflavone ether 176. 
 
entry
a
 solvent temp. 
product distribution 
(177:178:179:176)
b
 
ee% of 178
c
 
1 Dioxane/H2O = 9:1 40°C nd
d 
0 
2 CH3CN 50°C nd 0 
3 PhCF3/HFIP = 5:1 40°C 6:72:21:0 31% 
4 PhMe/HFIP = 3:1 40°C 5:71:19:0 47% 
5 PhH/HFIP = 2:1 40°C 7:76:17:0 51% 
6 Et2O/HFIP = 1:1 40°C 5:77:18:0 68% 
7 THF 40°C 0:22:12:66 40% 
8 CH2Cl2/HFIP = 5:1 40°C 2:87:11:0 72% 
a
 Unless otherwise specified, all reactions were carried out with 0.013 mmol of 176 and 
30 mol% of Sc(OTf)3/(R)-Ph-PyBox complex at 0.03 M in various solvents at 40 °C. 
The reactions were complete in 12 h. 
b
 Product distribution of 176, 177, 178, and 179 
was determined by integration of UPLC trace (ELSD channel). 
c
 ee determined on 
purified 178 by chiral HPLC analysis on a ChiraPak AD-H column. 
d
 Not determined. 
 
Table 2.6 Counterion and additive screen for the enantioselective 3-allyl 
rearrangement of bis-allyloxyflavone ether 176. 
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entry
a
 additive temp. ee% of 143
f
 
1
b
 AgSbF6 40°C 51% 
2
c
 AgSbF6 40°C 48% 
3
d
 AgSbF6 40°C 58% 
4 ---- 40°C 72% 
5
e
 LiClO4 40°C 60% 
6
e
 Pyruvic Acid 40°C -5% 
7
e
 Benzoic Acid 40°C 24% 
a
 Unless otherwise specified, all reactions were carried out 
with 0.013 mmol of 176 and 30 mol% of Sc(OTf)3/(R)-Ph-
PyBox complex at 0.03 M in CH2Cl2/HFIP at 40 °C. The 
reactions were complete in 12 h. 
b
 30 mol% AgSbF6 was 
used. 
c
 60 mol% AgSbF6 was used. 
d
 90 mol% AgSbF6 was 
used. 
e
 2.0 equiv of additive was used. 
f 
ee determined on 
purified 178 by chiral HPLC analysis on a ChiraPak AD-H 
column. 
 
With the optimized reaction parameters, the effect of different bisoxazoline-based 
ligands was surveyed.
106-108
 A number of non-commercially available PyBox ligands 
were synthesized from pyridinedicarbonitrile 181
109
 by varying the optically-active 
amino alcohol coupling partners (Scheme 2.21). 
Scheme 2.21 Two-step synthesis of PyBox ligands. 
 
As summarized in Scheme 2.22, PyBox ligands generally resulted in higher 
enantioselectivities than Box ligands, which gave no enantioselectivity in the two cases 
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examined. This may be because tridentate PyBox ligands provide a relatively bigger 
binding pocket for metals such as scandium, ytterbium, and lanthanum. Bulky 4-
substitutions on the PyBox ligands are necessary for asymmetric induction. In particular 
PyBox ligands with 4-phenyl substitutions (173, 183a,b) delivered the desired 3-allyl 
rearrangement product 178 in highest enantioselectivites (72% ee, 68% ee, and 57% ee 
respectively). -Stacking interactions between the 4-phenyl group and the flavone 
substrate may result in a highly organized and effective transition state, and may explain 
the observed moderate to high asymmetric induction. Consistent with the previous 
observation (cf. Scheme 2.18), in the present study, the ee of the double rearrangement 
byproduct is lower than that of the 3-allyl rearrangement product for all the catalysts 
screened. 
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Scheme 2.22 Ligand screen for the enantioselective 3-allyl rearrangement of bis-
allyloxyflavone ether 176. 
 
 Asymmetric syntheses of sanggenol F and sanggenon A. 2.4.2.
The asymmetric syntheses of sanggenol F and sanggenon A were completed 
utilizing Sc(OTf)3 and (R,R)-diPh-PyBox 183a complex. Bis-allyloxyflavone ether 142 
rearranged with 30 mol% of the complex at room temperature to yield a 4:1 mixture of 
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the single rearrangement products 143 and 145. The mixture was separated and 143 
further rearranged using Yb(OTf)3 to afford double rearrangement product 144 in 75% 
yield and 74% e.e as determined by chiral HPLC analysis. The product was then 
subjected to the silylation/cross-metathesis/desilylation sequence to provide sanggenol F 
(1) in 82% yield. The optical rotation of synthetic sanggenol F (1) was determined to be 
−45° (c = 0.1, MeOH). Comparing to the reported data of +82° (c = 0.135, MeOH) for 
(+)-sanggenol F (1),
17
 synthetic sanggenol F (1) derived using (R,R)-diPh-
PyBox/Sc(OTf)3 was determined to be the (2S,3R)-enantiomer. 
Scheme 2.23 Asymmetric synthesis of sanggenol F. 
 
 
2.5. Conclusion 
In summary, an efficient approach to the hydrobenzofuro[3,2-b]chromenone core 
of sanggenon-type natural products has been developed. The key transformation involves 
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a protecting group-free double rearrangement of a bis-allyloxyflavone ether substrate. A 
sequence involving asymmetric 3-allyl rearrangement followed by aromatic Claisen 
rearrangement has been established for the asymmetric synthesis of the 
hydrobenzofuro[3,2-b]chromenone core structure. This methodology has been 
successfully applied to asymmetric syntheses of both sanggenol F and sanggenon A. The 
mechanism of the Lewis acid-catalyzed rearrangement of the model allyloxyflavone ether 
was studied by fluorescence and 
13
C NMR, and shown to likely involve a benzopyrylium 
intermediate. 
2.6. Experimental section 
General Information 
1
H NMR spectra were recorded on a 400 MHz or 500 MHz spectrometer at ambient 
temperature with CDCl3 as the solvent or otherwise stated. 
13
C NMR spectra were 
recorded on a 100 MHz or 125 MHz spectrometer at ambient temperature with complete 
proton decoupling using CDCl3 as the solvent or otherwise stated. Chemical shifts for 
characterized compounds are reported in parts per million relative to CDCl3 (
1H, δ 7.26; 
13C, δ 77.0). Data for 1H NMR are reported as follows: chemical shift, multiplicity (app = 
apparent, par obsc = partially obscure, br = broad, ovrlp = overlapping, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet), coupling constants and integration. 
Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR spectrophotometer. Optical 
rotations were recorded on an AUTOPOL III digital polarimeter at 589 nm and are 
recorded as [α]D (concentration in grams/100 mL solvent). Enantiomeric ratio values 
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were determined by chiral HPLC analysis performed on a Waters Breeze high pressure 
liquid chromatography (HPLC) instrument equipped with a quaternary pump using a 
Daicel Chemical Ind. ChiralPak AD-H or ChiralCel OD-H column (15 cm × 4.6 mm) 
with UV detection monitored at 254 nm or 214 nm. High-resolution mass spectra were 
obtained in the Boston University Mass Spectrometry Laboratory using a Finnegan 
MAT-90 or a Waters Q-TOF mass spectrometer. Analytical thin layer chromatography 
was performed on 0.25 mm silica gel 60-F plates. Visualization was accomplished with 
UV light and aqueous ceric ammonium molybdate solution or basic aqueous potassium 
permanganate solution. Flash chromatography was performed using 200-400 mesh silica 
gel (Scientific Absorbents, Inc.). Yields refer to chromatographically and 
spectroscopically pure materials, unless otherwise stated. All reactions were performed in 
flame-dried glassware under an argon atmosphere unless otherwise noted. 
General procedure I for allylation of 3-hydroxyflavones. 
 
3-Allyloxy-5-MeO-flavone ether 142. To a solution of 5-methyoxy-3-
hydroxyflavone (500 mg, 1.86 mmol, 1.0 equiv) in dry acetone (30 mL) 
was slowly added allyl bromide (0.26 mL, 2.80 mmol, 1.5 equiv) and K2CO3 (277 mg, 
2.80 mmol, 1.5 equiv), the reaction was refluxed at 65°C overnight. The mixture was 
cooled to room temperature and filtered through a plug of Celite® and concentrated in 
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vacuo. The crude mixture was purified by silica gel chromatography (15% ethyl acetate 
in hexanes) to afford 142 as a yellow oil (545 mg, 95%). 
Rf: 0.36 (hexanes : ethyl acetate = 3:2). 
1
H NMR (400 MHz, CDCl3) δ 8.13–8.07 (m, 2H), 
7.55 (t, J = 8.4 Hz, 1H), 7.52–7.46 (m, 3H), 7.09 (dd, J = 8.5, 0.9 Hz, 1H), 6.79 (dd, J = 
8.4, 0.9 Hz, 1H), 5.97 (ddt, J = 17.2, 10.4, 6.1 Hz, 1H), 5.28 (dq, J = 17.2, 1.6 Hz, 1H), 
5.14 (ddt, J = 10.3, 1.7, 1.1 Hz, 1H), 4.62 (dt, J = 6.1, 1.3 Hz, 2H), 4.01 (s, 3H). 
13
C 
NMR (75 MHz,CDCl3) δ 174.8, 159.9, 157.3, 153.5, 140.5, 133.8, 133.5, 133.5, 130.9, 
130.4, 128.5, 128.4, 128.3, 118.3, 114.7, 110.0, 105.6, 105.0, 73.1, 56.4. IR max (film): 
3329, 3076, 3004, 2963, 2923, 2851, 1684, 1641, 1618, 1602, 1577, 1476, 1446, 1395, 
1329, 1262, 1231, 1201, 1149, 1101, 1080, 1032, 998, 975, 928, 879, 808, 757 cm
-1
. 
HRMS-ESI (m/z): [M + H]
+
 calculated C19H17O4 309.1127, found 309.1115. 
General procedure II for the asymmetric rearrangement of 3-allyloxyflavone ethers: 
To a suspension of 4Å molecular sieves (30 mg, flame-dried under high 
vacuum) in a sealed tube was added via cannula, a pre-stirred solution of 
La(OTf)3 (17.1 mg, 0.03 mmol, 0.30 equiv) and (R)-Ph-PyBox (11.9 mg, 
0.03 mmol, 0.33 equiv) in CH2Cl2 (1.0 mL). After stirring the 
suspension at room temperature for 0.5 h, a solution of allyloxyflavone 142 (30 mg, 0.10 
mmol, 1.0 equiv) in CH2Cl2 (0.5 mL) was slowly added via cannula. The mixture was 
allowed to stir at 35 °C overnight. After removal of the molecular sieves by filtration of 
the crude mixture through a pad of Celite®, the solvent was evaporated in vacuo. The 
residue was then purified by silica gel chromatography, or used as a crude mixture in the 
next condensation or deprotection step. 
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The crude mixture was dissolved in CH2Cl2 and 1,2-phenylenediamine (26 mg, 0.24 
mmol, 2.5 equiv) was added in one portion. After stirring at room temperature for 3h, the 
crude was concentrated in vacuo and purified by silica gel chromatography (5% ethyl 
acetate in hexanes) to yield 146 as a while solid (27.0 mg, 73%). 
Rf: 0.97 (hexanes : ethyl acetate = 1:1). m.p. = 173-175 °C (hexanes). 
1
H NMR (500 
MHz, CDCl3) δ 8.22 – 8.12 (m, 2H), 7.80 – 7.68 (m, 2H), 7.35 – 7.30 (m, 2H), 7.20 – 
7.09 (m, 4H), 6.90 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 5.96 (ddt, J = 17.2, 10.3, 
6.9 Hz, 1H), 5.18 (dd, J = 17.1, 1.6 Hz, 1H), 5.06 (dd, J = 10.3, 2.0 Hz, 1H), 3.92 (s, 3H), 
3.56 (dd, J = 14.7, 6.7 Hz, 1H), 3.35 – 3.12 (m, 1H). 13C NMR (125 MHz,CDCl3) 159.5, 
157.7, 151.4, 144.2, 141.8, 141.2, 140.1, 133.3, 132.5, 129.7, 129.5, 129.1, 129.1, 127.8, 
127.3, 126.2, 118.4, 111.6, 111.4, 106.0, 85.0, 56.3, 45.5. IR max (film): 3067, 3013, 
2954, 2928, 2842, 1724, 1602, 1587, 1555, 1489, 1447, 1437, 1395, 1353, 1279, 1254, 
1102, 1081, 1028, 921, 788, 762, 715 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated 
C25H21O2N2 381.1603, found 381.1599. 
Chiral HPLC analysis for quinoxaline 146.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
146: ChiralPak AD 150 × 4.6 mm column, 5% isopropanol in hexane. Flow rate: 1.0 
mL/min. UV detector: 214 nm. Retention time: 3.3 min and 4.0 min. 
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Racemic: 
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Prepared using La(OTf)3/(R)-Ph-PyBox: 90% ee 
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Prepared using Sc(OTf)3/(R)-Ph-PyBox: 96% ee 
 
 
3-Allyloxy-2-MeO-flavone ether 151e. According to General 
procedure I, 151e was synthesized from 3-hydroxy-2-methoxyflavone 
(121 mg, 0.34 mmol, 1.0 equiv) and allyl bromide (57 µL, 0.50 mmol, 
1.5 equiv) to yield 151e as a white solid (121 mg, 97%) 
Rf: 0.71 (hexanes : ethyl acetate = 3:2). m.p. = 73-75 °C (CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3) δ 8.29 (ddd, J = 8.0, 1.7, 0.5 Hz, 1H), 7.65 (ddd, J = 8.7, 7.1, 1.7 Hz, 1H), 7.53 – 
7.43 (m, 3H), 7.40 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.07 (td, J = 7.5, 1.0 Hz, 1H), 7.03 (dd, 
J = 8.3, 0.9 Hz, 1H), 5.79 (ddt, J = 17.2, 10.3, 5.9 Hz, 1H), 5.12 (dq, J = 17.2, 1.6 Hz, 
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1H), 5.05 (ddt, J = 10.4, 1.7, 1.2 Hz, 1H), 4.58 (dt, J = 5.9, 1.4 Hz, 2H), 3.84 (s, 3H). 
13
C 
NMR (75 MHz,CDCl3) δ 174.9, 157.4, 156.4, 155.8, 140.6, 133.9, 133.1, 131.8, 130.9, 
125.8, 124.6, 124.4, 120.3, 120.3, 118.2, 117.6, 111.3, 73.3, 55.7. IR max (film): 3074, 
3013, 2940, 2838, 1640, 1619, 1582, 1570, 1491, 1466, 1435, 1396, 1342, 1278, 1256, 
1233, 1198, 1146, 1110, 1048, 1024, 994, 931, 903, 754 cm
-1
. HRMS-ESI (m/z): [M + 
H]
+
 calculated C19H17O4 309.1127, found 309.1121. 
According to General procedure II, 153e was obtained from treatment 
of 3-allyloxy-2′-MeO-flavone ether 151e (20 mg, 0.06 mmol, 1.0 equiv) 
with Sc(OTf)3 (9.4 mg, 0.02 mmol 0.30 equiv) and (R)-Ph-PyBox (7.7 
mg, 0.02 mmol, 0.33 equiv) catalyst system as a white solid (20 mg, 82%).  
Rf: 0.93 (hexanes : ethyl acetate = 3:2). m.p. = 45-47 °C (CH2Cl2). 
1
H NMR (500 MHz, 
CDCl3) δ 8.41 (dd, J = 7.8, 1.3 Hz, 1H), 8.08 (ddd, J = 8.4, 1.5, 0.6 Hz, 1H), 7.92 (ddd, J 
= 8.3, 1.5, 0.6 Hz, 1H), 7.68 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.60 (ddd, J = 8.3, 6.9, 1.4 
Hz, 1H), 7.35 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 7.27 (ddd, J = 8.1, 7.4, 1.7 Hz, 1H), 7.07 
(ddd, J = 7.8, 7.2, 1.1 Hz, 1H), 6.99 – 6.92 (m, 3H), 6.80 (dd, J = 8.2, 1.1 Hz, 1H), 5.97 – 
5.83 (m, 1H), 5.03 (ddt, J = 17.1, 2.0, 1.4 Hz, 1H), 4.93 (ddt, J = 10.2, 2.1, 1.1 Hz, 1H), 
3.55 – 3.41 (m, 2H), 3.32 (s, 3H). 13C NMR (125 MHz,CDCl3) δ 157.8, 156.6, 153.1, 
143.8, 141.7, 141.7, 132.5, 132.5, 131.6, 129.7, 129.5, 129.1, 128.9, 128.6, 127.4, 125.1, 
121.4, 120.0, 119.1, 117.2, 112.4, 84.4, 55.5, 43.9. IR max (film): 3071, 2936, 2837, 
1604, 1588, 1555, 1492, 1460, 1436, 1394, 1359, 1320, 1249, 1228, 1110, 1029, 921, 768, 
752 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated C25H21O2N2 381.1603, found 381.1600. 
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3-Allyloxy-2-MOM-flavone ether 151d. According to General 
procedure I, 151d was obtained from 2′-MOM-3-hydroxyflavone110 
(145 mg, 0.49 mmol, 1.0 equiv) and allyl bromide (70 µL, 0.73 mmol, 
1.5 equiv) to afford 151d as yellow solid (163 mg, 99%).  
Rf: 0.54 (hexanes : ethyl acetate = 3:2). m.p. = 50-52 °C (hexanes). 
1
H NMR (500 MHz, 
CDCl3)8.30 (dd, J = 8.2, 1.3 Hz, 1H),  (ddd, J = 8.7, 7.0, 1.7 Hz, 1H), 7.49-7.44 
(m, 3H), 7.41 (dd, J = 8.1, 8.1 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 7.13 (ddd, J = 7.5, 7.5, 
1.0 Hz, 1H), 5.81-5.71 (m, 1H), 5.19 (s, 2H), 5.11 (ddd, J = 17.2, 3.1, 1.6 Hz, 1H), 5.04 
(ddd, J = 10.3, 2.7, 1.1 Hz, 1H), 4.54 (ddd, J = 6.0, 1.3, 1.3 Hz, 2H), 3.45 (s, 3H).
 13
C 
NMR (100 MHz, CDCl3) 174.9, 156.6, 155.7, 155.2, 140.6, 133.8, 133.3, 131.8, 131.0, 
125.9, 124.6, 121.5, 121.5, 121.2, 118.1, 117.9, 115.1, 94.7, 73.4, 56.2. IR max (film): 
3010, 2970, 2947, 2842, 1677, 1604, 1579, 1465, 1423, 1298, 1264, 1214, 1161, 1117, 
1028, 834, 769 cm
-1
. HRMS-ESI (m/z): [M + Na]
+
 calculated for C20H18O5Na 361.1052, 
found 361.1032.
 
3-Allyloxy-2-hydroxyflavone ether 151b. To a solution of 151d
 
(838 
mg, 2.48 mmol, 1.0 equiv) in dichloromethane (20 mL) was added p-
toluenesulfonic acid (707 mg, 3.72 mmol, 1.5 equiv) in one portion. 
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The reaction was stirred at room temperature for 2 h and was quenched with water. The 
mixture was extracted with dichloromethane and the organic layers were combined and 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture was 
purified by silica gel chromatography (10% ethyl acetate in hexanes) to afford 151b as a 
colorless solid (625 mg, 86%).  
Rf: 0.23 (hexanes : ethyl acetate = 4:1). m.p. = 123-125 °C (hexanes). 
1
H NMR (400 
MHz, CDCl3) 8.27 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.71 (m, 2H), 7.54 (d, J = 8.4 Hz, 
1H), 7.48 (t, J = 8.4 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 7.9 Hz, 2H), 5.84-5.74 
(m, 1H), 5.21 (d, J = 17.1 Hz, 1H), 5.16 (d, J = 10.3 Hz, 1H), 4.64 (d, J = 6.6 Hz, 2H). 
13
C NMR (100 MHz, CDCl3)  174.0, 156.0, 155.9, 155.4, 137.7, 133.9, 133.1, 131.7, 
129.5, 125.9, 125.0, 123.9, 120.9, 120.8, 119.8, 119.1, 118.2, 75.3. IR max (film): 3261, 
3085, 3010, 2925, 2854, 1610, 1562, 1467, 1455, 1399, 1346, 1293, 1253, 1195, 1147, 
1112, 1040, 994, 905, 755 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C18H15O4 
295.0970, found 295.0980. 
3-Allyloxy-2-TES-flavone ether 151c. To a solution of 151b
 
(200 mg, 
0.70 mmol, 1.0 equiv) in DMF at 0 °C was slowly added 
triethylchlorosilane (130 µL, 0.77 mmol, 1.1 equiv) and imidazole 
(104.8 mg, 1.54 mmol, 2.2 equiv) in one portion. The reaction was warmed to room 
temperature and after 12 h was quenched with water. The mixture was extracted with 
diethyl ether and the organic layer was combined, washed with brine, dried over Na2SO4, 
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and concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(5% ethyl acetate in hexanes) to afford compound 151c as a yellowish oil (136 mg, 48%).  
Rf: 0.60 (hexanes : ethyl acetate = 4:1). 
1
H NMR (400 MHz, CDCl3) 8.29 (d, J = 8.0 Hz, 
1H), 7.65 (t, J = 7.1 Hz, 1H), 7.46-7.36 (m, 4H), 7.05 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 8.2 
Hz, 1H), 5.85-5.75 (m, 1H), 5.14 (d, J = 16.3 Hz, 1H), 5.05 (d, J = 10.4 Hz, 1H), 4.55 (d, 
J = 6.0 Hz, 2H), 0.86 (t, J = 7.6 Hz, 9H), 0.67 (q, J = 7.8 Hz, 6H). 
13
C NMR (100 MHz, 
CDCl3)  175.0, 157.4, 155.6, 153.8, 140.5, 133.8, 133.2, 131.6, 131.3, 125.9, 124.4, 
122.7, 120.6, 119.3, 117.9, 117.9, 73.4, 6.5, 5.1. IR max (film): 3067, 3032, 2978, 2879, 
1742, 1642, 1609, 1488, 1466, 1451, 1397, 1279, 1231, 1200, 1148, 1111, 996, 903, 756 
cm
-1
.  
(Cis-5a,10a)-5a-allyl-10a-hydroxy-5aH-benzofuro[3,2-b]chromen-
11(10aH)-one 154. According to General procedure II, 3-allyloxy-2-
hydroxyflavone ether 151b (18 mg, 0.06 mmol, 1.0 equiv) was treated 
with Sc(OTf)3 (9.0 mg, 0.02 mmol, 0.30 equiv) and (R)-Ph-PyBox (7.5 mg, 0.02 mmol, 
0.33 equiv) catalyst system to yield a residue which was purified by flash column 
chromatography on silica gel (10% ethyl acetate in hexanes) to afford 154 as a colorless 
solid (5.4 mg, 30%).  
In the case of 3-allyloxy-2-TES-flavone ether 151c (5.1 mg, 0.01 mmol, 1.0 equiv), the 
residue was dissolved in THF (0.5 mL) and HF∙pyridine (50 µL, 0.12 mmol, 12.0 equiv) 
was added at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h before warming to 
room temperature and was quenched with H2O. The mixture was extracted with ethyl 
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acetate, and the organic layer was combined and washed with brine, dried over Na2SO4, 
and concentrated in vacuo. The residue was purified by silica gel chromatography to 
afford 154 as colorless solid (3.3 mg, 93%). 
Rf: 0.57 (hexanes : ethyl acetate = 4:1). m.p. = 103-105 °C (hexanes). 
1
H NMR (400 
MHz, CDCl3) 7.88 (dd, J = 7.9, 1.5 Hz, 1H), 7.51-7.46 (m, 2H), 7.32 (dt, J = 7.6, 1.4 
Hz, 1H), 7.08 (dt, J = 7.5, 0.9 Hz, 1H), 7.01 (dt, J = 7.1, 1.0 Hz, 1H), 6.95 (d, J = 8.1 Hz, 
1H), 6.87 (d, J = 8.5 Hz, 1H), 5.88-5.77 (m, 1H), 5.27 (s, 1H), 5.23 (d, J = 17.0 Hz, 1H), 
5.05 (d, J = 10.1 Hz, 1H), 3.14 (dd, J = 14.4, 7.6 Hz, 1H), 2.99 (d, J = 14.4, 6.8 Hz, 1H). 
13
C NMR (100 MHz, CDCl3)  185.6, 161.7, 158.7, 137.6, 131.2, 131.0, 128.6, 127.6, 
124.0, 122.4, 121.6, 120.6, 118.2, 116.2, 111.5, 100.9, 90.3, 36.8. IR max (film): 3440, 
2922, 2850, 1755, 1689, 1606, 1579, 1477, 1463, 1431, 1328, 1273, 1228, 1187, 1146, 
1088, 1006, 919, 802, 747 cm
-1
. HRMS-ESI (m/z): [M-H2O] calculated for C18H12O3 
277.0865, found 277.0866. 
HPLC analysis for compound 154.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
154: ChiralPak AD 150 × 4.6 mm column, 10% isopropanol in hexane. Flow rate: 1.0 
mL/min. UV detector: 214 nm. Retention time: 8.5 min and 14.0 min. 
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Racemic:  
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Prepared using 3-Allyloxy-2-TESflavone ether 151c: 98% ee 
 
 
(Cis-5a,10a)-10a-hydroxy-5a-(3-methylbut-2-enyl)-5aH-
benzofuro[3,2-b]chromen-11(10aH)-one 154b. To a solution of 154 
(20 mg, 0.068 mmol, 1.0 equiv) in CH2Cl2 in a flame-dried seal tube 
was added 2-methyl-2-butene (1.5 mL) and 2nd generation Grubbs catalyst (2.9 mg, 
0.003 mmol, 0.05 equiv). The reaction was stirred at 40 °C. After 12 h, the reaction 
mixture was cooled to room temperature and concentrated in vacuo, and followed by 
purification by silica gel chromatography (10% ethyl acetate in hexanes) to afford 154b 
as a colorless solid (20.5 mg, 94%). 
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Rf: 0.64 (hexanes : ethyl acetate = 3:2). m.p. = 103-105 °C (hexanes). 
1
H NMR (400 
MHz, CDCl3) 7.88 (d, J = 8.0 Hz, 1H), 7.51-7.45 (m, 2H), 7.32(t, J = 7.8 Hz, 1H), 7.08 
(t, J = 7.6 Hz, 1H), 6.99 (t, J = 7.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.84 (d, J = 8.4 Hz, 
1H), 5.24 (s, 1H), 5.13 (t, J = 6.8 Hz, 1H), 3.16 (dd, J = 14.7, 8.2 Hz, 1H), 2.84 (dd, J = 
14.7, 6.8 Hz, 1H), 1.60 (s, 3H), 1.45 (s, 3H). 
13
C NMR (100MHz,CDCl3) 185.7, 162.0, 
158.9, 137.4, 137.1, 131.0, 128.9, 127.5, 123.9, 122.3, 121.3, 117.8, 116.9, 116.1, 111.5, 
100.8, 91.4, 31.0, 25.6, 18.1. IR max (film): 2985, 2933, 1692, 1607, 1464, 1333, 1273, 
1234, 1200, 1037, 956, 925, 756 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated C20H19O4 
323.1283, found 323.1292. 
3-Methoxyflavone 166. To a solution of 3-hydroxyflavone (150 mg, 0.06 
mmol) in dry acetone (6 mL) was added dimethyl sulfate (0.10 mL, 0.09 
mmol) and K2CO3 (131 mg, 0.09 mmol), and the reaction mixture was 
refluxed overnight. The reaction mixture was then cooled to room temperature and 
filtered through a pad of Celite®. The solvent was removed in vacuo and the crude 
product was purified by column chromatography on silica gel (5% ethyl acetate in 
hexanes) to afford 166 as a yellow oil.  
Rf: 0.87 (hexanes : ethyl acetate = 3:2). 
1
H NMR (400 MHz, CD2Cl2) δ 8.21 (d, J = 8.1 
Hz, 1H), 8.13−8.07 (m, 2H), 7.70 (dd, J = 8.6, 1.5 Hz, 1H), 7.59-7.50 (m, 4H), 7.41 (dd, 
J = 7.8 Hz, 1H), 3.89 (s, 3H). 
13
C (400 MHz, CD2Cl2) δ 175.3, 156.0, 155.8, 142.0, 134.0, 
131.6, 131.2, 129.0, 129.0, 126.0, 125.2, 124.8, 118.6, 60.4. IRmax (film): 1640, 1614, 
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1467, 1383, 1213, 1147, 897, 759 cm
-1
. HRMS (ESI+) m/z calculated for C16H13O3 
253.0865 found 253.0857 (M+H). 
4-TBS-3-methoxy-2-phenylchromenylium triflate salt 164: To a 
solution of 3-methoxyflavone 164 (10.0 mg, 0.04 mmol) in CD2Cl2 (1.0 
mL) was added TBSOTf (9.6 μL, 0.04 mmol). The reaction mixture was 
stirred at 40 °C for 0.5 h. The crude mixture was directly used for 
13
C NMR and 
UV/fluorescence studies without further purification. 
1
H NMR (500 MHz, CD2Cl2) δ 
8.38 (dd, J = 8.2, 1.6 Hz, 1H), 8.25 (d, J = 7.1 Hz, 2H), 7.95 (dd, J = 7.5 Hz, 1H), 7.82 
(d, J = 8.4 Hz, 1H), 7.69-7.59 (m, 4H), 3.86 (s, 3H), 1.00, 0.88 (s, 9H), 0.46, 0.03 (s, 6H). 
13
C (500 MHz, CD2Cl2) δ 174.8, 162.0, 156.3, 140.9, 136.7, 133.5, 130.0, 129.8, 127.4, 
126.1, 121.5, 119.1, 61.7, 26.0, 18.6, -2.7. IRmax (film): 3452(br), 1736, 1245, 1186, 1029, 
640 cm
-1
.  
3-Methoxyflavone, scandium triflate complex 165. To a suspension of 
molecular sieves (4Å, 10.0 mg, flame-dried under high vacuum) was 
subsequently added CD2Cl2 (1.0 mL), 3-methoxyflavone 164 (10.0 mg, 
0.04 mmol) and scandium triflate (9.8 mg, 0.02 mmol). The mixture was stirred at room 
temperature for 0.5 h and was filtered through a pad of Celite® to remove undissolved 
solid. The clear solution was used for 
13
C NMR and UV/fluorescence studies without 
further purification.
 1
H NMR (400 MHz, CD2Cl2) δ 8.58 (br, 1H), 8.19 (d, J = 6.4 Hz, 
2H), 7.99 (dd, J = 7.7 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.69 (dd, J = 6.8 Hz, 1H), 7.61 
(dd, J = 7.6Hz, 3H), 3.79 (s, 3H). 
13
C NMR (400 MHz, CD2Cl2) δ 177.6, 165.0, 157.2, 
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142.2, 137.9, 134.3, 130.0, 129.3, 128.1, 124.0, 120.3, 119.2, 62.5, −4.5. IRmax (film): 
3284(br), 1601, 1245, 1166, 1035, 757, 643 cm
-1
.  
 
5-Hydroxy-3,7,2′,4′-tetra-MOM morin 172. To a solution 
of morin (5.0 g, 16.5 mmol, 1.0 equiv) in dichloromethane 
(80 mL) was slowly added at 0 °C N,N-
diisopropylethylamine (7.6 mL, 99.0 mmol, 6.0 equiv), and chloromethyl methyl ether 
(17.3 mL, 99.0 mmol, 6.0 equiv). The reaction was warmed to room temperature and 
stirred overnight. The mixture was neutralized with 1N aqueous HCl solution and 
extracted with ethyl acetate three times, the organic layer was combined, and washed 
with brine, dried over Na2SO4 and concentrated in vacuo. The crude mixture was purified 
by silica gel chromatography (10% ethyl acetate in hexanes) to afford 172 as a yellow oil 
(8.65 g, 55%).  
Rf: 0.54 (hexanes : ethyl acetate = 3:2). 
1
H NMR (500 MHz, CDCl3) 12.56 (s, 1H), 7.42 
(d, J = 8.5 Hz, 1H), 6.94 (d, J = 2.3 Hz, 1 H), 6.81 (dd, J = 8.5, 2.3 Hz, 1H), 6.53 (d, J = 
2.2 Hz, 1H), 6.47 (d, J = 2.2 Hz, 1H), 5.22 (s, 2H), 5.21 (s, 2H), 5.19 (s, 2H), 5.01 (s, 2H), 
3.50 (s, 3H), 3.47 (s, 6H), 2.98 (s, 3H).
 13
C NMR (125 MHz, CDCl3)  178.6, 162.9, 
162.0, 160.3, 157.6, 157.3, 156.6, 136.7, 132.0, 114.3, 108.7, 107.0, 103.6, 99.5, 97.5, 
94.6, 94.3, 94.2, 94.2, 56.6, 56.3, 56.2, 56.2. IR max (film): 2958, 2907, 2829, 1656, 
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1597, 1496, 1451, 1409, 1344, 1308, 1245, 1220, 1150, 1074, 1012, 970, 922, 872, 813, 
753, 720 cm
-1
. HRMS-ESI (m/z): [M + Na]
+
 calculated for C23H26O11Na 501.1373 found 
501.1384. 
5-Allyloxy-3,7,2′,4′-tetra-MOM morin 173. To a solution 
of 172 (8.65 g, 18.1 mmol, 1.0 equiv) in DMF (80 mL) was 
slowly added allyl bromide (1.88 mL, 21.7 mmol, 1.2 equiv) 
and Cs2CO3 (7.07 g, 21.7 mmol, 1.2 equiv). The reaction was heated at 60 °C overnight. 
The mixture was cooled to room temperature and neutralized with 1N aqueous HCl 
solution and extracted with diethyl ether three times. The organic layer was combined 
and washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture 
was recrystalized in methanol to afford 173 as a white solid (8.76 g, 93%).  
Rf: 0.20 (hexanes : ethyl acetate = 3:2). m.p. = 72-74 °C, (MeOH).
1
H NMR (500 MHz, 
CDCl3) 7.43 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.78 (dd, J = 8.6, 2.4 Hz, 1H), 
6.62 (d, J = 2.1 Hz, 1H), 6.44 (d, J = 2.3 Hz, 1H), 6.15-6.07 (m, 1H), 5.68 (ddd, J = 17.2, 
3.2, 1.7Hz, 1H), 5.35 (ddd, J = 10.5, 3.1, 1.5 Hz, 1H), 5.20 (s, 2H), 5.19(s, 2H), 5.17 (s, 
2H), 5.03 (s, 2H), 4.69 (ddd, J = 4.9, 1.7, 1.7 Hz, 2H), 3.48 (s, 3H), 3.47 (s, 3H), 3.46 (s, 
3H), 2.93 (s, 3H).
 13
C NMR (100 MHz, CDCl3) 173.5, 161.1, 160.0, 159.9, 159.1, 156.5, 
154.2, 138.8, 132.2, 132.0, 118.0, 114.9, 110.7, 108.6, 103.7, 97.9, 97.4, 95.7, 94.7, 94.4, 
94.3, 69.9, 56.4, 56.2, 56.2, 56.2. IR max (film): 3001, 2960, 2906, 2827, 1635, 1609, 
1575, 1504, 1486, 1433, 1409, 1344, 1312, 1266, 1219, 1150, 1076, 985, 937, 921, 867, 
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827, 752, 709 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C26H31O11 519.1866, 
found 519.1859. 
 
3-Hydroxy-5-allyloxy-7,2′,4′-tri-MOM morin 174. To a solution of 173 (1.375 g, 2.65 
mmol, 1.0 equiv) in methanol (100 mL) was added NaI (397 mg, 2.65 mmol, 1.0 equiv), 
and 1N aqueous HCl (265 µL, 0.27 mmol, 0.1 equiv) and the reaction was heated to 
40 °C and stirred for 18h. The mixture was added H2O and extracted with ethyl acetate 
three times. The organic layers were combined and washed with brine, dried over Na2SO4, 
and concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(10% ethyl acetate in hexanes) to afford 174 as a yellowish solid. 
 3,5-Bisallyloxy-7,2′,4′-triMOM morin 175. To a solution 
of 174 (1.26 g, 2.65 mmol, 1.0 equiv) in DMF (12 mL) was 
slowly added allyl bromide (459 µL, 5.30 mmol, 2.0 equiv), 
and Cs2CO3 (1.73 g, 5.30 mmol, 2.0 equiv), the reaction was heated to 60 °C and stirred 
overnight. The mixture was cooled to room temperature and then neutralized with 1N 
aqueous HCl solution and extracted with diethyl ether three times, the organic layers 
were combined and washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The mixture was then purified by silica gel chromatography (20% ethyl acetate in 
hexanes) to afford 175 as light yellow oil (571 mg, 43%).  
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Rf: 0.20 (hexanes : ethyl acetate = 3:2). 
1
H NMR (500 MHz, CDCl3) 7.36 (d, J = 8.6 Hz, 
1H), 6.91 (d, J = 2.3 Hz, 1H), 6.78 (dd, J = 8.5, 2.3 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 
6.44 (d, J = 2.2 Hz, 1H), 6.16-6.08 (m, 1H), 5.81-5.73 (m, 1H), 5.68 (dd, J = 17.3, 1.5Hz, 
1H), 5.35 (dd, J = 10.6, 1.5 Hz, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 5.15 (s, 2H), 5.10 (dd, J = 
17.2, 1.7 Hz, 1H), 5.02 (d, J = 10.3 Hz, 1H), 4.69 (ddd, J = 4.8, 1.7, 1.6 Hz, 2H), 4.49 
(ddd, J = 6.0, 1.4, 1.2 Hz, 2H), 3.50 (s, 3H), 3.48 (s, 3H), 3.44 (s, 3H).
 13
C NMR (125 
MHz, CDCl3)  173.9, 161.0, 160.0, 159.9, 159.0, 156.3, 153.6, 140.8, 134.2, 132.2, 
131.7, 117.9, 117.5, 114.8, 110.7, 108.6, 103.7, 97.8, 95.7, 94.8, 94.3, 94.3, 73.3, 69.9, 
56.4, 56.2, 56.2. IR max (film): 3082, 2960, 2919, 2826, 1635, 1608, 1576, 1505, 1486, 
1433, 1396, 1338, 1299, 1242, 1217, 1194, 1150, 1119, 1096, 1079, 1028, 990, 922, 868, 
827 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C27H31O10 515.1917, found 
515.1906. 
3,5-Bisallyloxy-7,2′,4′-trihydroxy morin 176. To a solution of 
175 (571 mg, 1.11 mmol, 1.0 equiv) in methanol (15 mL) was 
added concentrated HCl (0.75 mL), and the reaction was heated 
to 40 °C and stirred overnight. The mixture was cooled to room temperature, added H2O 
and extracted with ethyl acetate three times. The organic layer was combined and washed 
with brine, dried over Na2SO4 and concentrated in vacuo. The crude mixture was purified 
by silica gel chromatography (20% ethyl acetate in hexanes) to afford 176 as pale yellow 
crystals (394 mg, 93%).  
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Rf: 0.07 (hexanes : ethyl acetate = 3:2). m.p. = 130-132 °C (CHCl3). 
1
H NMR (400 MHz, 
Acetone-d6)  7.52 (d, J = 8.4 Hz, 1H), 6.55 (dd, J = 8.4, 2.3 Hz, 1H), 6.51 (d, J = 2.3 Hz, 
1H), 6.48 (d, J = 2.2 Hz, 1H), 6.44 (d, J = 2.2 Hz, 1H), 6.15-6.06 (m, 1H), 6.94-6.78 (m, 
2H, overlap), 5.30 (dq, J = 10.8, 1.6, 1.6 Hz, 1H), 5.21 (dq, J = 17.2, 1.6, 1.6 Hz, 1H), 
5.08 (dd, J = 9.2, 1.2 Hz, 1H), 4.66-4.64 (m, 2H), 4.54 (d, J = 5.9 Hz, 1H). 
13
C NMR 
(100 MHz, Acetone-d6)  172.3, 162.3, 161.1, 160.3, 159.3, 156.9, 153.4, 138.8, 133.8, 
132.8, 131.3, 117.6, 116.5, 110.4, 108.6, 107.9, 103.9, 97.2, 95.3, 73.6. IR max (film): 
3237, 1604, 1496, 1466, 1425, 1372, 1340, 1293, 1242, 1190, 1094, 980, 940, 828 cm
-1
. 
HRMS-ESI (m/z): [M + H]
+
 calculated for C21H19O7 383.1131, found 383.1141. 
General procedure III for the achiral rearrangement of bis-allyloxyflavone ether. 
 
To a suspension of 4Å molecular sieves (30 mg, flame-dried under high vacuum) in a 
sealed tube was added via cannula a solution of allyloxyflavone 176 (5.0 mg, 0.013 mmol, 
1.0 equiv) in a mixture of CH2Cl2 (0.45 mL) and HFIP (50 µL). Sc(OTf)3 (1.93 mg, 0.004 
mmol, 0.3 equiv) was added in one portion. The reaction mixture was allowed to stir at 
35 °C overnight. After removal of the molecular sieves by filtration of the crude mixture 
through a pad of Celite®, the solvent was evaporated in vacuo. The crude mixture was 
purified by preparative TLC (40% ethyl acetate in 3 mL of hexanes with 10 drops of 
methanol) to yield 177, 178, 179.  
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Double rearrangement 177 was obtained as a white oil (2.9 mg, 
57%). 
Rf: 0.58 (hexanes : ethyl acetate = 3:2, total 2.5 mL of solvent 
with 3 drops of methanol). 
1
H NMR (500 MHz, Acetone-d6) 11.91 (s, 1H), 9.89 (s, 1H), 
8.72 (s, 1H, br), 7.36 (d, J = 8.4 Hz, 1H), 7.14 (s, 1H), 6.52 (dd, J = 14.1, 7.8 Hz, 1H), 
6.40 (d, J = 8.1 Hz, 1H), 5.96 (s, 1H), 5.96-5.85 (m, 2H), 5.20 (d, J = 18.0 Hz, 1H), 5.03 
(d, J = 10.2 Hz, 1H), 4.98 (d, J = 17.1 Hz, 1H), 4.89 (d, J = 9.9 Hz, 1H), 3.28 (d, J = 6.5 
Hz, 2H), 3.10-2.92 (m, 2H).
 13
C NMR (125 MHz, CDCl3)  186.3, 165.5, 161.9, 161.1, 
160.1, 158.6, 135.6, 131.0, 124.9, 120.8, 120.3, 116.2, 109.4, 105.6, 100.9, 99.5, 99.4, 
95.7, 89.6, 36.9, 26.1. IR max (film): 3450, 3080, 3010, 2982, 2924, 1635, 1500, 1458, 
1343, 1277, 1215, 1141, 1089, 962, 926, 834, 762 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 
calculated for C21H19O7 383.1131, found 383.1133. 
3-Allyl rearrangement 178 was obtained as a white oil (1.7 mg, 
34%). 
Rf: 0.38 (hexanes : ethyl acetate = 3:2, total 2.5 mL solvent with 
3 drops of methanol). 
1
H NMR (400 MHz, Acetone-d6) δ 13.04 (s, 1H), 7.40 (dd, J = 8.1, 
0.7 Hz, 1H), 6.54 (dd, J = 10.5, 2.3 Hz, 1H), 6.53 (s, 1H), 6.48 (s, 1H), 6.02 – 5.91 (m, 
1H), 5.91 – 5.81 (m, 1H), 5.22 (dq, J = 17.2, 1.6 Hz, 1H), 5.09 (dq, J = 10.5, 1.2 Hz, 1H), 
5.03 (dq, J = 17.1, 1.8 Hz, 1H), 4.92 (dq, J = 10.0, 1.5 Hz, 1H), 4.57 (dt, J = 5.9, 1.4 Hz, 
2H), 3.41 (dt, J = 6.3, 1.6 Hz, 2H).
 13
C NMR (125 MHz, Acetone-d6)  181.2, 165.5, 
164.1, 161.8, 160.4, 160.2, 132.6, 132.2, 124.8, 120.3, 119.0, 116.3, 108.7, 102.9, 102.0, 
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98.2, 96.1, 94.2, 89.2, 68.7, 37.6. IR max (film): 2959, 2926, 2854, 1664, 1609, 1493, 
1462, 1390, 1327, 1262, 1174, 1109, 959, 812, 756 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 
calculated for C21H19O7 383.1131, found 383.1129. 
5-Allyl rearrangement 179 was obtained as a yellowish solid 
(1.7 mg, 34%). 
Rf: 0.38 (hexanes : ethyl acetate = 3:2, total 2.5 mL solvent with 3 drops of methanol). 
m.p. = 118-120 °C (CHCl3). 
1
H NMR (400 MHz, Acetone-d6) 
1
H NMR (500 MHz, 
Acetone-d6) δ 13.03 (s, 1H), 7.40 (d, J = 8.2 Hz, 1H), 6.57 – 6.51 (m, 2H), 6.49 (s, 1H), 
6.03 – 5.92 (m, 1H), 5.92 – 5.80 (m, 1H), 5.22 (dq, J = 17.2, 1.6 Hz, 1H), 5.09 (dd, J = 
10.4, 1.2 Hz, 1H), 5.03 (dq, J = 17.1, 1.6 Hz, 1H), 4.95 – 4.90 (m, 1H), 4.57 (d, J = 6.0 
Hz, 2H), 3.41 (d, J = 6.3 Hz, 2H). 
13
C NMR (125 MHz, Acetone-d6) δ 178.4, 161.7, 
161.2, 159.3, 157.1, 157.0, 155.7, 137.2, 135.8, 133.7, 131.7, 117.5, 113.9, 110.0, 109.3, 
107.7, 105.0, 103.6, 93.0, 73.6, 26.1.IR max (film): 3254, 2957, 2928, 2848, 1705, 1650, 
1612, 1575, 1474, 1364, 1312, 1259, 1240, 1220, 1190, 1167, 1215, 1085, 1023, 981, 912, 
814, 737 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C21H19O7 383.1131, found 
383.1121. 
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(±)-Sanggenol F (1). To a 20 mL dram vial was added 4Å 
molecular sieves (100 mg) and the vial was kept in the 
vacuum oven at 130 °C for 12 h. After activation of the 
molecular sieves, the vial was transferred from the vacuum oven and was purged with 
argon. A solution of 176 (500 mg, 1.31 mmol, 1 equiv) in 4:1 mixture of CH2Cl2 and 
1,1,1,2,2,2-hexafluoroisopropanol (HFIP) (5 mL) was transferred to the vial via cannula 
and Yb(OTf)3 (122 mg, 0.20 mmol, 0.15 equic) was added in one portion. The reaction 
mixture was stirred at 50 °C for 24 h. The reaction was cooled to room temperature and 
filtered through Celite® and finally concentrated in vacuo. The crude mixture was 
directly subjected to silylation without further purification.  
The crude mixture was dissolved in DMF, and tert-butyldimethylsilyl chloride (1.59 g, 
10.37 mmol, 8.0 equiv) and imidazole (1.43 g, 21.1 mmol, 16.0 equiv) were added in one 
portion. The reaction was stirred at room temperature for 6 h and was then quenched with 
water. The mixture was extracted with diethyl ether and the organic layer was combined 
and washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture 
was purified by silica gel chromatography (1% ethyl acetate in hexanes) to afford a crude 
yellow oil. 
The crude mixture was dissolved in CH2Cl2 (1.6 mL) in a flame-dried flask, and 2-
methyl-2-butene (1.6 mL) and 2nd generation Grubbs catalyst (21.0 mg, 0.003 mmol, 
0.05 equiv) was added sequentially. The reaction mixture was refluxed at 40 °C for 12 h, 
and cooled to room temperature and concentrated in vacuo. The crude mixture was 
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purified with silica gel chromatography (1% ethyl acetate in hexanes) to afford a crude 
light yellow oil and directly taken to desilylation step.  
The crude mixture was dissolved in dry CH3CN (4 mL) and 3HF∙NEt3 (452 µL, 2.77 
mmol, 8.0 equiv) was added dropwise at 0 °C. The reaction was stirred at 0 °C for 3 h 
and quenched with pH 7 buffer and extracted with ethyl acetate three times. The organic 
layer was combined and washed with brine, dried over Na2SO4, and concentrated in 
vacuo. The crude mixture was purified by silica gel chromatography (10% ethyl acetate 
in hexanes) to afford sanggenol F (1) a yellow oil (208 mg, 42% over four steps) 
Rf: 0.50 (hexanes : ethyl acetate = 3:2). m.p. = 63-65 °C (EtOAc). 
1
H NMR (500 MHz, 
Acetone-d6) 11.92 (s, 1H), 9.94 (br, 1H), 8.71 (br s, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.08 
(br s, 1H), 6.51 (dd, J = 8.2, 2.1 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 5.91 (s, 1H), 5.24 (tm, 
J = 7.5 Hz, 1H), 5.18 (tm, J = 7.1 Hz, 1H), 3.22 (d, J = 7.2 Hz, 2H), 3.12 (dd, J = 14.8, 
8.6 Hz, 1H), 2.77 (dd, J = 15.9, 6.4 Hz, 1H), 1.73 (s, 3H), 1.62 (s, 3H), 1.61(s, 3H), 
1.51(s, 3H). 
13
C NMR (100 MHz, Acetone-d6)  188.2, 166.5, 162.5, 161.4, 161.2, 161.0, 
136.5, 131.4, 125.6, 123.2, 121.3, 118.6, 118.6, 109.7, 109.0, 102.5, 100.1, 99.4, 95.2, 
91.7, 32.0, 25.9, 21.5, 18.1, 17.8. IR max (film): 3379, 2964, 2928, 2854, 1636, 1611, 
1501, 1455, 1343, 1281, 1206, 1152, 1089, 1040, 993, 960, 835, 761 cm
-1
. HRMS-ESI 
(m/z): [M + H]
+
 calculated for C25H27O7 439.1757, found 439.1747. 
(±)-Sanggenon A (2). To a solution of sanggenol F (1) (5.0 
mg, 0.01 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL) was added 
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DDQ (2.9 mg, 0.01 mmol, 1.1 equiv) in one portion. The reaction mixture was stirred at 
room temperature for 12 h and quenched with quenched with water. The mixture was 
extracted with ethyl acetate, and the organic layer was combined and washed with brine 
three times, dried over Na2SO4 and concentrated in vacuo. The crude mixture was 
purified by silica gel chromatography (5% ethyl acetate in hexanes) to afford sanggenon 
A (2) a yellow oil (1.5 mg, 30%). 
Rf: 0.64 (hexanes : ethyl acetate = 3:2). 
1
H NMR (500 MHz, CDCl3) δ 11.50 (s, 1H), 7.32 
(d, J = 8.2 Hz, 1H), 6.59 (d, J = 10.1 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.44 (d, J = 2.1 
Hz, 1H), 5.78 (s, 1H), 5.50 (d, J = 10.1 Hz, 1H), 5.22 – 5.15 (m, 1H), 3.07 (dd, J = 14.6, 
8.7 Hz, 1H), 2.77 (dd, J = 14.6, 6.4 Hz, 1H), 1.62 (s, 3H), 1.44 (s, 3H), 1.40 (s, 3H), 1.25 
(s, 3H). 
13
C NMR (100 MHz, Acetone-d6) δ 188.8, 164.3, 163.2, 161.4, 161.2, 159.4, 
136.9, 127.6, 125.7, 121.1, 118.6, 115.4, 109.9, 103.2, 102.5, 100.5, 99.6, 96.4, 92.6, 79.5, 
32.1, 30.5, 28.5, 28.4, 25.9, 18.1. IR max (film): 3366, 2961, 2918, 2850, 1746, 1628, 
1572, 1501, 1473, 1377, 1341, 1262, 1168, 1153, 1096, 1049, 961, 856, 805, 762 cm
-1
. 
HRMS-ESI (m/z): [M + H]
+
 calculated for C25H25O7 437.1600, found 437.1610. 
General procedure IV for reaction screen in the asymmetric rearrangement of bis-
allyloxyflavone ether . 
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Similar to General procedure II, to a suspension of 4Å molecular sieves (30 mg, flame-
dried under high vacuum) in a sealed tube was added via cannula, a pre-stirred solution of 
Sc(OTf)3 (1.92 mg, 0.004 mmol, 0.3 equiv) and (R)-Ph-PyBox (1.6 mg, 0.004 mmol, 0.33 
equiv) in CH2Cl2 (0.2 mL). After stirring the suspension at room temperature for 0.5 h, a 
solution of bis-allyloxyflavone 176 (5 mg, 0.013 mmol, 1.0 equiv) in a mixture of CH2Cl2 
(0.20 mL) and HFIP (100 µL) was slowly added via cannula. The mixture was allowed to 
stir at the reported temperature for 12 h. After removal of the molecular sieves by 
filtration of the crude mixture through a pad of Celite®, the solvent was evaporated in 
vacuo. The crude mixture was purified by preparative TLC to yield 177, 178, 179.  
 
Chiral HPLC analysis for compound 178.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
178: ChiralPak AD 150 × 4.6 mm column, 20% isopropanol in hexane. Flow rate: 1.0 
mL/min. UV detector: 214 nm. Retention time: 11.3 min and 18.4 min. 
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Chiral HPLC analysis for compound 177. 
The following chiral HPLC conditions were used for the separation of enantiomers of 
177: ChiralPak AD 150 × 4.6 mm column, 10% isopropanol in hexane. Flow rate: 1.0 
mL/min. UV detector: 214 nm. Retention time: 18.6 min and 24.4 min. 
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2.7. Select NMR spectra 
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3. Chapter 3 
 
 
Syntheses of Sanggenons C and O 
 
 
3.1. Retrosynthetic strategy for the synthesis of sanggenons C and O. 
Sanggenons C (4), D (6) and O (5) are considered to be Diels-Alder cycloadducts 
between a flavonoid diene and a 2′-hydroxyflavone. Among them, sanggenons C and O 
were shown to be endo adducts and epimers at C-2 and C-3; sanggenon D was 
established as an exo cycloadduct. For the synthesis of sanggenons C, D and O, we 
envisioned a biomimetic route starting from sanggenol F (1) or sanggenon A (2) (Scheme 
3.1). The requisite flavonoid diene 185 may be derived from oxidation of the benzylic 
prenyl group on the flavone A ring in sanggenol F or related substrates. Alternatively, 
diene 185 may be derived from isomerization of the chromene ring in sanggenon A or 
related substrates. We planned to utilize the silver nanoparticle catalyst system (cf. 
Chapter 1) for the desired Diels-Alder cycloaddition between flavonoid diene 185 and 
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the oxygenated 2′-hydroxychalcone 186. In this chapter, we will first review literature 
precedents on the in situ generation of 1,3-dienes. Diels-Alder cycloadditions of 
flavonoid diene 185 generated via both oxidation and isomerization will be described in 
detail. Total syntheses of sanggenons C (4) and O (5) will be also discussed. 
Scheme 3.1 Retrosynthetic strategy for sanggenons C, D, O . 
 
3.2. Literature examples of methods for in situ generation of 1,3-dienes. 
3.2.1. Dehydrogenative diene and dienophile generation. 
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White and coworkers reported the first example of a dehydrogenative Diels-Alder 
reaction between an in situ generated 1,3-diene 189 and N-phenylmaleimide 190 
(Scheme 3.2).
111
 Dehydrogenation of terminal olefin 188 via C-H activation and β-
hydride elimination was achieved with Pd(II)/bis-sulfoxide catalyst to afford a 4:1 
mixture of E/Z 1,3-diene 189. It is believed that Pd(II) catalyzes the isomerization of the 
(Z)-diene to the (E)-diene, thereby achieving high diastereoselectivity through reaction of 
the (E)-diene. 
Scheme 3.2 Pd(II)-catalyzed dehydrogenative Diels-Alder cycloaddition. 
 
In the synthesis of chamaecypanone analogues by Porco and coworkers,
112
 
thermolytic retro-Diels-Alder reaction of homodimer 192 afforded the monomer o-quinol 
194. O-Quinol 194 underwent subsequent endo and face-selective Diels-Alder 
cycloaddition with cyclopentadienone 195, the latter of which was formed in situ via 
dehydrogenation of cyclopentenone 193 in the presence of Rh/C in an argon atmosphere. 
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Scheme 3.3 Diels-Alder reaction of in situ generated cyclopentadienone. 
 
3.2.2. Diene formation via isomerization. 
Padwa and coworkers
113
 have reported the retro 6π opening of chromene 198 to 
yield ortho-quinone methide intermediate 199 under photochemical conditions (Scheme 
3.4). In the presence of nucleophiles such as methanol, quinonemethide 199 may undergo 
conjugate addition at both C-2 and C-4 positions. In inert solvents, intermediate 199 may 
undergo a formal [1,7]-sigmatropic hydrogen shift to afford 1,3-diene 200. Importantly, 
as precedent for the generation of a reactive diene from 2-H chromenes, this methodology 
represents an alternative route to the oxidative conditions. 
Scheme 3.4 Photochemical chromene isomerization. 
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An example of a Diels-Alder reaction of a diene generated via isomerization of a 
chromene is shown in Scheme 3.5. In the synthesis of vepridimerines by Connolly and 
coworkers,
114
 the chromene monomer veprisine 201 was treated under thermal conditions 
to afford vepridimerines A to E (205-209, Scheme 3.5). Mechanistically, veprisine is 
thought to undergo retro-6π ring opening and a subsequent 1,7-sigmatropic hydrogen 
shift to afford 1,3-diene 203, a compound which dimerizes in situ to yield the homo 
dimeric Diels-Alder cycloadduct 204. At high temperatures, the trisubstituted alkene 
moiety in 204 undergoes further cyclization to yield the regioisomeric natural products 
vepridimerines A, B, as well as vepridimerines C through E. 
Scheme 3.5 Synthesis of vepridimerines. 
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3.3. Methodology development. 
3.3.1. Evaluation of oxidative Diels-Alder cycloaddition of sanggenol F and related 
substrates. 
For the envisioned biomimetic synthesis of sanggenon C (cf. Scheme 3.1), we 
first evaluated the oxidative Diels-Alder cycloaddition between sanggenol F (1) and 2′-
hydroxychalcone 210, a simple dienophile (Scheme 3.6). Inspired by previous work by 
Chao Qi and Dr. Huan Cong on brosimones A and B in the Porco laboratory (cf. Chapter 
1), we surveyed a number of dehydrogenative and oxidative reagents in conjunction with 
silver nanoparticle catalysts. These included platinum on activated carbon (Pt/C), Rh/C, 
Pd/C, Rh/Al2O3, and Pd(OAc)2, as well as Ag2O, PIDA/TEMPO, Mn(OAc)3, and DDQ. 
Among these, Pt/C and DDQ successfully catalyzed the oxidation of the benzylic prenyl 
group. When sanggenol F (1) was treated with Pt/C and molecular oxygen in the presence 
of AgNP and 2′-hydroxychalcone 210, sanggenol F successfully underwent the desired 
cycloaddition to afford 211 as a mixture of four diastereomers in 5% yield along with 
sanggenon A (2) in 30% yield. 
Scheme 3.6 Oxidative Diels-Alder cycloaddition of sanggenol F. 
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The transformation was thought to be initiated by platinum coordination to the 
phenol oxygen (pathway a) and the alkene moiety of the benzylic prenyl group (pathway 
b) (Scheme 3.7). Hydrogen atom extraction at the benzylic position of the prenyl group 
may form the ortho-quinonemethide species 216a,b. The ortho-quinonemethide may 
isomerize to form s-cis-217 which may be followed by 6- electrocyclization to afford 
sanggenon A (2). Alternatively, a small amount of diene may be generated via a formal 
1,7-sigmatropic hydrogen shift, which in the presence of AgNP’s may react with 2′-
hydroxychalcone to form the desired cycloadduct 211. Diene 218 may also be derived 
from 216a or 216b via an intermolecular deprotonation/protonation sequence catalyzed 
by silica gel. 
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Scheme 3.7 Proposed mechanism of the dehydrogenative Diels-Alder cycloaddition. 
 
Several Brønsted acids were surveyed as additives in order to facilitate the 
intermolecular deprotonation/protonation sequence. Brønsted acids such as acetic acid 
may protonate the ortho-quinonemethide ketone at C-5 while the acetate counterion may 
deprotonate the prenyl methyl group (Scheme 3.8). Stronger Brønsted acids led to 
qualitative increase in the amount of cycloadduct 211. However the chromene sanggenon 
A was still a significant product in these transformations. 
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Scheme 3.8 Proposed isomerization of ortho-quinonemethide facilitated by Brønsted 
acids. 
 
In order to suppress the chromene formation, MOM- and TBS-protected 
sanggenol F ethers 219 and 220 were investigated in the dehydrogenative Diels-Alder 
cycloaddition (Table 3.1). Among a series of conditions evaluated, 1.1 equivalents of 
DDQ was found to promote the desired oxidation of 219 to produce cycloadduct 221 in 
the presence of AgNP/SiO2 and 2′-hydroxychalcone. The cycloadduct 221 was isolated in 
49% yield as a 1.5:1.5:1:1 mixture of four diastereomers. The diastereomeric ratio was 
determined by 
1
H NMR integration of H-8 (Figure 3.1). At lower temperature (50°C), 
the selectivity was increased to 3:3:1:1 (entry 2). Chromene 222, along with a DDQ 
adduct of 218 (detected by UPLC-MS spectrum, not isolated) was also formed in the 
reaction. Treatment of the corresponding TBS ether 220 under similar conditions led to 
decomposition of the starting material, possibly due to the cleavage of TBS groups as a 
result of the harsh reaction conditions (entry 3). 
Table 3.1 Oxidative Diels-Alder cycloaddition of sanggenol F ethers. 
 
109 
 
 
 
entry
a
 substrate R T(°C) yield% of 221 d.r.
e
 
1 219 MOM 90 49%
b 
1.5:1.5:1:1 
2 219 MOM 50 n.d.
c
 3:3:1:1 
3 220 TBS 90 decomp.
d
 ---- 
a 
Unless otherwise specified, all reactions were carried out with 0.01 mmol of 
chromene with 1 equivalent of DDQ at 0.02 M in DCE. 
b
 Yield was 
calculated based on recovered starting material. Byproduct chromene 222 
was produced in 22% yield. 
c
 Yield was not determined.
 d
 Decomposition of 
starting material was observed. 
e
 Diastereomeric ratio determined by 
1
H 
NMR integration. 
 
Figure 3.1 
1
H NMR analysis of Diels-Alder cycloadduct mixture (cf. Table 3.1). 
 
 
Mechanistically, DDQ may extract a hydride from the benzylic position of the 
prenyl group in prenylflavone 219 to form a benzylic-stabilized carbocation, which may 
be followed by deprotonation to afford the ortho-quinonemethide species 223a,b 
(Scheme 3.9). S-trans Quinonemethide 223b may go through a 1,7-hydrogen shift to 
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form 1,3-diene 224 (pathway a, blue arrow), while s-cis quinonemethide 223a may 
undergo 6π-electrocyclization to form chromene 222 (pathway b, red arrow).  
Scheme 3.9 Proposed mechanism for the oxidative Diels-Alder cycloaddition in the 
presence of DDQ. 
 
 
3.3.2. Evaluation of diene generation via isomerization. 
To utilize the chromene side product 222 in the cycloaddition, chromene 222 was 
treated with 2′-hydroxychalcone and AgNP/SiO2 at 80 °C. Under these conditions, 
cycloadduct 221 was obtained as a 3:3:1:1 mixture of diastereomers (Scheme 3.10), 
suggesting that chromene 222 can be a reactive precursor for the requisite diene 224. It is 
believed that chromene 222 undergoes a retro 6- electrocyclization to afford 
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quinonemethide 223a which after alkene isomerization and 1,7-sigmatropic hydrogen 
shift (or intramolecular deprotonation/protonation) may yield diene 224.  
Scheme 3.10 Diels-Alder cycloaddition of chromene 222 and a 2′-hydroxychalcone. 
 
A number of Lewis acids and Brønsted acids were evaluated in the Diels-Alder 
cycloaddition to facilitate the formal 1,7-sigmatropic hydrogen shift (Table 3.2). Lewis 
acids such as Zn(OTf)2 and FeCl3∙6H2O led to decomposition of the starting material 222 
(entries 2, 3). In the presence of Brønsted acids such as acetic acid, the reaction 
proceeded at a lower temperature to yield the cycloadduct in 3:3:1:1 selectivity (entry 4). 
3-Hydroxychromene 225 also underwent the desired Diels-Alder cycloaddition with good 
selectivity (entry 8).  
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Table 3.2 Additive effect on the Diels-Alder cycloaddition of chromene 222 and 2′-
hydroxychalcone. 
 
entry
a
 R additive pKa T(°C) 
conversion 
(yield) 
d.r.
f
 
1 MOM FeCl3∙6H2O
b
  25 ---- decomp.
c
 
2 MOM Zn(OTf)2
b
  40 ---- decomp.
c
 
3 MOM HOAc
d
 4.76 60 (21%) 3:3:1:1 
4 MOM ClCH2CO2H
d
 2.86 60 (28%) 1:1:1:1 
5 MOM TFA
d
 0.23 60 ---- decomp.
c
 
6 MOM DDQH
e
  90 100% (27%) 3:3:1:1 
7 H ----  80 (55%) 3:2:1.5:1 
a 
Unless otherwise specified, all reactions were carried out with 0.002 mmol of chromene at 
0.01 M in DCE. 
b
 30 mol% of Lewis acids were used as an additive. 
c
 Decomposition of 
starting material was observed. 
d 
One equivalent of Brønsted acids were used as an additive. 
b
 Two equivalent of acid additive was used. 
e 
DDQH was thought to be carried through 
from the previous DDQ oxidation reaction. 
f 
Diastereomeric ratio determined by 
1
H NMR 
integration of H-8. 
 
Mechanistically, chromene 222 may undergo retro 6π electrocyclization to form 
ortho-quinonemethide 223a,b which may go through a 1,7-sigmatropic hydrogen shift to 
afford the requisite 1,3-diene 224 for the desired Diels-Alder cycloaddition. Alternatively, 
the Brønsted acid may act as a proton shuttle to promote an intramolecular protonation-
deprotonation sequence (Scheme 3.11a).  
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Interestingly, the attempted reaction of sanggenon A (2) in the presence of the 
model 2′-hydroxychalcone 210 and AgNP at 110 °C failed to produce any cycloadduct. 
For both chromene 222 and sanggenon A (2), the pKa’s of the 5- and 7-hydroxyl groups 
(~12 and ~7 respectively) are lower than the pKa of the prenyl methyl protons (~20), 
therefore proton transfer from the terminal methyl group to the carbonyl groups at C5 or 
C7 is not favored (Scheme 3.11). However, the hydrogen bond in diene 224 between the 
5-hydroxyl group and carbonyl oxygen at C4 may render diene 224 thermodynamically 
more stable. Rationally, this effect may serve to drive the equilibrium in favor of the open 
form 224. Once the diene is formed, Diels-Alder cycloaddition may serve as a sink to 
drive the equilibrium further towards the formation of diene 224.  
Scheme 3.11 Proposed mechanism for the isomerization of chromene 222. 
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The transformation of prenyl flavonoids 219 and 220 to chromenes 222 and 228, 
respectively, was further investigated using dehydrogenative (e.g. Pt/C, Pd/C, Rh/C, 
Pd(II)) and oxidative conditions (Table 3.3). Among these conditions, Pd(II) catalyzed 
the desired oxidation of sanggenol F ether 219 to afford chromene 222 in 40% yield 
under open-flask conditions. Polar solvents such as DMSO and HOAc were found to be 
necessary for the reaction to proceed (entries 1-3), possibly because they disrupt the 
hydrogen bond between the 5-hydroxyl and 4-carbonyl groups and free the 5-hydroxyl 
group for cyclization. Oxidation
94-96,115
 of substrate 219 with DDQ afforded the desired 
chromene 222 in 38% yield (entry 6). Oxidation of TBS ether 220 was achieved under 
similar conditions in lower yield, possibly due to the instability of the TBS groups 
(entries 7, 8). In future studies, palladium-catalyzed oxidation of sanggenol F ethers 219 
and 220 should be further optimized. Ligands for palladium, such as bis-sulfoxide
111
 (cf. 
Scheme 3.2), DMSO
116
 and pyridine based 4,5-diazafluorenone
117
 may be evaluated. 
These ligands may facilitate substrate coordination to palladium and help catalyst turn 
over.
118
  
Table 3.3 Oxidation of protected sanggenol F ethers. 
 
entry
a
 R catalyst oxidant solvent T (°C) 
conversion% 
(yield%)
d
 
1 MOM Pd(dba)2 air DMSO/H2O 60 NR 
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2 MOM Pd(OAc)2 air DMSO/H2O 60 100% (40%) 
3 MOM Pd(OAc)2 air HOAc 60 30% (n.d.) 
4
b
 MOM Pd(OAc)2 Cu(OAc)2 DMSO 60 NR 
5
b
 MOM Pd(OAc)2 BQ DMSO 60 NR 
6
c
 MOM ---- DDQ CH2Cl2 90 60% (38%
e
) 
7 TBS Pd(OAc)2 air DMSO/H2O 60 100% (23%) 
8
c
 TBS ---- DDQ CH2Cl2 25 100% (18%) 
a
 Unless otherwise specified, all reaction were carried out with 10 mol% of catalyst and 1.1 
equivalent of K2CO3 with an open flask conditions. 
b
 Reactions were carried out with 10 mol% 
of catalyst, 1.1 equivalent of oxidant and 1.1 equivalent of K2CO3 under 1 atmosphere of 
argon. 
c
 Reactions were carried out with 1.1 equivalent of DDQ under 1 atmosphere of argon. 
d
 Conversion to 222 and 228 was measured by 
1
H NMR and TLC. Yield was calculated with 
purified 222 and 228. 
e
 The reaction produced 23% 222, and 38% of 219 was recovered. The 
38% yield for 222 was calculated based on recovered starting material. 
 
3.4. Total syntheses of sanggenons C and O. 
A stepwise strategy for the total syntheses of sanggenons C (4) and O (5) entails 
the isomerization of a flavonoid chromene to form the requisite diene in situ which in the 
presence of AgNP may undergo the desired Diels-Alder cycloaddition to generate the 
sanggenon C core structure. Considering the presence of two acid-sensitive 
functionalities, the cyclohexene ring and hemiacetal, TBS-protected chromene 228 was 
employed in cycloadditions with acetylated 2′-hydroxychalcone 229 (prepared following 
a literature precedent,
50
 Scheme 3.12) in the presence of AgNP and AcOH as an additive 
to yield 233 as a mixture of two endo-cycloadducts (1.3:1 diastereomeric ratio, based on 
1
H NMR analysis) (Scheme 3.13). Cycloadduct mixture 233 was subsequently treated 
with 3HF∙NEt3 and aqueous NaHCO3 to yield a 1.3:1 mixture of (±)-sanggenon C (4) and 
(±)-sanggenon O (5). Finally, (±)-sanggenon C and O were separated by preparative TLC 
to afford (±)-sanggenon C and (±)-sanggenon O.  
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The structures of both sanggenons C and O were supported by comparison of 
1
H 
NMR spectra, HRMS, and UPLC co-injections with literature reported data
1,4
 and a 
natural sample of sanggenon C (Figure 3.2). However, insufficient amounts of synthetic 
samples of sanggenons C and O have been obtained for acceptable 
13
C NMR spectra. In 
an attempt to obtain larger amounts of final products sanggenons C and O, a slightly 
different 
1
H NMR spectrum was observed, especially for the chemical shifts in the 
aromatic region (H-27, H-6′, H-33, H-5′, H-3′, H-26, H-24, H-32, H-30). Possible metal 
chelation to the polyphenol after preparative TLC purification may explain the observed 
chemical shift changes. Further purification utilizing preparative HPLC will be required 
in order to obtain high quality spectroscopy data for both sanggenons C and O. 
Scheme 3.12 Preparation of the acetylated 2′-hydroxychalcone 229. 
 
Scheme 3.13 Total synthesis of sanggenons C (4) and O (5). 
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Figure 3.2 Overlay of 
1
H NMR spectra of synthetic and natural sanggenon C. 
 
To better understand the cycloadditions leading to sanggenons C and O, the 
conformations of both diene 234 and 2′-hydroxychalcone 229 were calculated (Spartan 
11, AM1, semi-empirical method). The ring systems in the flavonoid diene 234 form a 
concaved face between the A/C and B/D ring planes (Figure 3.3). The B and D rings 
may block the β face and favor chalcone 239 approaching from the α face in 
cycloaddition. However, the rotational barrier of the diene moiety around the C-6/C-14 
bond is about 1.1 kcal∙mol-1, so that both diene conformers 234a and 234b are present at 
the reaction temperature (60 and 90 °C). Though the concave conformation of flavonoid 
diene 234 provides a large facial bias, the diastereomeric outcome is largely governed by 
the diene conformation. This may explain the lack of selectivity observed in the reaction 
(1.3:1). Further computational studies (e.g. transition state analyses
119
) will be required in 
order to understand the apparent endo vs. exo cycloaddition preference. 
ppm (t1)
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Figure 3.3 Proposed endo selective Diels-Alder cycloaddition between diene 234 and 
2′-hydroxychalcone 229.a 
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a TBS groups and hydrogen atoms omitted for clarity. 
 
In future experiments, the asymmetric Diels-Alder cycloaddition between 
flavonoid diene precursor 228 and 2′-hydroxychalcone 229 will be evaluated. The 
B(OPh)3/BINOL catalytic system developed by Dr. Huan Cong will be tested (Scheme 
3.14). The B(OPh)3/o-Bromo-BINOL complex was shown to catalyze the Diels-Alder 
cycloadditions between 2′-hydroxychalcone 235 and 1,3-disubstituted diene 236 in good 
diastereo- and enantioselectivity. Both the aromatic diene 235 and 2′-hydroxychalcone 
dienophile 236 are simplified models for 234 and 229. Since sanggenons C and O are 
a) 
b) 
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diastereomers at C-2 and C-3, racemic 229 will be used in a ligand-controlled, 
diastereoselective Diels-Alder cycloaddition. The mixture of diastereomers may be 
separated after deprotection to yield enantiomerically enriched sanggenons C, O and D. 
Scheme 3.14 B(OPh)3/3,3′-dibromo-BINOL catalyzed Diels-Alder cycloadditions. 
 
Scheme 3.15 Proposed asymmetric synthesis of sanggenons C and O. 
 
Enantiomerically enriched diene precursor 228, derived from the asymmetric 
double rearrangement of bis-allyloxyflavone 176 (cf. Chapter 2), may also be used in the 
Diels-Alder cycloaddition with 2′-hydroxychalcone 229. It is anticipated that the chiral 
centers at C-2 and C-3 may influence the facial selectivity in similar ways as shown in 
Figure 3.3 to produce the enantiomer of sanggenon C and sanggenon O (5).  
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Scheme 3.16 Proposed asymmetric synthesis of sanggenons C and O using 
enantiomerically enriched diene precursor. 
 
 
3.5. Conclusion 
In summary, an oxidative Diels-Alder cycloaddition between a prenylated flavone 
and a 2′-hydroxychalcone has been achieved using DDQ and silver nanoparticles. The 
protected chromene side products in these reactions were found to be effective diene 
precursors. This discovery led to the development of Diels-Alder cycloadditions between 
2′-hydroxychalcones and the in situ formed diene derived from the isomerization of the 
chromenes. Efficient racemic total syntheses of sanggenons C and O have been 
successfully accomplished utilizing this methodology. 
 
3.6. Experimental section 
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General Information 
1
H NMR spectra were recorded on a 400 MHz or 500 MHz spectrometer at ambient 
temperature with CDCl3 as the solvent or otherwise stated. 
13
C NMR spectra were 
recorded on a 100 MHz or 125 MHz spectrometer at ambient temperature with complete 
proton decoupling using CDCl3 as the solvent or otherwise stated. Chemical shifts for 
characterized compounds are reported in parts per million relative to CDCl3 (
1H, δ 7.26; 
13C, δ 77.0). Data for 1H NMR are reported as follows: chemical shift, multiplicity (app = 
apparent, par obsc = partially obscure, br = broad, ovrlp = overlapping, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet), coupling constants and integration. 
Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR spectrophotometer. Optical 
rotations were recorded on an AUTOPOL III digital polarimeter at 589 nm and are 
recorded as [α]D (concentration in grams/100 mL solvent). High-resolution mass spectra 
were obtained in the Boston University Mass Spectrometry Laboratory using a Finnegan 
MAT-90 or a Waters Q-TOF mass spectrometer. Analytical thin layer chromatography 
was performed on 0.25 mm silica gel 60-F plates. Visualization was accomplished with 
UV light and aqueous ceric ammonium molybdate solution or basic aqueous potassium 
permanganate solution. Flash chromatography was performed using 200-400 mesh silica 
gel (Scientific Absorbents, Inc.). Yields refer to chromatographically and 
spectroscopically pure materials, unless otherwise stated. All reactions were performed in 
flame-dried glassware under an argon atmosphere unless otherwise noted. 
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Tri-MOM-sanggenol F 219. To a solution of 3,5-bis-
allyloxy-7,2′,4′-triMOM morin 175 (110 mg, 0.21 mmol, 
1.0 equiv) in DCE (2 mL, 0.1 M) was added Eu(fod)3 (20 
mg, 0.02 mmol, 0.10 equiv). The reaction mixture was treated with microwave condition 
at 120 °C for 30 min, before the mixture was cooled to room temperature and 
concentrated in vacuo. The crude mixture was quickly passed through silica gel 
chromatography (15% ethyl acetate in hexanes) to afford a yellow oil (80.3 mg, 73%), 
which was carried on to the cross metathesis step. The yellow oil (45 mg, 0.09 mmol, 1 
equiv) was dissolved in CH2Cl2 (1 mL, 0.09 M) in a flame-dried flask, and 2-methyl-2-
butene (1 mL) and 2
nd
 generation Grubbs catalyst (7.0 mg, 0.001 mmol, 0.05 equiv) was 
added sequentially. The reaction mixture was refluxed at 40 °C for 12 h, and cooled to 
room temperature and concentrated in vacuo. The crude mixture was purified with silica 
gel chromatography (15% ethyl acetate in hexanes) to afford 219 as a yellow oil (45 mg, 
90%).  
Rf: 0.44 (hexanes : ethyl acetate = 4:1). 
1
H NMR (500 MHz, CDCl3) δ 11.92 (s, 1H), 7.43 
(dd, J = 8.3, 0.6 Hz, 1H), 6.74 (s, 1H), 3.45 – 3.45 (m, 3H), 6.72 (dd, J = 11.1, 2.4 Hz, 
1H), 6.17 (s, 1H), 5.21 (s, 2H), 5.15 (s, 2H), 5.18 – 5.13 (m, 1H), 5.13 – 5.09 (m, 1H), 
4.91 (d, J = 7.0 Hz, 1H), 4.85 (d, J = 7.1 Hz, 1H), 3.46 (s, 3H), 3.44 (d, J = 3.6 Hz, 2H), 
123 
 
 
 
3.31 – 3.27 (m, 1H), 3.15 (s, 3H), 3.10 (d, J = 7.6 Hz, 1H), 1.78 (s, 3H), 1.68 (s, 3H), 
1.58 – 1.52 (m, 6H). 13C NMR (125 MHz, CDCl3) δ 194.4, 176.5, 165.0, 161.6, 161.2, 
159.1, 154.8, 137.9, 131.8, 127.7, 122.4, 121.9, 115.6, 110.3, 108.4, 105.5, 102.9, 94.3, 
94.0, 93.9, 93.3, 89.5, 56.4, 56.2, 56.1, 36.2, 25.8, 25.8, 21.2, 18.0, 17.7. IR υmax (film): 
2967, 2933, 1733, 1638, 1574, 1505, 1451, 1316, 1221, 1155, 1079, 1012, 926, 756 cm
-1
. 
HRMS-ESI (m/z): [M + H]
+
 calculated for C31H38O10Na 593.2363, found 593.2375. 
Tri-MOM-chromene 222. To a solution of 219 (5.2 mg, 
0.009 mmol, 1 equiv) in CH2Cl2 (0.5 mL, 0.02 M) in a 
flame-dried sealed tube was added DDQ (2.3 mg, 0.01 
mmol, 1.1 equiv) in one portion. The reaction mixture was 
stirred at 90 °C for 36 h and then cooled to room temperature. The mixture was quenched 
with water and several drops of aqueous NaHCO3 and extracted with ethyl acetate. The 
organic layers were combined and washed with water, brine, dried over Na2SO4, and 
concentrated in vacuo. The crude mixture was purified by silica gel chromatography (20% 
ethyl acetate in hexanes) to afford 222 as a crude yellow oil (1.5 mg, 38% brsm). 
Rf: 0.14 (hexanes : ethyl acetate = 4:1). 
 1
H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 8.7 
Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 8.6, 2.4 Hz, 1H), 6.56 (d, J = 9.9 Hz, 1H), 
6.21 (s, 1H), 5.53 (d, J = 9.9 Hz, 1H), 5.22 – 5.17 (m, 2H), 5.14 (d, J = 1.3 Hz, 2H), 5.13 
– 5.08 (m, 1H), 4.96 – 4.87 (m, 2H), 3.48 (s, 3H), 3.45 (s, 3H), 3.22 (s, 3H), 3.09 (dd, J = 
7.3, 3.8 Hz, 2H), 1.55 (d, J = 1.8 Hz, 6H), 1.54 (s, 3H), 1.43 (s, 3H). 
13
C NMR (125 MHz, 
CDCl3) δ 194.9, 172.9, 162.9, 159.1, 159.0, 156.6, 155.0, 137.3, 127.6, 127.0, 122.3, 
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116.2, 115.8, 108.3, 108.1, 105.7, 103.1, 94.7, 94.3 (2C), 93.9, 89.0, 77.8, 56.5, 56.2, 
56.1, 36.0, 27.9, 27.3, 25.8, 17.9. IR υmax (film): 3489, 3059, 2954, 2927, 2863, 1703, 
1608, 1587, 1501, 1463, 1449, 1379, 1360, 1302, 1266, 1220, 1150, 1069, 1053, 1008, 
968, 886, 792, 751cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C31H36O10Na 
591.2206, found 591.2202. 
 
Tri-TBS-sanggenol F 220. To a solution of racemic 
sanggenol F (1) (110 mg, 0.25 mmol, 1.0 equiv) in CH2Cl2 
(2 mL, 0.1 M) at 0 °C was added triethylamine (259.5 µL, 
1.13 mmol, 4.5 equiv), and TBSOTf (157.6 µL, 1.13 mmol, 4.5 equiv) subsequently. The 
reaction mixture was warmed to room temperature and stirred for 6 h. The reaction was 
quenched with pH 7 buffer and extracted with ethyl acetate. The organic layers were 
combined and washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
crude mixture was purified by quick silica gel chromatography (5% ethyl acetate in 
hexanes) to afford 220 as a crude yellow oil, which was carried on to the next step. 
Rf: 0.88 (hexanes : ethyl acetate = 8:1). 
1
H NMR (500 MHz, CDCl3) δ 12.01 (s, 1H), 7.31 
(d, J = 8.2 Hz, 1H), 6.52 (dd, J = 8.2, 2.1 Hz, 1H), 6.43 (d, J = 2.1 Hz, 1H), 5.81 (s, 1H), 
5.28 (ddq, J = 8.5, 4.3, 1.6 Hz, 1H), 5.13 (tq, J = 3.7, 1.6 Hz, 1H), 3.25 (d, J = 6.7 Hz, 
2H), 3.06 (dd, J = 14.9, 9.4 Hz, 1H), 2.76 (dd, J = 14.7, 5.5 Hz, 1H), 1.77 (s, 3H), 1.68 (s, 
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3H), 1.62 (s, 3H), 1.60 (s, 3H), 1.01 (s, 9H), 1.00 (s, 9H), 0.76 (s, 9H), 0.34 (s, 3H), 0.30 
(s, 3H), 0.27 (s, 3H), 0.23 (s, 3H), 0.21 (s, 6H). 
13
C NMR (125 MHz, CDCl3) δ 187.6, 
163.3, 162.0, 160.1, 159.7, 158.2, 135.9, 131.4, 124.4, 122.6, 122.3, 117.6, 113.9, 112.6, 
103.8, 103.1, 101.2, 97.9, 92.0, 34.7, 31.6, 31.3, 25.8, 25.7, 25.7, 25.6, 25.6, 25.5, 25.3, 
22.7, 21.5, 18.6, 18.3, 18.2, 18.0, 17.9, 14.1, −3.4, −3.5, −4.0, −4.1, −4.5. IR υmax 
(film): 2956, 2930, 2897, 2884, 2859, 1636, 1599, 1571, 1496, 1472, 1439, 1338, 1289, 
1255, 1226, 1209, 1178, 1155, 1096, 1050, 1006, 970, 867, 839, 799, 783 cm
-1
. 
Tri-TBS-chromene 228. To a solution of crude 220 (120 mg, 
0.15 mmol, 1 equiv) in CH2Cl2 (2.0 mL, 0.1 M) in a flame-
dried sealed tube was added DDQ (52 mg, 0.23 mmol, 1.5 
equiv) in one portion. The reaction mixture was stirred at room temperature for 3 h. The 
mixture was quenched with water and several drops of aqueous NaHCO3 and extracted 
with ethyl acetate. The organic layers were combined and washed with water, brine, dried 
over Na2SO4, and concentrated in vacuo. The crude mixture was purified by silica gel 
chromatography (5% ethyl acetate in hexanes) to afford 228 as a crude yellow oil (20 mg, 
18%, 2 steps). 
Rf: 0.64 (hexanes : ethyl acetate = 8:1). 
1
H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.2 Hz, 
1H), 6.45 (d, J = 9.9 Hz, 1H), 6.44 (dd, J = 8.1, 2.2 Hz, 1H), 6.36 (d, J = 2.1 Hz, 1H), 
5.80 (s, 1H), 5.45 (d, J = 9.9 Hz, 1H), 5.30 (ddd, J = 7.7, 5.6, 3.0 Hz, 1H), 2.97 (dd, J = 
15.1, 9.0 Hz, 1H), 2.76 – 2.67 (m, 1H), 1.61 (s, 3H), 1.58 (s, 3H), 1.47 (s, 3H), 1.46 (s, 
3H), 0.97 (s, 9H), 0.96 (s, 9H), 0.73 (s, 9H), 0.31 (s, 3H), 0.23 (s, 3H), 0.22 (s, 3H), 0.20 
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(s, 3H), 0.16 (d, J = 0.9 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) δ 181.7, 161.4, 160.2, 
158.0, 157.2, 156.3, 135.2, 126.6, 124.4, 122.5, 118.0, 116.6, 113.5, 108.2, 105.3, 104.7, 
103.6, 100.0, 91.4, 77.3, 31.7, 27.7, 27.7, 25.8, 25.7 (3C), 25.6 (3C), 25.6 (3C), 18.6, 18.3, 
18.2, 18.0, −3.4, −3.7, −4.3, −4.3, −4.5, −4.5. IR υmax (film): 2957, 2919, 2850, 1737, 
1589, 1473, 1377, 1256, 1159, 1099, 968, 842, 778 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 
calculated for C43H66O7Si3Na 801.4014 found 801.3975. 
 
Sanggenon C (4): To a solution of bis-TBS-
chromene (15 mg, 0.02 mmol, 1 equiv) in DCE 
(0.2 mL, 0.1 M) in a 10 mL drum vial was added 
acetylated 2′-hydroxychalcone (15 mg, 0.04 mmol, 
2 equiv), silver nanoparticle loaded on silica gel (20 mg, 0.25% loading) and HOAc (2.0 
µL, 0.04 mmol, 2 equiv) subsequently. The vial was sealed and the reaction was stirred at 
60 °C for 3 days before being cooled to room temperature. The crude mixture was 
concentrated in vacuo and purified by preparative TLC (40 % ethyl acetate in hexanes) to 
afford a mixture of diastereomers as a colorless oil (12 mg, 50%, 68% brsm). 
The mixture (6 mg, 0.005 mmol, 1 equiv) was dissolved in CH3CN (0.1 mL, 0.05 M) and 
NEt3∙3HF (5 µL, 0.03 mmol, 6 equiv) was added at 0 °C. The reaction mixture was 
warmed to room temperature and stirred for 3 h. The mixture was quenched with pH 7 
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buffer and extracted with ethyl acetate. The organic layers were combined and washed 
with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture was 
purified by preparative TLC (40 % ethyl acetate in hexanes) to afford a mixture of 
diastereomers as a colorless oil. The crude was then dissolved in MeOH (0.5 mL, 0.01 
M), and saturated aqueous NaHCO3 solution (3 drops) was added. The reaction mixture 
was stirred at room temperature for 4 h and quenched with pH 7 buffer. The mixture was 
extracted with ethyl acetate, and the organic layers were combined and washed with brine, 
dried over Na2SO4, and concentrated in vacuo. The crude mixture was purified by 
preparative TLC (40 % ethyl acetate in hexanes) to afford sanggenon C (4) as a colorless 
solid (1.7 mg, 43%). 
Rf: 0.25 (hexanes : ethyl acetate = 3:2). 
1
H NMR (500 MHz, Acetone-d6) δ 8.36 (d, J = 
9.0 Hz, 1H), 7.32 (dd, J = 2317.3, 8.2 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.48 (dd, J = 8.2, 
2.2 Hz, 1H), 6.45 (d, J = 2.5 Hz, 1H), 6.36 (dd, J = 9.0, 2.4 Hz, 1H), 6.32 (d, J = 2.1 Hz, 
1H), 6.27 (dd, J = 8.4, 2.5 Hz, 1H), 6.18 (d, J = 2.4 Hz, 1H), 5.74 (s, 1H), 5.54 (s, 1H), 
5.19 (d, J = 7.2 Hz, 1H), 4.56 (t, J = 6.0 Hz, 1H), 4.11 (s, 1H), 3.86 (q, J = 5.8 Hz, 1H), 
3.10 (dd, J = 14.7, 8.8 Hz, 1H), 2.73 (dd, J = 14.2, 7.0 Hz, 2H), 2.41 (d, J = 17.5 Hz, 1H), 
2.27 (t, J = 7.4 Hz, 1H), 1.87 (s, 3H), 1.60 (s, 3H), 1.52 (s, 1H). IR υmax (film): 3360, 
2963, 2928, 2848, 1718, 1626, 1505, 1452, 1362, 1265, 1221, 1165, 1096, 984, 959, 846, 
797 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C40H37O12 709.2285 found 
709.2291. 
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Sanggenon O (5) was obtained as a colorless solid 
(1.3 mg, 33%) 
Rf: 0.25 (hexanes : ethyl acetate = 3:2). 
1
H NMR 
(500 MHz, acetone-d6) δ 8.37 (d, J = 9.0 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 6.93 (d, J = 
8.4 Hz, 1H), 6.50 (dd, J = 8.3, 2.0 Hz, 1H), 6.47 (d, J = 2.5 Hz, 1H), 6.37 (dd, J = 8.9, 2.5 
Hz, 1H), 6.37 (d, J = 2.1 Hz, 1H), 6.27 (dd, J = 8.4, 2.5 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 
5.73 (s, 1H), 5.56 (s, 1H), 5.06 (t, J = 7.3 Hz, 1H), 4.57 (dd, J = 5.7 Hz, 1H), 4.09 (s, 1H), 
3.84 (d, J = 5.6 Hz, 1H), 3.09 (dd, J = 14.8, 9.1 Hz, 1H), 2.68 (dd, J = 14.7, 6.3 Hz, 1H), 
2.44 (d, J = 17.9 Hz, 1H), 2.26 (d, J = 20.4 Hz, 1H), 1.87 (s, 3H), 1.29 (s, 2H), 1.21 (s, 
3H). IR υmax (film): 3360, 2954, 2923, 2852, 1713, 1628, 1463, 1379, 1362, 1262, 1232, 
1164, 1095, 1024, 840, 803 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 calculated for C40H37O12 
709.2285 found 709.2298. 
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natural (+)-4 
synthetic (±)-4 
(this work) 
Positions δ (JH-H in Hz) δ (JH-H in Hz) 
8 5.75 5.74 
9 2.73 (dd, 14.7, 6.4) 2.73 (dd, 14.2, 7.0) 
9 3.10 (dd, 14.7, 8.8) 3.10 (dd, 14.7, 8.8) 
10 5.19 (t, 7.8) 5.19 (d, 7.2) 
12 1.60 1.60 
13 1.52 1.52 
3′ 6.45 (d, 2.5) 6.45 (d, 2.5) 
5′ 6.48 (dd, 2.1, 8.2) 6.48 (dd, 2.2, 8.2) 
6′ 7.32 (d, 8.2) 7.32 (d, 8.2) 
14 4.11 4.11 
15 5.53 5.54 
17 1.87 1.87 
18 2.31, 2.26 2.26, 2.41 
19 3.86 (q, 5.7) 3.86 (q, 5.8) 
20 4.57 (t, 6.0) 4.56 (t, 6.0) 
24 6.32 (d, 2.1) 6.32 (d, 2.1) 
26 6.36 (dd, 8.9, 2.4) 6.36 (dd, 9.0, 2.4) 
27 8.35 (d, 8.9) 8.36 (d, 9.0) 
30 6.19 (d, 2.4) 6.18 (d, 2.4) 
32 6.27 (dd, 8.4, 2.4) 6.27 (dd, 8.4, 2.5) 
33 6.93 (d, 8.4) 6.93 (d, 8.4) 
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natural (−)-5 
synthetic (±)-5 
(this work) 
Positions δ lit. (JH-H in Hz) δ (JH-H in Hz) 
8 5.72 5.73 
9 2.68 (dd, 6, 14) 2.68 (dd, 14.7, 6.3) 
9 3.08 (dd, 9, 14) 3.09 (dd, 14.8, 9.1) 
10 5.08 (dd, 6, 9) 5.06 (t, 6.5) 
12 1.22 1.21 
13 1.53 1.53 
3′ 6.47 (d, 2) 6.47 (d, 2.5) 
5′ 6.50 (dd, 2, 8) 6.50 (dd, 2.0, 8.3) 
6′ 7.36 (d, 8) 7.34 (d, 8.3) 
14 4.11 (6) 4.09 
15 5.54 5.56 
17 1.86 1.87 
18 2.28, 2.43 2.26, 2.44 
19 3.86 3.84 (q, 5.9) 
20 4.54 4.57 (dd, 5.7) 
24 6.38 (d, 2) 6.37 (d, 2.1) 
26 6.36 (dd, 2, 8) 6.37 (dd, 8.9, 2.5) 
27 8.34 (d, 8) 8.37 (d, 9.0) 
30 6.19 (d, 2) 6.21 (d, 2.4) 
32 6.27 (dd, 2, 8) 6.27 (dd, 8.4, 2.5) 
33 6.93 (d, 8) 6.93 (d, 8.4) 
 
 
3.7. Select NMR spectra.  
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4. Chapter 4 
 
 
Metal-Catalyzed Rearrangements of 3-Flavone Ethers 
 
 
4.1. Introduction. 
An ongoing focus of the Porco laboratory is the examination of different 
reactivities of flavones and related compounds. The flavone ring as an extended 
conjugation system displays various resonance forms
85
 which offer different modes of 
reactivity within the molecule (Scheme 4.1). In addition to the rearrangements of 3-
allyloxyflavone ethers (cf. Chapter 2), we have also investigated alkynyl-Claisen (Saucy-
Marbet) rearrangements of 3-alkynylflavone ethers 239b, as well as 1,3-rearrangements 
of 3-benzylic substituted flavone ethers 239c (Scheme 4.2). These rearrangements 
allowed us to access different substituted 3,4-chromanediones and enabled diversity-
oriented synthesis of novel, complex chemotypes, which was conducted in the CMLD-
BU. 
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Scheme 4.1 Structure and resonance of flavones. 
 
Scheme 4.2 Reactivities of 3-substituted flavone ethers. 
 
4.2. Cascade rearrangements of 3-alkynylchromenone ethers. 
4.2.1. Examples of alkynyl Claisen rearrangements. 
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In comparison to Lewis acid-catalyzed Claisen rearrangements of allyl vinyl 
ethers, reports on catalytic alkynyl Claisen rearrangements are relatively scarce. These 
transformations are usually initiated via activation of the alkyne moiety by transition 
metal catalysts such as Au(I),
120-123
 Ag(I),
124-126
 Pd(II),
127,128
 Rh(I),
129,130
 Cu(I),
131
 and 
Fe(III).
132
 Toste and coworkers have thoroughly studied stereospecific acetylenic Claisen 
rearrangements using gold catalysts (Scheme 4.3).
121
 In the Au(I)-catalyzed [3,3]-
rearrangement of propargyl vinyl ethers (e.g. 243), a detailed mechanistic study 
suggested that the irreversible rearrangement proceeds through a concerted pathway.
133
 
Transient oxocarbenium intermediate 247 may be formed through Au(I)-catalyzed 
cyclization of both propargyl vinyl ether 243 and allenic aldehyde 245, and 247 may be 
subsequently trapped by nucleophiles such as water to yield the hemiacetal product 246.  
Scheme 4.3 Au(I)-catalyzed alkynyl Claisen rearrangement. 
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More recently, the Kozlowski group reported the first asymmetric Saucy-Marbet 
rearrangement to access chiral allenyl oxindoles 249 using chiral Lewis acid catalysts 
Pd(II)/BINAP or Pd(II)/tBuPHOS (Scheme 4.4).
67,76
 The significance of their work lies 
in successfully addressing the challenges in the asymmetric rearrangement of alkynes. In 
such transformations, the alkyne sp-hybridized centers distort the transition-state from the 
usual chair-like geometry, and the cylindrically symmetric alkyne lacks facial 
discrimination. The methodology also permits rapid assembly of complex spirooxindoles 
250, an important class of biologically active compounds. 
Scheme 4.4 Pd(II)/BINAP-catalyzed Saucy Marbet rearrangement of 248. 
 
Transition metal-catalyzed cyclizations of alkynes have also been coupled with 
further cascade reactions to construct complex scaffolds. For example, the Kirsch group 
has designed a Claisen rearrangement/5-exo heterocyclization cascade of propargyl vinyl 
ether 253 to synthesize tri- and tetra-substituted furans 256 in high yield (Scheme 4.5).
123
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Similar strategies have been utilized in the Kirsch group to synthesize other heterocyclic 
scaffolds including pyrroles,
125
 pyrans,
134
 and dihydropyridines.
126
  
Scheme 4.5 Au(I)-catalyzed synthesis of highly substituted furans 256. 
 
Iwasawa and coworkers reported the PtCl2-catalyzed [3+2] cycloaddition cascade 
of the metal-containing azomethine ylides 258 and 259 (Scheme 4.6).
135
 The azomethine 
ylide is believed to be derived from 5-endo cyclization of imine 257, which may 
subsequently undergo dipolar cycloadditions with vinyl ethers to afford the metal carbene 
intermediate 260. Intermediate 260 may subsequently undergo 1,2-alkyl migration to 
yield the tricyclic indole derivative 261. 
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Scheme 4.6 [3+2] Cycloaddition cascade of a platinum-containing azomethine ylide. 
 
 
4.2.2. Evaluation of metal catalysts for the cascade rearrangement of 3-
alkynylflavone ethers 
For the metal-catalyzed alkynyl-Claisen (Saucy-Marbet) rearrangements of 3-
alkynylflavone ethers 262, we began our investigation with the evaluation of alkynophilic 
metal catalysts.
136
 These include late transition metal catalysts containing palladium, gold, 
silver, rhodium, and platinum, as well as metal triflates such as La(OTf)3, Yb(OTf)3, and 
In(OTf)3. Among a panel of catalysts studied, AuCl3 was found to catalyze the 
rearrangement of 262 to afford allenyl 3,4-chromanedione 263 (Table 4.1, entry 1). For 
purification purposes, the resulting chromanedione 263 was condensed with 1,2-
phenylenediamine to provide the chromenoquinoxaline 264.
65
 Other Au(III) aurate salts 
proved to be more efficient catalysts due to their stability. In particular, 5 mol% of 
NaAuCl4∙2H2O at elevated temperature cleanly catalyzed the rearrangement of 262 to 
263, which was followed by diamine condensation to afford 264 in 74% yield (entry 3). 
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In addition to the allene product 264, a small amount of benzofuranone 266 was also 
observed in the AuCl3-catalyzed reaction (entry 1). Due to the lack of conclusive carbon-
proton bond correlations (HSQC and HMBC), NMR studies were found to be 
inconclusive for the structure determination of 266. X-Ray crystal structure analysis 
ultimately confirmed the structure of benzofuranone 266. Use of PtCl2 or PtCl4 also led to 
the formation of 266. At 60 °C, PtCl4 afforded both allene 264 (40%) and 266 (28%). At 
a higher reaction temperature, PtCl2 was more efficient in producing benzofuranone 266 
(53%). The catalyst Rh2(tfa)4
137
 also promoted the rearrangement to afford 266 in 24% 
yield along with a significant amount of propargyl ether cleavage to yield 3-
hydroxyflavone as a major side product.  
Other Pt(II) and Pt(IV) catalysts including Zeise's salt and chloroplatinate(II) and 
(IV) were found to be less effective in catalyzing the desired rearrangement cascade. 
Similarly, Au (I) catalysts in general were found to be unreactive, while the cationic Au(I) 
catalyst (AuCl(PPh3)/AgSbF6) afforded a mixture of products. Other metal catalysts 
including Cu(I), Ag(I), Pd(0) and Pd(II) proved to be unreactive. Rare earth triflates 
(Sc(OTf)3, Yb(OTf)3 and La(OTf)3), which catalyzed the rearrangement of 3-
allyloxyflavone ethers (cf. Chapter 2), were also not effective for rearrangement of 
substrate 262.  
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Table 4.1 Metal screen for alkynyl-Claisen rearrangements of 3-alkynylflavone 
ethers 262. 
 
entry
a
 catalyst T (°C) time (h) 
yield 
264 266 262 
1 AuCl3 60 36 53% 14% 33% 
2 NaAuCl4∙2H2O 60 36 50% trace --- 
3 NaAuCl4∙2H2O 80 60 74% trace --- 
4 PtCl2 60 36 21% -- 60% 
5 PtCl4 60 36 40% 28% 24% 
6 PtCl2 80 60 --- 53%
b
 --- 
7 PtCl4 80 60 --- 44%
b
 --- 
8 Rh2(tfa)4 80 36 --- 24%
b
 --- 
a
 Unless otherwise specified, all reactions were carried out with 0.05 mmol of 
262 and 5 mol% of catalyst at 0.07 M in DCE. Yield calculated on purified 
products 264, 266 and recovered starting material 262. 
b
 The rest of mass 
balance is the deprotection product 3-hydroxyflavone. 
 
4.2.3. Mechanistic studies. 
In order to probe the reaction mechanism, crossover experiments were conducted 
to exclude the possibility of an intermolecular reaction pathway (Scheme 4.7). In the 
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event, rearrangement of an equimolar mixture of closely related butynyl ether 262 and 
pentynyl ether 267 (PtCl2, PtCl4, or NaAuCl4∙H2O, 60°C) solely produced quinoxalines 
264 and 268, respectively, after condensation with 1,2-phenylenediamine. The absence of 
crossover products by mass spectrometric analysis of the crude reaction mixture strongly 
suggests an intramolecular pathway as opposed to an ion pair mechanism.
138
 
Scheme 4.7 Crossover experiments. 
 
Inspired by the work of Toste and coworkers, we also attempted to intercept the 
reaction intermediates with nucleophiles. Treatment of substrate 262 with Au (III) or Pt 
catalysts in the presence of methanol afforded the spirodihydrofuran 270 as a single 
diastereomer (36-58% yield, Scheme 4.8). The formation of product 270 indicates that 
the catalysts preferentially activate the alkyne of chromenone ether substrates towards 5-
endo
139-142
 and not 6-endo cycloisomerization. The greater nucleophilicity of C-3 
adjacent to the carbonyl group may explain the observed selectivity. In the case of PtCl4, 
additional bidentate coordination of the metal catalyst to the O-3 and O-4 may contribute 
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to lower nucleophilicity at C-2, thereby rendering addition at C-3 more preferable. The 
produced platinum-containing oxocarbenium intermediate 269 may be trapped by 
methanol to afford the spirodihydrofuran 270. To understand the observed 
diastereoselectivity for 270, protonated oxonium intermediate 271 was modeled in 
Spartan (Figure 4.1). Steric shielding of the α face of the oxonium by the vinyl methyl 
group may lead to diastereoselective addition of methoxide to the β face, syn to the 
dihydrofuran oxygen (Figure 4.1a). Alternatively, the dihydrofuran oxygen may 
hydrogen-bond with methanol and direct delivery of methanol from the β face (Figure 
4.1b). 
Scheme 4.8 Intermolecular trapping of the oxonium intermediate. 
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Figure 4.1 Molecular model for the formation of cis-spirodihydrofuran 270 (Spartan 
10, Conformer Distribution, DFT/B3LYP/6-31G(d)). 
 
We also evaluated a 3-alkynyl flavone ether substrate bearing an internal 
nucleophile (Scheme 4.9). Treatment of 2′-hydroxyflavone ether 272 with PtCl2 afforded 
allene 273 (45%) along with a trace amount of the bridged dihydropyran product 274. 
The structure of 274 was confirmed by X-ray crystal structure analysis. Both 273 and 274 
are presumably derived from intramolecular trapping of the oxocarbenium 275 by the 
adjacent 2′-hydroxyl group. Use of PtCl4 and NaAuCl4·H2O as catalysts facilitate the 
formation of 274. Eventually, we found that addition of 1,1,1,2,2,2-
hexafluoroisopropanol (HFIP) as a proton source143 provided the bridged dihydropyran 
274 in 44% yield, conceivably by promoting the protodemetalation pathway (Scheme 4.9, 
pathway b) over the elimination pathway (pathway a). Overall, the formation of product 
274 supports the intermediacy of platinum oxocarbenium 275 (cf. Scheme 4.8). 
  
144 
 
 
 
Scheme 4.9 Intramolecular trapping of oxocarbenium intermediate. 
 
 
Additional mechanistic information was also obtained from allenyl 
chromanedione substrate 277, derived from alkynyl flavone ether 276 using Au(III)-
catalyzed rearrangement. When 277 was resubjected to rearrangement conditions at 
80 °C, benzofuranone 278 was isolated in 60-80% yield (Scheme 4.10). This observation 
suggests that allenyl chromanedione substrates may also participate in the metal-
catalyzed cycloisomerization cascade to produce benzofuranone products (Scheme 
4.11).144,145 
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Scheme 4.10 Rearrangement of an allenyl chromanedione. 
 
Based on these experimental results, we propose the overall mechanistic pathway 
as shown in Scheme 4.11. Following the initial 5-endo enyne cyclization
146-150
 of alkynyl 
flavone ether 279, the resulting platinum-containing spiro-oxocarbenium intermediate 
282 may undergo a pinacol-type 1,2-rearrangement
151-155
 to form dipole 284.
156
 
Alternatively, the transformation from 282 to 284 may proceed through the cyclopropyl 
platinacarbene intermediate 283.
157
 Dipole 284 may further fragment to yield allenyl 
chromanedione 280 through platinum dissociation (Scheme 4.11, pathway a, blue arrow). 
At elevated temperatures, intermediate 282 may rearrange via a formal 1,2-acyl migration 
to obtain oxocarbenium 285, which after protodemetalation and aromatization may afford 
furan 281 as the thermodynamic product (Scheme 4.11, pathway b, red arrow). 
Conceivably, allenyl chromanedione 280 may also undergo metal catalyzed 6-endo 
cycloisomerization
 
to yield oxocarbenium intermediates 284 and 282, which following 
similar pathways may produce benzofuranone 281 (Scheme 4.11, pathway b, red arrow). 
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Scheme 4.11 Possible mechanistic pathways. 
 
 
4.2.4. Evaluation of substrate scope. 
Regarding the substrate scope, different substitutions at the terminal position of 
the alkyne such as hydrogen (286a), ethyl (286b) and phenyl (286c) groups (Table 4.2, 
entries 1-3) are tolerated. In the case of a substrate bearing a terminal alkyne, the reaction 
suffered low a yield possibly from side reactions such as metal alkylidene formation 
(entry 1). Reaction of trimethylsilyl alkyne substrate 286d was found to be less successful, 
likely due to inhibition of coordination of the platinum to the alkyne by the silyl moiety 
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(entry 4). Flavone ether 286e derived from a secondary propargylic alcohol was highly 
reactive and afforded the 2,3,5-trisubstituted furanyl benzofuranone 287e in high yield 
(entry 5). 5-Methoxy substrate 286f with increased electron density on the flavone A ring 
underwent smooth acyl migration to afford benzofuranone 287f in high yield (entry 6). In 
contrast, electron withdrawing groups in substrates such as 286g disfavored acyl 
migration yielding 1,2-chromenedione- derived products even at an elevated reaction 
temperature (entry 7). Substrate 286h containing a 6-methoxy group suffered from 
significant loss of the alkynyl group as a side reaction, suggesting the subtle effects of 
substitution patterns on reactivity. Electron rich B rings found in substrates 286j and 
286k (entry 8) favored the cascade process producing benzofuranones 287j and 287k in 
high yields. The electron poor 2′-trifluoromethyl substrate 286i was not a useful substrate 
and did not lead to appreciable amounts of benzofuranone 287i (entry 9). Increased 
nucleophilicity of C-3 and the ability to stabilize the developing positive charge of 
oxocarbenium intermediate 282 (cf. Scheme 4.11) in substrates 286j, k may explain the 
observed reactivity. Different modes of reactivity were observed for substrates 286l-o. 
Reaction of 2-methylchromenone ether 286l terminated at the dicarbonyl stage (entry 10). 
The lack of stabilization by the 2-methyl group of the oxocarbenium intermediate 282 (cf. 
Scheme 4.11) may prompt facile pinacol-type rearrangement to yield oxocarbenium 
intermediate 284 and subsequently the allenyl chromanedione product. Similarly, 3-
hydroxypyrone ether 286m underwent a metal-catalyzed alkynyl-Claisen rearrangement 
to produce allene 287m (entry 11). Related thermal rearrangements have been reported in 
the literature.
158
 In contrast, Pt-mediated rearrangements of chromenone ethers 286n and 
148 
 
 
 
286o (entry 12, 13) furnished pyranochromenones 287n and 287o. The reactions are 
likely to proceed via a cascade involving an alkynyl Claisen rearrangement, 1,3-hydrogen 
migration and final 6π electrocyclization as depicted in Scheme 4.12. 
Table 4.2 Substrate scope of the rearrangement cascade of alkynyl chromenone 
ethers. 
 
entry
a
 substrate product yield% 
1 
  
PtCl2, 20% 
PtCl4, 10% 
2 
  
PtCl2, 43% 
PtCl4, 31% 
3 
  
PtCl2, 31% 
PtCl4, 43% 
4 
 
--- NR
c
 
5 
  
PtCl2, 70% 
PtCl4, 65% 
6 
 
 
PtCl2, 80% 
PtCl4, 64% 
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7
b
 
 
 
PtCl2, 18% 
PtCl4, 12% 
8 
  
PtCl2, 15% 
PtCl4, 15% 
9 
  
PtCl2 
287i: NR
c
 
287j: 53% (48h) 
287k: 67% (24h) 
10
b
 
 
 
PtCl2, 83% 
PtCl4, 36% 
11 
 
 
PtCl2, 50% 
PtCl4, 28% 
12 
 
 
PtCl2, 70% 
 PtCl4, 45%
d 
13 
  
PtCl2, 55% 
PtCl4, 54% 
a
 Unless otherwise specified, all reactions were carried out with 0.05 mmol of 286a-o and 5 
mol% of PtCl2 or PtCl4 at 0.07 M in DCE at 80 °C. The reactions were complete in 12 h. 
b
 
Reaction mixture was treated with 1.5 equivalents of 1,2-phenylenediamine to yield 
quinoxaline. 
c
 No reaction.
 d
 Reaction performed at 60 °C.  
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Scheme 4.12 Proposed mechanism for formation of pyranochromenone 287n. 
 
In future experiments, flavone ethers 286p with bulky substitution at C-9 may 
undergo the rearrangement cascade with chirality transfer
42,43
 to produce 
enantiomerically enriched benzofuranone 287p.
120
 As depicted in Scheme 4.13, 
platinum(II) may chelate to the alkynyl moiety of (S)-286p away from the bulky alkyl 
group and promote a 5-endo enyne cyclization to form intermediate 291 which minimizes 
steric interactions between the alkyl group and platinum. Spiro-oxocarbenium 
intermediate 291 may undergo stereospecific 1,2-acyl migration, protodemetalation, and 
aromatization to form the R enantiomer of 287p. Reactive substrates with bulky 
substitutions at C-9 should be evaluated at lower reaction temperature to test the 
proposed pathway. 
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Scheme 4.13 Planned chirality transfer in the rearrangement cascade of 286p. 
 
 
4.2.5. Diversity-oriented library synthesis based on nucleophilic trapping. 
As part of a collaborative project in the CMLD-BU, we further elaborated the 
reaction pathways in diversity-oriented synthesis. In particular, we were interested in 
intercepting the oxocarbenium intermediate 282 with a variety of nucleophiles (Scheme 
4.14). Among the nucleophiles investigated in a pilot screen, aromatic tethered alcohols 
were successfully added to the oxonium ion to produce spirodihydrofurans 292a,b. These 
reactions resulted in one major diastereomer (dr > 10:1). Based on the nucleophilic 
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trapping reaction with methanol (cf. Scheme 4.8), these spirofurans were assigned cis 
configuration for the nucleophile with respect to the dihydrofuran oxygen. Under various 
reaction conditions, carbon nucleophiles evaluated failed to afford any addition products 
(e.g. methyl malonate, trimethoxyphloroglucinol, and malononitrile). Nitrogen containing 
nucleophiles were also incompatible with the reaction conditions, possibly due to the 
coordination effects of the nitrogen to the catalysts. The scope of the alkynyl flavone 
ethers as well as additional alcohols as nucleophilic reaction partners is currently under 
investigation by Mr. Ahmed Hilmy in the CMLD-BU. 
Scheme 4.14 Nucleophilic trapping of oxonium ion 282. 
 
 
4.3. [1,3]-Rearrangement of 3-benzylic flavone ethers. 
4.3.1. Examples of 1,3-rearrangement. 
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In addition to the [3,3]-rearrangement of 3-allyloxyflavone and 3-alkynyl flavone 
ethers, we also investigated the [1,3]-rearrangement reactivity of 3-benzylic substituted 
flavone ethers. Although [1,3] O-to-C rearrangement was reported more than 100 years 
ago, this class of reactions has received less attention. In terms of frontier molecular 
orbital theory, a [1,3]-rearrangement is symmetry-allowed when it occurs in an 
antarafacial fashion (Figure 4.2). The suprafacial [1,3] shift is symmetry-allowed if the 
migrating group possesses a p-orbital and will proceed with inversion of stereochemistry 
at the migrating carbon.
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Figure 4.2 Frontier molecular orbital theory analysis of the [1,3]-rearrangement. 
 
In the study of the Claisen rearrangement of substituted β-allyoxy amines, 
Barluenga and coworkers observed exclusively the [1,3] shift products when the allylic 
double bond was contained in an aromatic system (Scheme 4.15).
160
  Large secondary 
kinetic isotope effects at C-4 (kH/kD = 1.83) strongly suggest that C-O bond breakage is 
the rate-limiting step. The tendency of the system to preserve aromaticity may account 
for the observed [1,3] reactivity. 
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Scheme 4.15 [1,3] Rearrangement of β-oxy enamines. 
 
4.3.2. Methodology development. 
In the 3-benzylic substituted flavone ethers, we envisioned that the Lewis acid 
catalysts would chelate to the substrates at both O-3 and O-4 (Scheme 4.16). The 
chelation would promote fragmentation of the C-O bond to afford a closely associated 
ion pair intermediate 297 which may recombine to form 3,4-chromanedione 296. The 
outcome of the reaction greatly depends on the ability of the aromatic ring and flavone 
moiety to stabilize the forming charge in intermediate 297. 
  
155 
 
 
 
Scheme 4.16 [1,3]-rearrangement of 3-benzylic substituted flavone ethers. 
 
A catalyst and solvent study showed that Lewis acids such as La(OTf)3 and 
Yb(OTf)3, and non-polar solvents CH2Cl2 and DCE were optimal for the 1,3-
rearrangement. Polar solvents such as acetonitrile and nitromethane and strong Lewis 
acids such as SnCl4, Bi(OTf)3 and Zn(OTf)2 led to cleavage of the ether bond and yielded 
3-hydroxyflavone as a main undesired product. 
Various aromatic substitutions such as 2-furanyl (entry 1), 2-thiophenyl (entry 2), 
and aromatic rings with para electron-donating groups (entry 4), were found to be 
suitable substrates (Table 4.3). Substrates with 3-furanyl (entry 3) and a meta electron-
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donating group (entry 5) were found to be unreactive. The 1,2-dicarbonyl form of the 
intermediates 302 (rather than hydrated hemiacetal form) was confirmed by 
13
C NMR 
analysis. The 3,4-chromanediones were further condensed with 1,2-phenylenediamine to 
afford quinoxalines 303a-e. Quinoxalines 303a-e are currently being tested against four 
gram positive bacteria strains including multidrug resistant methicillin resistant 
staphylococcus aureus strain S. aureus 2996, and vancomycin resistant strain E. faecium 
80. 
Table 4.3 Substrate scope of [1,3]-rearrangement of 301. 
 
entry
a
 substrate 
Substitution 
Ar 
yield%
b
 
1 301a 
 
303a: 90% 
2 301b 
 
303b: 33% 
3 301c 
 
NR
c
 
4 301d 
 
303d: 70% 
5 301e 
 
NR 
a
 Unless otherwise specified, all reactions carried out with 
0.03 mmol of 301a-e and 10 mol% of La(OTf)3 at 0.06 M in 
CH2Cl2 at 40 °C. The reactions were complete in 24 h. 
Reaction mixture was treated with 1.5 equivalents of 1,2-
phenylenediamine to yield quinoxalines 303a-e. 
b
 Yield 
measured on purified 303a-e. 
c
 No reaction. 
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In an attempted asymmetric [1,3]-rearrangement, the La(OTf)3/(R)-Ph-PyBOX 
catalytic system showed low asymmetric induction (38% to 43% ee) (Table 4.4). A less 
organized transition state geometry as well as possible intramolecular reaction pathways 
may explain the observed low enantioselectivity. 
Table 4.4 Asymmetric [1,3]-rearrangement of 3-benzylic substituted flavone ethers. 
 
entry
a
 substrate 
Substitution 
Ar 
yield% of 303
b
 ee of 303
c
 
1 301a 
 
80% 43% 
2 301b 
 
30% 38% 
a
 Unless otherwise specified, all reactions were carried out with 0.05 mmol 
of 301a-e and 10 mol% of La(OTf)3/(R)-Ph-PyBox at 0.07 M in CH2Cl2 at 
40 °C. The reactions were quenched at 24 h. Reaction mixture was then 
treated with 1.5 equivalents of 1,2-phenylenediamine to yield quinoxaline 
303a-e. 
b
 Yield measured on purified 303a-e. 
c
 ee determined on purified 
303a, b by chiral HPLC analysis on a ChiraPak AD-H column. 
 
 
 
 
4.4. Conclusion. 
In summary, we have evaluated the metal-catalyzed alkynyl Claisen (Saucy-
Marbet) rearrangements of 3-alkynyl flavone ethers and discovered a 1,2-acyl migration 
cascade which afforded novel furanyl benzofuranone scaffolds. Mechanistic studies have 
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revealed that the rearrangement is likely initiated by 5-endo enyne cyclization to a 
platinum-containing spiro-oxocarbenium intermediate which is intercepted by methanol 
and other alcohol reaction partners to produce spirodihydrofurans or further rearranged to 
afford allenyl chromanediones and benzofuranones under thermodynamic conditions at 
higher reaction temperatures. Lewis acid-catalyzed [1,3]-rearrangement of 3-benzylic 
substituted flavone ethers was also developed. The resulting chromanedione products 
have been further elaborated to access highly substituted quinoxaline scaffolds. 
 
4.5. Experimental section. 
General Information 
1
H NMR spectra were recorded on a 400 MHz or 500 MHz spectrometer at ambient 
temperature with CDCl3 as the solvent or otherwise stated. 
13
C NMR spectra were 
recorded on a 100 MHz or 125 MHz spectrometer at ambient temperature with complete 
proton decoupling using CDCl3 as the solvent or otherwise stated. Chemical shifts for 
characterized compounds are reported in parts per million relative to CDCl3 (
1H, δ 7.26; 
13C, δ 77.0). Data for 1H NMR are reported as follows: chemical shift, multiplicity (app = 
apparent, par obsc = partially obscure, br = broad, ovrlp = overlapping, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet), coupling constants and integration. 
Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR spectrophotometer. High-
resolution mass spectra were obtained in the Boston University Mass Spectrometry 
Laboratory using a Finnegan MAT-90 or a Waters Q-TOF mass spectrometer. Analytical 
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thin layer chromatography was performed on 0.25 mm silica gel 60-F plates. 
Visualization was accomplished with UV light and aqueous ceric ammonium molybdate 
solution or basic aqueous potassium permanganate solution. Flash chromatography was 
performed using 200-400 mesh silica gel (Scientific Absorbents, Inc.). Yields refer to 
chromatographically and spectroscopically pure materials, unless otherwise stated. All 
reactions were performed in flame-dried glassware under an argon atmosphere unless 
otherwise noted. 
General procedure V for the preparation of 3-substituted ethers. 
 
To a solution of 3-hydroxyflavone (1.0 g, 4.2 mmol, 1.0 equiv) in DMF (10 mL) was 
slowly added 1-bromo-2-butyne (478 µL, 5.5 mmol, 1.3 equiv) and Cs2CO3 (1.78 g, 5.5 
mmol, 1.3 equiv). The reaction was heated to 60°C and stirred overnight. The mixture 
was cooled to room temperature, neutralized with 1N aqueous HCl solution, and 
extracted with diethyl ether three times. The organic layers were combined and washed 
with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture was 
purified by silica gel chromatography. 
3-(But-2-ynyloxy)-2-phenyl-4H-chromen-4-one (262): 
According to General procedure V, compound 262 was obtained 
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as a white solid (1.20 g, 98%).  
Rf: 0.59 (hexanes : ethyl acetate = 4:1). m.p. = 91-93 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) 8.27 (dd, J = 8.0, 1.6 Hz, 1H), 8.16-8.14 (m, 2H), 7.69 (ddd, J = 8.6, 7.0, 1.6 
Hz, 1H), 7.55(dd, J = 8.4 Hz, 1H), 7.52-7.49 (m, 3H), 7.40 (t, J = 7.6 Hz, 1H), 4.89 (q, J 
= 2.3 Hz, 2H), 1.63 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) 175.0, 156.8, 
155.3, 138.8, 133.4, 131.2, 130.5, 128.8 (2C), 128.3 (2C), 125.8, 124.7, 124.0, 118.0, 
84.4, 74.2, 60.0, 3.5. IR max (film): 3079, 2938, 2913, 2860, 2239, 1636, 1615, 1563, 
1467, 1446, 1467, 1395, 1235, 1189, 1147, 1110, 989, 757, 697 cm
-1
. HRMS-ESI (m/z): 
[M+H]
+
 calculated for C19H15O3 291.1021, found 291.1035. 
6-Methyl-3-(pent-2-ynyloxy)-2-phenyl-4H-chromen-4-one 
(267): According to General procedure V, compound 267 
was prepared from the commercially available reagent 3-
hydroxy-6-methylflavone (200 mg, 0.79 mmol) and obtained as a white solid (250 mg, 
99%).
  
Rf: 0.60 (hexanes : ethyl acetate = 4:1). m.p. = 82-84 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) 8.17-8.15 (m, 2H), 8.03 (s, 1H), 7.52-7.42 (m, 5H), 4.91(t, J = 2.3 Hz, 2H), 
2.46 (s, 3H), 2.01-1.96 (m, 2H), 0.89 (t, J = 7.5 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) 
175.1, 156.6, 153.6, 138.8, 134.8, 134.6, 131.3, 130.5, 128.9, 128.2, 125.0, 123.7, 117.7, 
90.2, 74.5, 60.0, 20.9, 13.4, 12.3.IR max (film): 2977, 2938, 2226, 1638, 1618, 1487, 
1447, 1384, 1210, 1161, 810 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C21H19O3 
319.1334, found 319.1331.
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3-(But-2-ynyloxy)-2-(2-hydroxyphenyl)-4H-chromen-4-one 
(272): To a solution of 3-(but-2-ynyloxy)-2-(2-
(methoxymethoxy)phenyl)-4H-chromen-4-one (155 mg, 0.44 mmol, 
1.0 equiv) in dichloromethane (5 mL) was added p-toluenesulfonic acid (101 mg, 0.53 
mmol, 1.2 equiv) in one portion. The reaction was stirred at room temperature for 6 h and 
quenched with water. The mixture was extracted with dichloromethane, the organic 
layers were combined and washed with brine, dried over Na2SO4, and concentrated in 
vacuo. The crude product mixture was purified by silica gel chromatography (10% ethyl 
acetate in hexanes) to afford compound 272 as a light yellow solid (110 mg, 81%).  
Rf: 0.14 (hexanes : ethyl acetate = 4:1). m.p. = 147-149 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) 8.23 (dd, J = 7.9, 1.5 Hz, 1H), 7.86 (s, 1H), 7.72 (dd, J = 7.8, 1.5 Hz, 1H), 
7.67 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.43 (ddd, J = 8.4, 7.2, 1.7 
Hz, 1H), 7.39 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 7.12 (dd, J = 8.2, 1.1 Hz, 1H), 7.07 (ddd, J 
= 7.9, 7.2, 1.1 Hz, 1H), 4.82 (q, J = 2.3 Hz, 2H), 1.49 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 
MHz, CDCl3)  173.8, 156.7, 155.8, 155.1, 137.0, 133.8, 132.8, 129.4, 125.7, 124.9, 
123.7, 120.5, 119.6, 119.4, 118.1, 85.9, 72.8, 61.8, 3.3.IR max (film): 3274, 2233, 1610, 
1562, 1467, 1400, 1190, 1149, 990, 755 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for 
C19H15O4 307.0970, found 307.0984. 
3-(But-2-ynyloxy)-2-(2,4-dimethoxyphenyl)-4H-chromen-4-one 
(276): According to General procedure V, compound 276 was 
prepared from the commercially available reagent 3-hydroxy-2′-
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methoxyflavone (100 mg, 0.34 mmol) and was obtained as a colorless solid (106 mg, 
90%).
  
m.p. = 115-118 °C (EtOAc). 
1
H NMR (500 MHz, CDCl3) 8.25 (dd, J = 7.9, 1.7 Hz, 
1H), 7.61 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 7.9 Hz, 
1H), 7.36 (dd, J = 8.1, 7.2, 1.1 Hz, 1H), 6.58 (dd, J = 8.4, 2.3 Hz, 1H), 6.56 (d, J = 2.3 
Hz, 1H), 4.80 (q, J = 2.3 Hz, 2H), 3.85 (s, 3H), 3.82 (s, 3H), 1.72 (t, J = 2.3 Hz, 3H). 
13
C 
NMR (125 MHz, CDCl3) 174.6, 162.7, 158.7, 157.0, 155.6, 139.3, 133.0, 132.0, 125.6, 
124.3, 124.3, 118.0, 113.0, 104.5, 98.7, 83.3, 74.6, 59.8, 55.7, 55.4, 3.6.IR max (film): 
3007, 2945, 2841, 2223, 1610, 1506, 1466, 1394, 1285, 1210, 1192, 1162, 1111, 1029, 
759 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C21H19O5 351.1232, found 351.1230. 
2-Phenyl-3-(prop-2-ynyloxy)-4H-chromen-4-one (286a): 
According to General procedure V, compound 286a was prepared 
from the commercially available reagent 3-hydroxyflavone (75 mg, 
0.32 mmol) and 3-bromopropyne (50.9 µL, 0.47 mmol, 1.5 equiv) and was obtained as a 
white solid (68 mg, 78%).  
Rf: 0.26 (hexanes : ethyl acetate = 4:1). m.p. = 90-92 °C (EtOAc). 
1
H NMR (500 MHz, 
CDCl3) 8.27 (ddd, J = 8.1, 1.7, 0.5 Hz, 1H), 8.15-8.13 (m, 2H), 7.70 (ddd, J = 8.5, 7.2, 
1.7 Hz, 1H), 7.56 (ddd, J = 8.4, 1.1, 0.5 Hz, 1H), 7.53-7.50 (m, 3H), 7.42 (ddd, J = 7.9, 
7.0, 1.1 Hz, 1H), 4.99 (d, J = 2.4 Hz, 2H), 2.32 (d, J = 2.4 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3) 174.9, 156.7, 155.3, 138.6, 133.6, 130.9, 130.8, 128.9, 128.3, 128.3, 125.8, 
124.8, 124.0, 118.0, 78.6, 76.1, 59.2.IR max (film): 3292, 3242, 3064, 2117, 1637, 1615, 
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1563, 1468, 1396, 1194, 1148, 759 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for 
C18H13O3 277.0865, found 277.0870.  
3-(Pent-2-ynyloxy)-2-phenyl-4H-chromen-4-one (286b): 
According to General procedure V, compound 286b was prepared 
from the commercially available reagent 3-hydroxyflavone (100 mg, 
0.42 mmol) and was obtained as a white solid (120 mg, 94%). 
Rf: 0.60 (hexanes : ethyl acetate = 4:1). m.p. = 79-81 °C (EtOAc). 
1
H NMR (500 MHz, 
CDCl3) 8.27 (dd, J = 8.0, 1.6 Hz, 1H), 8.19-8.17 (m, 2H), 7.69 (ddd, J = 8.6, 7.0, 1.6 
Hz, 1H), 7.56 (dd, J = 8.4, 1.0 Hz, 1H), 7.52-7.50 (m, 3H), 7.41 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1H), 4.92 (t, J = 2.3 Hz, 2H), 1.99 (qt, J = 7.4, 2.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) 174.8, 156.5, 155.1, 138.7, 133.3, 131.0, 130.4, 128.7, 
128.1, 125.5, 124.5, 123.8, 117.8, 90.1, 74.3, 59.8, 13.2, 12.2.IR max (film): 3055, 2977, 
2938, 2238, 1638, 1467, 1395, 1190, 1147, 989, 758 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 
calculated for C20H17O3 305.1178, found 305.1164. 
General procedure VI for the preparation of 3-substituted flavone ethers. 
 
To a flame dried flask was added 3-hydroxyflavone (100 mg, 0.42 mmol, 1.00 equiv), 
triphenylphosphine (110 mg, 0.42 mmol, 1.00 equiv), 3-phenyl-2-propyn-1-ol (58 µL, 
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0.46 mmol, 1.10 equiv), and THF (2 mL). The reaction mixture was cooled to 0°C and 
diisopropyl azodicarboxylate (83 µL, 0.42 mmol, 1.00 equiv) was added in a dropwise 
fashion. The mixture was allowed to warm to room temperature and stirred for 24 h. 
After consumption of starting material, the mixture was concentrated in vacuo and 
purified by silica gel chromatography.  
 2-Phenyl-3-(3-phenylprop-2-ynyloxy)-4H-chromen-4-one (286c) 
was obtained as a colorless solid (125 mg, 85%). 
Rf: 0.36 (hexanes : ethyl acetate = 4:1). m.p. = 107-110 °C (EtOAc). 
1
H NMR (500 MHz, 
CDCl3) 8.29 (dd, J = 8.1, 1.7 Hz, 1H), 8.22-8.20 (m, 2H), 7.68 (ddd, J = 8.7, 7.2, 1.7 
Hz, 1H), 7.54 (dt, J = 8.4, 0.5 Hz, 1H), 7.51-7.50 (m, 3H), 7.41 (ddd, J = 7.8, 7.2, 0.8 Hz, 
1H), 7.26-7.23 (m, 1H), 7.20 (t, J = 7.6 Hz, 2H), 7.10 (dd, J = 8.1, 1.2 Hz, 2H), 5.20 (s, 
2H). 
13
C NMR (125 MHz, CDCl3) 175.0, 156.9, 155.3, 138.8, 133.5, 131.5, 131.1, 
130.7, 129.0, 128.4, 128.4, 128.1, 125.8, 124.8, 124.1, 122.3, 118.0, 87.9, 84.3, 60.1. IR 
max (film): 3057, 2935, 1637, 1615, 1563, 1490, 1467, 1394, 1236, 1189, 1146, 1110, 
993, 895, 755, 703 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C24H17O3 353.1178, 
found 353.1162.  
2-phenyl-3-(3-(trimethylsilyl)prop-2-ynyloxy)-4H-chromen-4-
one: 286d was prepared from the commercially available 
compound 3-hydroxyflavone (150 mg, 0.63 mmol) and 3-bromo-
1-(trimethylsilyl)-1-propyne (123 µL, 0.76 mmol, 1.20 equiv) to afford 286d as a 
colorless oil (208 mg, 95%).
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1
H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 7.9 Hz, 1H), 8.16-8.15 (m, 2H), 7.61 (t, J = 
8.2 Hz, 1H), 7.49-7.45 (m, 4H), 7.33 (t, J = 7.5 Hz, 1H), 4.96 (s, 2H), -0.05 (s, 9H). 
13
C 
NMR (125 MHz, CDCl3) δ 174.6, 156.4, 155.0, 138.6, 133.3, 130.8, 130.5, 128.8, 128.1, 
125.5, 124.5, 123.7, 117.8, 100.2, 93.2, 59.8, -  υmax (film): 3063, 2959, 2183, 
1639, 1611, 1467, 1393, 1250, 1187, 1145, 1022, 842, 757 cm
-1
. HRMS-ESI (m/z): 
[M+H]
+
 calculated for C21H21O3Si 349.1260, found 349.1275.  
3-(Pent-3-yn-2-yloxy)-2-phenyl-4H-chromen-4-one (286e): 
According to General procedure V, compound 286e was prepared 
from the commercially available reagent 3-hydroxyflavone (50 mg, 0.21 mmol) and 4-
bromopent-2-yne
161
 (46 mg, 0.32 mmol) and was obtained as a colorless solid (50 mg, 
78%).  
m.p. = 83-85 °C (CHCl3). 
1
H NMR (500 MHz, CDCl3)8.27 (d, J = 8.0 Hz, 1H), 8.17 (d, 
J = 7.0 Hz, 2H), 7.68 (t, J = 8.2 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.53-7.46 (m, 3H), 
7.40 (t, J = 7.5 Hz, 1H), 5.45-5.37 (m, 1H), 1.58 (d, J = 6.5 Hz, 3H), 1.52 (d, J = 2.2 Hz, 
3H). 
13
C NMR (125 MHz, CDCl3)  175.2, 157.0, 155.3, 138.7, 133.3, 131.6, 130.3, 
129.0, 128.1, 125.8, 124.6, 124.1, 118.0, 82.7, 78.5, 67.5, 22.5, 3.3. IR max (film): 3063, 
2982, 2921, 2851, 1641, 1616, 1565, 1468, 1393, 1303, 1237, 1203, 1145, 1112, 1056, 
993, 903, 760 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C20H17O3 305.1178, found 
305.1180.  
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3-(But-2-ynyloxy)-5-methoxy-2-phenyl-4H-chromen-4-one 
(286f): According to General procedure V, compound 286f was 
prepared from the commercially available reagent 3-hydroxy-5-
methoxyflavone (80 mg, 0.56 mmol) and was obtained as a colorless solid (92 mg, 96%).
 
m.p. = 124-125 °C (EtOAc).  
1
H NMR (500 MHz, CDCl3)  8.12 (dd, J = 8.2, 1.8 Hz, 2H), 7.50 (t, J = 8.4 Hz, 1H), 
7.48-7.41 (m, 3H), 7.06 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 4.87 (q, J = 2.3 Hz, 
2H), 3.96 (s, 3H), 1.60 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) 174.6, 159.8, 
157.2, 154.2, 139.2, 133.4, 130.9, 130.2, 128.5, 128.1, 114.5, 109.9, 105.5, 84.1, 74.4, 
59.8, 56.3, 3.4.IR max (film): 2939, 2842, 2236, 1641, 1599, 1477, 1446, 1395, 1328, 
1262, 1196, 1150, 1100, 1081, 996, 957, 803, 775, 706 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 
calculated for C20H17O4 321.1127, found 321.1138.  
3-(But-2-ynyloxy)-6-nitro-2-phenyl-4H-chromen-4-one 
(286g): 3-Hydroxy-6-nitroflavone was synthesized according 
to literature precedent.
162
 Compound 286g was prepared from 
the resulting 3-hydroxy-6-nitroflavone (280 mg, 0.99 mmol) using General procedure V 
and was obtained as a white solid (265 mg, 80%).  
Rf: 0.37 (hexanes : ethyl acetate = 4:1). m.p. = 165-167 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3)  9.10 (d, J = 2.7 Hz, 1H), 8.49 (dd, J = 9.2, 2.3 Hz, 1H), 8.15-8.12 (m, 2H), 
7.70 (d, J = 9.2 Hz, 1H), 7.54-7.51 (m, 3H), 4.91 (q, J = 2.3 Hz, 2H), 1.62 (t, J = 2.3 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3)  173.7, 157.9, 157.3, 144.3, 139.0, 131.2, 130.1, 
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128.8, 128.4, 127.7, 124.0, 122.6, 119.7, 85.0, 73.7, 60.1, 3.5. IR max (film): 3111, 2238, 
1642, 1604, 1527, 1450, 1387, 1192, 1148, 955, 831, 771 cm
-1
. HRMS-ESI (m/z): 
[M+H]
+
 calculated for C19H14O5N 336.0872, found 336.0880.
3-(But-2-ynyloxy)-6-methoxy-2-phenyl-4H-chromen-4-one 
(286h): 286h was prepared from commercially available 3-
hydroxy-6-methoxyflavone (150 mg, 0.56 mmol) to afford a 
colorless solid (165 mg, 92%).
  
m.p. = 118-121 °C. 
1
H NMR (500 MHz, CDCl3) δ 8.15-8.13 (m, 2H), 7.62 (d, J = 3.2 Hz, 
1H), 7.53-7.49 (m, 3H), 7.48 (d, J = 9.0 Hz, 1H), 7.29 (dd, J = 9.1, 3.1 Hz, 1H), 4.89 (q, J 
= 2.3 Hz, 2H), 3.92 (s, 3H), 1.63 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ 
174.6, 156.5 (2C), 150.1, 138.3, 131.2, 130.4, 128.7, 128.2, 124.6, 123.8, 119.4, 104.4, 
84.3, 74.2, 59.9, 55.8, 3.5. υmax (film): 3076, 2942, 2832, 2223, 1633, 1615, 1566, 
1487, 1452, 1389, 1275, 1213, 1167, 1031, 766 cm
-1
. HRMS-ESI (m/z): [M+H]+ 
calculated for C20H17O4 321.1127, found 321.1127. 
3-(But-2-ynyloxy)-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-
one (286i): 3-Hydroxy-2′-trifluoromethylflavone was synthesized 
using AFO (Algar-Flynn-Olyamada) reaction sequence according to 
literature precedent.
162
 Compound 286i was prepared from 3-hydroxy-2′-
trifluoromethylflavone (169 mg, 0.57 mmol) according to General procedure V and was 
obtained as a white solid (155 mg, 78%).  
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Rf: 0.06 (hexanes : ethyl acetate = 4:1). m.p. = 90-93 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) 8.27 (dd, J = 7.9, 1.7 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 7.5 Hz, 
1H), 7.68-7.64 (m, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.40 (dt, J = 
7.6, 0.8 Hz, 1H), 4.84 (q, J = 2.3 Hz, 2H), 1.65 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, 
CDCl3) 174.7, 156.4, 155.2, 138.7, 133.6, 132.4, 131.3, 130.3, 129.1 (q, 
2
J (C,F) = 31.6 
Hz), 128.84 (q, 
3
J (C,F) = 1.9 Hz), 126.8 (q, 
3
J (C,F) = 5.1 Hz), 125.7, 124.8, 124.3, 
123.6 (q, J (C,F) = 274.0 Hz), 118.0, 84.2, 74.0, 59.8, 3.4.IR max (film): 3073, 2951, 
2227, 1643, 1610, 1467, 1399, 1312, 1272, 1192, 1173, 1130, 1108, 1061, 1036, 990, 903, 
757 cm
-1
.  
3-(But-2-ynyloxy)-2-(2-methoxyphenyl)-4H-chromen-4-one 
(286j): According to General procedure V, compound 286j was 
prepared from the commercially available 3-hydroxy-2′-
methoxyflavone (100 mg, 0.37 mmol) and was obtained as a colorless solid (112 mg, 
94%).  
Rf: 0.42 (hexanes : ethyl acetate = 4:1). m.p. = 137-140 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) 8.28 (dd, J = 7.9, 1.7 Hz, 1H), 7.64 (ddd, J = 8.7, 7.0, 1.7 Hz, 1H), 7.52 (dd, J 
= 7.5, 1.7 Hz, 1H), 7.49-7.45 (m, 2H), 7.38 (dd, J = 8.1, 7.2, 1.1 Hz, 1H), 7.07 (ddd, J = 
7.5, 7.5, 0.9 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.81 (q, J = 2.3 Hz, 2H), 3.85 (s, 3H), 
1.72 (t, J = 2.3 Hz, 3H). 
13
C NMR (125 MHz, CDCl3)  174.7, 157.4, 156.8, 155.7, 139.5, 
133.1, 131.8, 131.1, 125.7, 124.4, 120.3, 120.1, 118.1, 111.3, 83.4, 74.5, 59.9, 55.7, 
3.6.IR max (film): 3070, 2998, 2945, 2829, 2227, 1724, 1640, 1620, 1489, 1466, 1399, 
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1277, 1257, 1193, 1149, 1110, 1024, 991, 756 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 
calculated for C20H17O4 321.1127, found 321.1129. 
3-(But-2-ynyloxy)-2-methyl-4H-chromen-4-one (286l): 286l was 
prepared from 3-hydroxy-2-methyl-4H-chromen-4-one
163
 (300 mg, 
1.7 mmol) to afford as a colorless solid (320 mg, 75%).
  
Rf: 0.59 (hexanes : ethyl acetate = 4:1). m.p. = 88-90 °C. 
1
H NMR (400 MHz, CDCl3) 
(dd, J = 7.9, 1.7 Hz, 1H), (ddd, J = 8.6, 7.0, 1.7 Hz, 1H), dd, J = 8.4, 0.5 
Hz, 1H), (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), (q, J = 2.4 Hz, 2H), 2.47 (s, 3H), 
(t, J = 2.4 Hz, 3H). 13C NMR (100 MHz, CDCl3)  173.5, 160.7, 155.2, 138.5, 132.9, 
125.6, 124.4, 124.2, 117.7, 83.6, 74.6, 59.7, 16.0, 3.5. IR max (film): 2960, 2295, 1636, 
1465, 1411, 1189, 1093, 997, 968, 762 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated for 
C14H12O3Na 251.0684, found 251.0696. 
3-(But-2-ynyloxy)-2-methyl-4H-pyran-4-one (286m): 286m was 
prepared from the commercially available reagent maltol (50 mg, 0.40 
mmol) to afford a yellowish solid (56 mg, 79%).
  
Rf: 0.22 (hexanes : ethyl acetate = 3:2). m.p. = 54-57 °C. 
1
H NMR (400 MHz, CDCl3) 
7.63 (d, J = 5.7 Hz, 1H), 5.34 (d, J = 5.7 Hz, 1H), 4.79 (q, J = 2.3 Hz, 2H), 2.37 (s, 3H), 
1.81 (t, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3)  174.7, 160.5, 153.5, 142.9, 116.9, 
83.6, 74.3, 59.3, 15.0, 3.4.IR max (film): 2923, 2228, 1643, 1427, 1348, 1245, 1174, 961, 
170 
 
 
 
824 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated for C10H10O3Na 201.0528, found 
201.0535. 
3-(But-2-ynyloxy)-4H-chromen-4-one (286n): 286n was prepared 
from 3-hydroxy-4H-chromen-4-one
164
 (50 mg, 0.31 mmol) to afford 
a yellowish solid (45 mg, 68%).  
Rf: 0.37 (hexanes : ethyl acetate = 4:1). m.p. = 120-122 °C. 
1
H NMR (500 MHz, CDCl3) 
8.25 (dd, J = 8.1, 1.7 Hz, 1H), 7.96 (s, 1H), 7.63 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.44 (d, 
J = 8.6 Hz, 1H), 7.36 (ddd, J = 8.1, 7.2, 0.8 Hz, 1H), 4.76 (q, J = 2.5 Hz, 2H), 1.82 (t, J = 
2.5 Hz, 3H). 
13
C NMR (125 MHz, CDCl3)  173.7, 155.7, 144.9, 142.1, 133.4, 125.9, 
124.6, 124.3, 118.1, 85.1, 73.5, 59.2, 3.6. IR max (film): 3110, 3063, 2978, 2227, 1641, 
1608, 1470, 1277, 1191, 1162, 1014, 755 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated 
for C13H11O3 215.0708, found 215.0697.  
3-(But-2-ynyloxy)-2H-chromen-2-one (286o): 286o was prepared 
from the commercially available coumarin (100 mg, 0.62 mmol) to 
afford a yellowish solid (117 mg, 80%).
  
Rf: 0.34 (hexanes : ethyl acetate = 4:1). m.p. = 130-132 °C. 
1
H NMR (500 MHz, CDCl3) 
7.46 (d, J = 7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.31-7.28 (m, 2H), 7.06 (s, 1H), 4.79 
(t, J = 2.3 Hz, 2H), 1.87 (d, J = 2.3 Hz, 3H). 
13
C NMR (125 MHz, CDCl3)  153.8, 146.0, 
138.7, 125.0, 123.0, 121.0, 115.8, 112.5, 111.8, 82.0, 68.6, 53.8, 0.0.IR max (film): 3057, 
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1724, 1626, 1607, 1459, 1299, 1140, 1115, 973, 764 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 
calculated for C13H10O3Na 237.0528, found 237.0528.  
General procedure VII for Metal-Catalyzed Rearrangement of 3-(but-2-nyloxy)-2-
phenyl-4H-chromen-4-one: 
 
To a flame dried 1 mL vial was added substrate 262 (10 mg, 0.03 mmol, 1.0 equiv) and 
1,2-dichloroethane (0.5 mL, 0.07 M). To the mixture was added PtCl4 (0.6 mg, 0.002 
mmol, 0.05 equiv) in one portion. The reaction was heated to 60°C for 36 h and then 
cooled to room temperature before 1,2-phenylenediamine (5.6 mg, 0.05 mmol, 1.5 equiv) 
was added. The mixture was then stirred at room temperature for 2h at which time the 
solvent was removed in vacuo and the crude product purified by silica gel 
chromatography (15% ethyl acetate in hexanes). 
6-(Buta-2,3-dien-2-yl)-6-phenyl-6H-chromeno[4,3-b]quinoxaline 
(264): Allene 264 was obtained as a white solid in 40% yield.  
m.p. = 160-163 °C (EtOAc). 
1
H NMR (500MHz, CDCl3)  8.42 (dd, J 
= 7.9, 1.5 Hz, 1H), 8.09 (dd, J = 8.2, 0.9 Hz, 1H), 7.95 (dd, J = 8.2, 0.9 Hz, 1H), 7.70 
(ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.66 (d, J = 7.3 Hz, 2H), 7.64 (ddd, J = 8.2, 7.2, 1.2 Hz, 
1H), 7.45 (ddd, J = 8.2, 8.2, 1.5 Hz, 1H), 7.40 (dd, J = 7.3 Hz, 2H), 7.34 (dd, J = 7.3 Hz, 
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1H), 7.20 (dd, J = 7.0, 5.1 Hz, 2H), 4.36 (ddd, J = 10.7, 5.8, 2.8 Hz, 1H), 4.25 (ddd, J = 
10.7, 5.8, 3.1 Hz, 1H), 1.76 (dd, J = 3.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) 209.1, 
155.0, 151.5, 143.8, 142.0, 141.3, 139.0, 132.6, 129.9, 129.8, 129.0, 128.8, 128.2, 127.8, 
127.6, 125.4, 122.8, 122.4, 118.4, 102.6, 15.3. IR max (film): 3061, 2916, 2850, 1956, 
1606, 1492, 1461, 1346, 1229, 1030, 944, 751 cm
-1
. HRMS-ESI (m/z): [M + H]
+
 
calculated for C25H19N2O 363.1497, found 363.1489. 
2-(3-Methylfuran-2-yl)-2-phenylbenzofuran-3(2H)-one (266): 
Benzofuranone 266 was obtained as a white solid in 28% yield.  
Rf: 0.59 (hexanes : ethyl acetate = 4:1). m.p. = 102-105 °C (Hexanes). 
1
H NMR (500 
MHz, CDCl3)  7.70 (d, J = 7.6 Hz, 1H), 7.69-7.65 (m, 3H), 7.40-7.33 (m, 3H), 7.29 (d, J 
= 1.5 Hz, 1H), 7.23 (d, J = 8.5 Hz, 1H), 7.12 (t, J = 7.2 Hz, 1H), 6.20 (d, J = 1.5 Hz, 1H), 
1.63 (s, 3H). 
13
C NMR (125 MHz, CDCl3) 197.4, 171.3, 144.8, 142.2, 138.4, 135.1, 
128.6, 128.5, 126.0, 125.4, 122.4, 121.8, 119.5, 114.4, 113.3, 88.4, 10.6.IR max (film): 
3063, 2928, 1726, 1607, 1475, 1462, 1448, 1323, 1298, 1245, 1195, 1165, 1146, 1106, 
953, 875, 747 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C19H15O3 291.1021, found 
291.1035.
 
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Table 4.5 Metal screening for rearrangement of flavone ether 262. 
 
entry metal solvent 
conversion %
a
 
264 266 3HF 
1 PtCl2 DCE 14% --- 21% 
2 PtCl4 DCE 47% 1% 28% 
3 PtCl2 DCE w/ 4ÅMS 8% --- 15% 
4 PtCl4 DCE w/ 4ÅMS 28% 4% 66% 
5 PtCl2 Toluene 44% 14% 37% 
6 PtCl4 Toluene 68% --- 21% 
7 cis-[PtCl2(PPh3)2], AgSbF6 DCE NR
c
, (80°C) 
8 PtI2 DCE NR
c
 
9 PtI4 DCE multiple Products 
10 [Cl2Pt(CH2CH2)]2 DCE --- 29% 71% 
11 Dichloro(ethylenediamine)Pt(II) DCE NR
c
 
12 
[1,1′-
Bis(diphenylphosphino)ferrocene] 
dichloropalladium(II) 
DCE NR
c
 
13 
cis-
Dichlorobis(triphenylphosphine) 
platinum(II) 
DCE NR
c
 
14 
(2,2′-
Bipyridine)dichloroplatinum(II) 
DCE NR
c
 
15 
cis-
Dichlorobis(pyridine)platinum(II) 
DCE NR
c
 
16
b
 K2PtCl4(II) DCE(80°C) NR
c
 
17
b
 K2PtCl6(IV) DCE(80°C) NR
c
 
18 PdCl2 DCE/Toluene decomp. 
19 Pd(OAc)2 DCE/Toluene NR
c
 
20 Au(OAc)3 DCE/Toluene NR
c
 
21
b
 NaAuCl4 2H2O MeOH mostly 3HF 
22
b
 NaAuCl4 2H2O DCE 96% 4% --- 
23
b
 HAuCl4 4H2O DCE 95% 5% --- 
24
b
 NH4AuCl4 xH2O DCE NR
c
 
25 AuCl3, AgOTF DCE NR
c
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26 AuCl3, AgSbF6 DCE NR
c
 
27
b
 HAuBr4 H2O DCE NR
c
 
28
b
 AuBr3 DCE NR
c
 
29 AuCl(PPh3), AgSbF6 DCE multiple Products 
30 [(PPh3Au)3O]BF4 DCE NR
c
 
31
b
 Bu4NAuCl2 DCE NR
c
 
32
b
 IPrAuCl DCE NR
c
 
33
b
 KAu(CN)2 DCE NR
c
 
34 CuI DCE NR
c
 
35 AgOTf DCE NR
c
 
36 AgBF4 DCE NR
c
 
37 Sc(OTf)3 DCE NR
c
 
38 La(OTf)3 DCE NR
c
 
a 
Conversion
 
of the starting material was measured by 
1
H NMR integration. 
b
 5 mol% Catalyst 
used. 
c
 No reaction. 
 
Experimental Procedures and Characterization Data for Mechanistic Studies: 
i). Cross-over Experiment: 
 
Starting from equimolar of butynyl ether 262 (10 mg, 0.034 mmol) and pentynyl ether 
267 (11 mg, 0.034 mmol) and following the general procedure for metal-catalyzed 
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rearrangement of 3-(but-2-ynyloxy)-2-phenyl-4H-chromen-4-one, quinoxaline 264 and 
268 were isolated by preparative thin layer chromatography. 
 2-Methyl-6-(penta-1,2-dien-3-yl)-6-phenyl-6H-chromeno[4,3-
b]quinoxaline (268): Allene 268 was obtained as a colorless solid.  
m.p. = 176-179 °C (EtOAc). 
1
H NMR (400 MHz, CDCl3) 8.21 (d, 
J = 1.7 Hz, 1H), 8.09 (dd, J = 8.4, 1.4 Hz, 1H), 7.94 (dd, J = 8.2, 1.4 Hz, 1H), 7.70 (ddd, 
J = 8.4, 6.9, 1.4 Hz, 1H), 7.66-7.64 (m, 2H), 7.61 (ddd, J = 8.2, 6.9, 1.4 Hz, 1H), 7.40 (t, 
J = 7.2 Hz, 2H), 7.34 (t, J = 7.3 Hz, 1H), 7.26 (dd, J = 8.2, 2.3 Hz, 1H), 7.07 (d, J = 8.2 
Hz, 1H), 4.48 (ddd, J = 10.7, 3.8 Hz, 1H), 4.35 (ddd, J = 10.7, 4.1, 3.5 Hz, 1H), 2.43 (s, 
3H), 2.13-1.97 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) 208.4, 
153.0, 151.9, 143.9, 141.9, 141.3, 139.4, 133.5, 132.2, 129.9, 129.8, 128.8, 128.7, 128.2, 
127.7, 127.6, 125.3, 121.9, 118.2, 109.6, 87.8, 79.5, 20.8, 11.9. IR max (film): 3060, 
2966, 2930, 2854, 1952, 1619, 1497, 1447, 1340, 1238, 1216, 1130, 1002, 755 cm
-1
. 
HRMS-ESI (m/z): [M+H]
+
 calculated for C27H23ON2 391.1810, found 391.1816. 
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Figure 4.3 Combined MS traces for crude reaction mixtures for crossover experiments. a: 
PtCl4. b: PtCl2. c: NaAuCl4∙H2O. 
 
ii). Trapping Experiments: 
 
2-Methoxy-3′-methyl-2-phenyl-5′H-spiro[chroman-3,2′-furan]-4-one 
(270): A flame dried 1 mL vial was charged with substrate 262 (10 mg, 
a 
b 
c 
m
+1 
m
+1 
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0.03 mmol, 1.0 equiv) and 1,2-dichloroethane (0.5 mL, 0.07 M). To the mixture was then 
added freshly distilled methanol (1.4 µL, 0.03 mmol, 1.0 equiv) and catalyst 
NaAuCl4∙H2O (0.7 mg, 0.002 mmol, 0.05 equiv) in one portion. The reaction was heated 
to 60°C for 12 h, cooled to room temperature, filtered through a cotton plug, concentrated 
in vacuo, and purified by silica gel chromatography (5% ethyl acetate in hexanes) to 
produce the spirodihydrofuran 270 as a white solid (8.1 mg, 58%).  
Rf: 0.43 (hexanes : ethyl acetate = 4:1). m.p. = 204-210 °C (decomp) (Hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) (dd, J = 8.2, 1.7 Hz, 1H), 7.79-7.77 (m, 2H), 7.58 
(ddd, J = 9.0, 7.8, 1.8 Hz, 1H), 7.42-7.40 (m, 3H), 7.16 (d, J = 7.8 Hz, 1H), 7.15 (dt, J = 
7.2, 1.1 Hz, 1H), 5.38 (q, J = 1.5 Hz, 1H), 4.73 (dquint, J = 12.7, 2.0 Hz, 1H), 4.16 
(dquint, J = 12.7, 2.3 Hz, 1H), 3.03 (s, 3H), 1.65 (q, J = 1.7 Hz, 3H).13C NMR (125 
MHz, CDCl3)  193.1, 156.4, 136.1, 134.9, 133.8, 129.0, 127.8, 127.7, 126.8, 126.7, 
122.5, 121.9, 118.0, 108.2, 97.0, 75.7, 50.5, 13.2. IR max (film): 3066, 3010, 2854, 1704, 
1608, 1462, 1299, 1234, 1126, 1072, 1051, 1002, 973, 886, 749 cm
-1
. HRMS (ESI+) m/z 
calculated for C20H18O4Na 345.1103, found 345.1106.
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5a-(Buta-2,3-dien-2-yl)-10a-hydroxy-5aH-benzofuro[3,2-
b]chromen-11(10aH)-one (273): A flame dried 1 mL vial was charged 
with substrate 272 (10 mg, 0.03 mmol, 1.0 equiv) and 1,2-
dichloroethane (1.0 mL, 0.03 M). To the mixture was added freshly distilled 1,1,1,2,2,2-
hexafluoroisopropanol (HFIP) (7.2 µL, 0.06 mmol, 2.0 equiv) and PtCl4 (0.6 mg, 0.002 
mmol, 0.05 equiv) in one portion. The reaction was stirred at 80°C for 18 h, and then 
cooled to room temperature, concentrated in vacuo, and purified by silica gel 
chromatography (5% ethyl acetate in hexanes) to afford allene 273 as a yellow oil (4.0 
mg, 40%).  
Rf: 0.46 (hexanes : ethyl acetate = 4:1). 
1
H NMR (400 MHz, CDCl3) 7.90 (dd, J = 7.8, 
1.8 Hz, 1H), 7.54 (dd, J = 7.6, 1.4 Hz, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.31 (dt, J = 7.6, 1.4 
Hz, 1H), 7.06 (dt, J = 7.4, 0.8 Hz, 1H), 7.03 (dt, J = 7.2, 0.8 Hz, 1H), 6.93 (d, J = 8.2 Hz, 
1H), 6.89 (dd, J = 8.6, 0.6 Hz, 1H), 5.28 (s, 1H), 4.88-4.81 (m, 2H), 1.80 (t, J = 3.1 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3)  208.7, 185.5, 161.8, 159.1, 137.6, 131.2, 127.7, 
127.1, 126.4, 122.1, 121.8, 118.4, 116.1, 111.4, 101.0, 96.6, 91.9, 78.0, 16.4. IR max 
(film): 3429, 2907, 2848, 1949, 1691, 1605, 1462, 1327, 1230, 1148, 1110, 993, 958, 747 
cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated for C19H14O4Na 329.0790, found 329.0792. 
Tetracycle 274 was also obtained as a white solid (4.4 mg, 44%).  
Rf: 0.17 (hexanes : ethyl acetate = 4:1). m.p. = 128-132 °C (Hexanes). 
1
H 
NMR (500 MHz, CDCl3)(ddd, J = 7.9, 1.8, 0.6 Hz, 1H), 7.51 (ddd, J = 8.4, 7.2, 
1.7 Hz, 1H), 7.36 (ddd, J = 7.6, 1.4, 0.6 Hz, 1H), 7.22 (ddd, J = 8.1, 7.5, 1.4 Hz, 1H), 
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7.05-7.01 (m, 2H), 6.93 (dt, J = 7.5, 0.9 Hz, 1H), 6.88 (dt, J = 8.1, 0.6 Hz, 1H), 5.83-5.81 
(m, 1H), 4.61-4.56 (m, 1H), 4.38-4.32 (m, 1H), 2.06 (q, J = 1.7 Hz, 3H). 
13
C NMR (100 
MHz, CDCl3) 185.2, 158.6, 157.6, 137.1, 131.0, 129.7, 127.9, 126.5, 124.4, 124.2, 
122.5, 122.2, 120.7, 118.8, 111.4, 103.7, 83.0, 61.7, 16.4.IR max (film): 3067, 2921, 
2870, 1697, 1606, 1462, 1314, 1230, 1198, 1114, 1015, 966, 917, 753 cm
-1
. HRMS-ESI 
(m/z): [M+Na]
+
 calculated for C19H14O4Na 329.0790, found 329.0795. 
iii). Rearrangement of the Allenyl Chromanedione. 
2-(Buta-2,3-dien-2-yl)-2-(2,4-dimethoxyphenyl)chroman-3,4-dione 
(275): A flame dried 1 mL vial was charged with 2′,4′-dimethoxyflavone 
ether 273 (20 mg, 0.06 mmol, 1.0 equiv) and 1,2-dichloroethane (0.5 mL, 
0.12 M). To the mixture was added NaAuCl4∙2H2O (1.1 mg, 0.003 
mmol, 0.05 equiv) in one portion. The reaction was stirred at room temperature for 24 h 
before the solvent was removed in vacuo and the crude mixture purified by silica gel 
chromatography (10% ethyl acetate in hexanes) to afford 275 as a yellow oil (16 mg, 
80%).  
1
H NMR (400 MHz, CDCl3)  7.99 (dd, J = 8.0, 1.6 Hz, 1H), 7.59 (ddd, J = 6.8, 5.6, 1.6 
Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.55 
(dd, J = 8.6, 2.2 Hz, 1H), 6.50 (d, J = 2.2 Hz, 1H), 4.85 (dq, J = 11.5, 3.1 Hz, 1H), 4.75 
(dq, J = 11.5, 3.1 Hz, 1H), 3.82 (s, 3H), 3.63 (s, 3H), 1.82 (t, J = 3.1 Hz, 3H). 
13
C NMR 
(100 MHz, CDCl3)  208.8, 188.5, 176.1, 162.1, 160.6, 158.5, 137.5, 129.8, 128.5, 122.3, 
122.0, 119.5, 119.0, 104.6, 100.0, 95.7, 91.2, 79.1, 55.9, 55.5, 15.6. IR max (film): 2940, 
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2839, 1953, 1736, 1687, 1605, 1505, 1462, 1305, 1210, 1159, 1119, 1029, 758 cm
-1
. 
HRMS-ESI (m/z): [M+H]
+
 calculated for C21H19O5 351.1232, found 351.1222. 
2-(2,4-Dimethoxyphenyl)-2-(3-methylfuran-2-yl)benzofuran-3(2H)-
one (274): Starting from allenyl chromanedione 275 (5.0 mg, 0.01 
mmol, 1.0 equiv), compound 274 was obtained as a yellow oil 
following similar rearrangement procedures (80°C, 24 h, NaAuCl4∙2H2O: 4.0 mg, 80%; 
PtCl2: 3.3 mg, 66%, PtCl4: 3.0 mg, 60%). 
1
H NMR (500 MHz, CDCl3)  7.74 (dd, J = 7.8, 0.6 Hz, 1H), 7.60 (ddd, J = 8.4, 7.2, 1.1 
Hz, 1H), 7.36 (s, 1H), 7.13 (d, J = 8.4 Hz, 1H), 7.09 (t, J = 7.3 Hz, 1H), 6.83 (dd, J = 8.5, 
1.1 Hz, 1H), 6.46-6.43 (m, 2H), 6.23 (s, 1H), 3.79 (s, 3H), 3.48 (s, 3H), 2.11 (s, 3H). 
13
C 
NMR (125 MHz, CDCl3) 198.0, 170.2, 162.2, 159.0, 142.1, 141.8, 137.1, 131.7, 124.7, 
121.7, 121.1, 120.5, 117.9, 114.5, 112.7, 104.7, 99.7, 89.3, 55.6, 55.4, 10.8.IR max 
(film): 3004, 2938, 2840, 1729, 1607, 1463, 1298, 1210, 1160, 1028, 878, 755 cm
-1
. 
HRMS-ESI (m/z): [M+Na]
+
 calculated for C21H18O5Na 373.1052, found 373.1048. 
General procedure VIII for Substrate Scope. 
A flame dried 1 mL vial was charged with chromenone ether 286a (15 mg, 0.05 mmol, 
1.0 equiv) and 1,2-dichloroethane (0.5 mL, 0.07 M). To the mixture was added PtCl2 (0.7 
mg, 0.002 mmol, 0.05 equiv) or PtCl4 (0.8 mg, 0.002 mmol, 0.05 equiv) in one portion. 
The reaction was stirred at 80°C for 24 h and was then cooled to room temperature. The 
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solvent was removed in vacuo and the crude mixture purified by silica gel 
chromatography. 
2-(Furan-2-yl)-2-phenylbenzofuran-3(2H)-one (287a): According to 
General procedure VIII, benzofuranone 287a was obtained as a colorless 
solid after silica gel chromatography (10% ethyl acetate in hexanes) (PtCl2: 3.0 mg, 20%; 
PtCl4: 1.5 mg, 10%).  
m.p. = 95-100 °C (EtOAc). 
1
H NMR (500 MHz, C6D6) 7.89-7.87 (m, 2H)(ddd, J 
= 7.8, 1.5, 0.8 Hz, 1H), 7.10-7.06 (m, 2H), 7.04-7.00 (m, 1H), 6.69 (ddd, J = 8.5, 7.2, 1.5 
Hz, 1H), 6.87 (dd, J = 1.8, 0.8 Hz, 1H), 6.82 (dt, J = 8.4, 0.8 Hz, 1H), 6.49 (ddd, J = 7.9, 
7.2, 0.9 Hz, 1H), 6.27 (dd, J = 3.4, 0.8 Hz, 1H), 5.86 (dd, J = 3.4, 1.8 Hz, 1H). 
13
C NMR 
(125 MHz, C6D6)  196.7, 171.6, 151.7, 144.1, 138.2, 135.8, 128.8, 128.7, 126.4, 125.5, 
122.5, 120.1, 113.4, 111.8, 110.4, 88.2.IR max (film): 2955, 2917, 2860, 1727, 1609, 
1496, 1476, 1463, 1448, 1324, 1299, 1246, 1198, 1152, 1106, 1074, 1016, 977, 977, 755 
cm
-1
.  
2-(3-Ethylfuran-2-yl)-2-phenylbenzofuran-3(2H)-one (287b): Starting 
from substrate 286b (15 mg, 0.05 mmol, 1.0 equiv), benzofuranone 287b 
was obtained as a colorless oil after silica gel chromatography (10% ethyl acetate in 
hexanes) (PtCl2: 6.4 mg, 43%; PtCl4: 4.7 mg, 31%).  
1
H NMR (500 MHz, CDCl3) 7.71 (d, J = 7.6 Hz, 1H), 7.68-7.65 (m, 3H), 7.39-7.35 (m, 
3H), 7.31 (br s, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 6.29 (br s, 1H), 
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1.99 (sp, J = 7.6 Hz, 2H), 0.94 (t, J = 7.6 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) 197.4, 
171.3, 144.3, 142.4, 138.4, 135.3, 128.6, 128.4, 128.2, 126.0, 125.4, 122.4, 119.5, 113.3, 
112.4, 88.4, 18.1, 14.4. IR max (film): 2916, 2849, 1742, 1608, 1463, 1265, 1205, 1062, 
1024, 757, 701 cm
-1
.  
2-Phenyl-2-(3-phenylfuran-2-yl)benzofuran-3(2H)-one (287c): Starting 
from phenylpropynyl ether 286c (20 mg, 0.06 mmol, 1.0 equiv), 
benzofuranone 287c was obtained as a colorless oil following General procedure VIII 
(PtCl2: 6.2 mg, 31%; PtCl4: 8.5 mg, 43%).  
Rf: 0.50 (hexanes : ethyl acetate = 4:1). 
1
H NMR (500 MHz, CDCl3) 7.67 (ddd, J = 8.5, 
7.2, 1.5 Hz, 1H), 7.59 (ddd, J = 7.6, 1.5, 0.6 Hz, 1H), 7.49-7.46 (m, 2H), 7.43 (d, J = 1.8 
Hz, 1H), 7.22 (dt, J = 8.4, 0.6 Hz, 1H), 7.16-7.13 (m, 3H), 7.11-7.02 (m, 6H), 6.51 (d, J 
= 1.8 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) 196.9, 171.0, 145.1, 142.5, 138.4, 134.3, 
132.4, 129.0, 128.3, 128.1, 128.0, 127.5, 127.0, 126.1, 125.4, 122.4, 119.6, 113.5, 113.3, 
88.5. IR max (film): 2930, 2855, 1731, 1610, 1463, 1299, 1202, 956, 857, 756 cm
-1
. 
HRMS-ESI (m/z): [M+Na]
+
 calculated for C24H16O3Na 375.0997, found 375.1015.  
2-(3,5-Dimethylfuran-2-yl)-2-phenylbenzofuran-3(2H)-one (287e): 
Starting from flavone ether 286e (10 mg, 0.03 mmol, 1.0 equiv), 
benzofuranone 287e was obtained as a colorless solid following General procedure 
VIII (PtCl2: 7.0 mg, 70%; PtCl4: 6.5 mg, 65%).  
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m.p. = 85-87 °C (CHCl3).
 1
H NMR (500 MHz, CDCl3) δ 7.72-7.62 (m, 4H), 7.40-7.33 (m, 
3H), 7.23 (d, J = 8.4 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 5.80 (s, 1H), 2.17 (s, 3H), 1.53 (s, 
3H). 
13
C NMR (125 MHz, CDCl3)  197.7, 171.3, 152.0, 142.9, 138.3, 135.3, 128.5, 
128.5, 126.0, 125.4, 123.1, 122.2, 119.6, 113.3, 110.7, 88.8, 13.5, 10.6. IR max (film): 
3066, 2923, 2851, 1728, 1612, 1476, 1463, 1448, 1323, 1300, 1254, 1197, 1147, 990, 949, 
880, 758, 729 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for C20H17O3 305.1178, found 
305.1179. 
4-Methoxy-2-(3-methylfuran-2-yl)-2-phenylbenzofuran-3(2H)-one 
(287f): Starting from 5-methoxyflavone ether 286f (20 mg, 0.06 mmol, 1.0 
equiv), benzofuranone 287f was obtained as a white solid following 
General procedure VIII (12 h, PtCl2: 16.0 mg, 80%; PtCl4: 12.8 mg, 64%).  
m.p. = 156-158 °C (EtOAc). 
1
H NMR (500 MHz, CDCl3) 7.67 (dd, J = 8.4, 1.8 Hz, 
2H), 7.57 (t, J = 8.2 Hz, 1H), 7.38-7.33 (m, 3H), 7.28 (d, J = 1.7 Hz, 1H), 6.78 (d, J = 
8.3 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.19 (d, J = 1.8 Hz, 1H), 3.93 (s, 3H), 1.62 (s, 3H). 
13
C NMR (125 MHz, CDCl3)  194.7, 172.3, 159.0, 145.0, 142.1, 139.8, 135.4, 128.5, 
128.4, 126.0, 121.8, 114.3, 108.7, 105.0, 103.6, 88.2, 56.1, 10.6.IR max (film): 3018, 
2925, 2848, 1729, 1714, 1605, 1492, 1449, 1340, 1262, 1162, 1097, 964, 860, 790, 747, 
730 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated for C20H16O4Na 343.0946, found 
343.0946. 
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6-(Buta-2,3-dien-2-yl)-2-nitro-6-phenyl-6H-chromeno[4,3-
b]quinoxaline (287g): A flame dried 1 mL vial was charged with 
substrate 286g (15 mg, 0.04 mmol, 1.0 equiv) and 1,2-
dichloroethane (0.5 mL, 0.07 M). To the mixture was added PtCl2 (0.6 mg, 0.002 mmol, 
0.05 equiv) or PtCl4 (0.8 mg, 0.002 mmol, 0.05 equiv) as catalyst in one portion and the 
reaction was heated to 80°C for 12 h. The reaction was cooled to room temperature and 
1,2-phenylenediamine (7.1 mg, 0.05 mmol, 1.5 equiv) was added. The mixture was then 
stirred at room temperature for 2h before solvent was removed in vacuo. The crude 
product was purified by silica gel chromatography (5% ethyl acetate in hexanes) to 
produce 287g as a white solid (PtCl2: 3.3 mg, 18%; PtCl4: 2.1 mg, 12%).  
m.p. = 215-218 °C (decomp) (EtOAc). 
1
H NMR (400 MHz, CDCl3) 9.35 (d, J = 2.7 Hz, 
1H), 8.34 (dd, J = 9.0, 2.7 Hz, 1H), 8.15 (dd, J = 8.4, 0.8 Hz, 1H), 7.99 (dd, J = 8.4, 0.8 
Hz, 1H), 7.78 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H), 7.70 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H), 7.63-
7.60 (m, 2H), 7.45-7.38 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 4.41 (dq, J = 11.1, 2.9 Hz, 1H), 
4.30 (dq, J = 11.1, 2.9 Hz, 1H), 1.76 (t, J = 2.9 Hz, 3H). 
13
C NMR (100 MHz, CDCl3)  
209.1, 159.6, 150.2, 143.4, 142.0, 141.7, 141.7, 138.0, 130.6, 129.9, 129.8, 129.2, 128.2, 
128.0, 127.9, 127.5, 122.8, 121.8, 119.3, 102.3, 89.2, 77.6, 15.3. IR max (film): 2961, 
2921, 1738, 1619, 1523, 1148, 1341, 1261, 1091, 1012, 794, 752 cm
-1
. HRMS-ESI (m/z): 
[M+H]
+
 calculated for C25H18O3N3 408.1348, found 408.1347. 
2-(2-Methoxyphenyl)-2-(3-methylfuran-2-yl)benzofuran-3(2H)-
one (287j): Starting from 2′-methoxyflavone ether 286j (15 mg, 0.05 
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mmol, 1.0 equiv), benzofuranone 287j was obtained as a yellowish oil following General 
procedure VIII after 48 h (8.7 mg, 53%).  
1
H NMR (500 MHz, CDCl3)  7.76 (d, J = 7.5 Hz, 1H), 7.62 (dddd, J = 8.9, 7.3, 1.5, 1.5 
Hz, 1H), 7.37-7.34 (m, 2H), 7.14 (d, J = 8.2 Hz, 1H), 7.11 (t, J = 7.3 Hz, 1H), 6.96-6.88 
(m, 3H), 6.25 (d, J = 1.5 Hz, 1H), 3.50 (s, 3H), 2.11 (s, 3H). 
13
C NMR (100 MHz, CDCl3) 
197.9, 170.2, 157.8, 142.2, 141.5, 137.2, 131.1, 130.8, 125.4, 124.7, 121.9, 121.1, 121.0, 
120.7, 114.6, 112.7, 112.0, 89.3, 55.6, 10.8.IR max (film): 2929, 2842, 1729, 1601, 1490, 
1463, 1286, 1252, 1199, 1023, 879, 752 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 calculated for 
C20H16O4Na 343.0946, found 343.0948. 
6-(Buta-2,3-dien-2-yl)-6-methyl-6H-chromeno[4,3-b]quinoxaline 
(287l): A flame dried 1 mL vial was charged with 286l (10 mg, 0.04 
mmol, 1.0 equiv) and 1,2-dichloroethane as solvent (0.5 mL, 0.07 M). 
To the mixture was then added metal catalyst (PtCl2 (0.5 mg, 0.002 mmol, 0.05 equiv) or 
PtCl4 (0.6 mg, 0.002 mmol, 0.05 equiv)) in one portion and the reaction was stirred at 
80°C for 12 h before being cooled to room temperature. 1,2-Phenylenediamine (7.1 mg, 
0.05 mmol, 1.5 equiv) was added and the reaction mixture was then stirred at room 
temperature for 2h before solvent was removed in vacuo. The crude was purified by silica 
gel chromatography (5% ethyl acetate in hexanes) to yield 287l as a white solid (PtCl2: 
10.9 mg, 83%; PtCl4: 9.4 mg, 36%).  
m.p. = 95-98 °C. 
1
H NMR (500 MHz, CDCl3) 8.40 (dd, J = 7.8, 1.7 Hz, 1H), 8.11 (dd, 
J = 8.4, 1.4 Hz, 1H), 8.07 (dd, J = 8.1, 1.2 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 
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7.69 (ddd, J = 8.4, 7.0, 1.7 Hz, 1H), 7.42 (ddd, J = 8.1, 7.3, 1.7 Hz, 1H), 7.17 (ddd, J = 
7.6, 7.6, 1.1 Hz, 1H), 7.05 (dd, J = 8.2, 0.9 Hz, 1H), 4.27 (dq, J = 10.5, 3.1 Hz, 1H), 4.20 
(dq, J = 10.5, 3.1 Hz, 1H), 2.12 (s, 3H), 1.78 (t, J = 3.1 Hz, 3H). 
13
C NMR (125 MHz, 
CDCl3) 207.3, 155.2, 152.5, 143.6, 142.2, 141.5, 132.5, 129.8, 129.3, 129.1, 128.9, 
125.3, 122.5, 122.3, 118.2, 102.3, 82.8, 22.7, 14.0. IR max (film): 3061, 2987, 2924, 
2855, 1956, 1606, 1492, 1460, 1346, 1234, 1100, 1080, 1001, 850, 763 cm
-1
. HRMS-ESI 
(m/z): [M+H]
+
 calculated for C20H17ON2 301.1341, found 301.1331. 
2-(Buta-2,3-dien-2-yl)-2-methyl-2H-pyran-3,4-dione (287m): Starting 
from maltol ether 286m (10 mg, 0.06 mmol, 1.0 equiv), 287m was obtained 
following General procedure VIII after 36 h as a yellow oil (PtCl2: 5.0 mg, 
50%; PtCl4: 2.8 mg, 28%).  
Rf: 0.51 (hexanes : ethyl acetate = 3:2). 
1
H NMR (400 MHz, CDCl3) 7.47 (d, J = 6.2 
Hz, 1H), 5.86 (d, J = 6.2 Hz, 1H), 4.89 (q, J = 3.1 Hz, 2H), 1.72 (m, 6H). 
13
C NMR (100 
MHz, CDCl3) 206.1, 191.7, 176.4, 163.7, 108.9, 96.5, 93.0, 79.5, 20.5, 13.3.IR max 
(film): 2925, 2854, 1724, 1624, 1444, 1386, 1101, 1045, 755 cm
-1
.  
4-Methylpyrano[3,2-b]chromen-10(2H)-one (287n): Starting from 3-
(but-2-ynyloxy)-2-methyl-4H-chromen-4-one 286n (10 mg, 0.04 mmol, 
1.0 equiv), 287n was obtained following General procedure VIII (at 
60 °C) as a white solid (PtCl2: 36h, 7 mg, 70%; PtCl4: 12h, 4.5 mg, 45%).  
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Rf: 0.08 (hexanes : ethyl acetate = 4:1). m.p. = 94-97 °C (decomp). 
1
H NMR (400 MHz, 
CDCl3) 8.27 (dd, J = 8.0, 1.5 Hz, 1H), 7.62 (ddd, J = 8.4, 7.2, 1.5 Hz, 1H), 7.46 (d, J = 
8.4 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 5.88-5.86 (m, 1H), 4.83 (q, J = 1.8 Hz, 2H), 2.09 (d, 
J = 1.6 Hz, 3H). 
13
C NMR (100 MHz, CDCl3)  171.2, 154.3, 149.6, 137.2, 132.9, 127.9, 
126.0, 124.6, 124.5, 124.4, 117.9, 65.5, 15.1.IR max (film): 2993, 2918, 1723, 1627, 
1610, 1469, 1197, 1113, 1075, 756 cm
-1
. HRMS-ESI (m/z): [M+H]
+
 calculated for 
C13H11O3 215.0708, found 215.0716.  
1-Methylpyrano[2,3-c]chromen-5(3H)-one (287o): Starting from 
coumarin ether 286o (10 mg, 0.05 mmol, 1.0 equiv), 287o was obtained 
following General procedure VIII after 36 h as a yellow oil (PtCl2: 24 h, 
5.5 mg, 55%; PtCl4: 12 h, 5.4 mg, 54%).  
Rf: 0.17 (hexanes : ethyl acetate = 4:1). 
1
H NMR (400 MHz, CDCl3) 7.75 (d, J = 8.2 
Hz, 1H), 7.41 (t, J = 7.1 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.27 (t, J = 7.1 Hz, 1H), 5.90 
(m, 1H), 4.69 (d, J = 3.1 Hz, 2H), 2.31 (s, 3H). 
13
C NMR (125 MHz, C6D6)  155.9, 
150.4, 140.5, 129.9, 128.1, 126.1, 125.4, 123.6, 122.0, 118.2, 117.3, 64.6, 20.5. IR max 
(film): 3408, 1721, 1613, 1454, 1291, 1153, 756 cm
-1
. HRMS-ESI (m/z): [M+Na]
+
 
calculated for C13H10O3Na 237.0528, found 237.0524. 
General procedure IX for nucleophilic trapping. 
A flame dried 1 mL vial was charged with substrate 262 (62 mg, 0.21 mmol, 1.0 equiv) 
and 1,2-dichloroethane (1.5 mL, 0.14 M). To the mixture was then added 2-furfuryl 
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alcohol (27 µL, 0.21 mmol, 1.5 equiv) and catalyst NaAuCl4∙H2O (4.2 mg, 0.012 mmol, 
0.05 equiv) in one portion. The reaction was heated to 60°C for 12 h, cooled to room 
temperature, filtered through a cotton plug, concentrated in vacuo, and purified by silica 
gel chromatography.  
Spirodihydrofuran 292a was produced as a colorless oil (39 mg, 47%).
 
Rf: 0.29 (hexanes : ethyl acetate = 4:1). 
1H NMR (400 MHz, ) δ 7.93 (dd, 
J = 7.8, 1.6 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.56 (td, J = 7.8, 1.5 Hz, 1H), 
7.46 – 7.39 (m, 3H), 7.17 – 7.09 (m, 3H), 6.12 (dd, J = 3.1, 1.7 Hz, 1H), 
5.89 (d, J = 3.2 Hz, 1H), 5.38 (d, J = 1.6 Hz, 1H), 4.71 (d, J = 12.8 Hz, 1H), 4.16 (d, J = 
12.8 Hz, 1H), 4.12 (q, J = 7.3 Hz, 2H), 1.66 (d, J = 2.0 Hz, 3H). 
13
C NMR (100 MHz, 
CDCl3) δ 193.0, 156.4, 150.5, 142.2, 136.1, 135.1, 133.7, 129.2, 127.9, 127.8, 126.9, 
126.7, 122.5, 121.8, 118.1, 110.1, 108.9, 108.2, 96.9, 75.7, 58.0, 13.3. IR υmax (film): 
3385, 3069, 2954, 2926, 2860, 1704, 1609, 1585, 1463, 1149, 1322, 1300, 1276, 1230, 
1150, 1126, 1067, 1053, 1029, 1008, 970, 886, 750 cm
-1
. HRMS (ESI+) m/z calculated 
for C24H20O5Na 411.1208, found 411.1209. 
Spirodihydrofuran 292b was produced using furan-3-ylmethanol (27 µL, 
0.21 mmol, 1.5 equiv) according to General procedure IX as a colorless 
oil (42 mg, 51%). 
Rf: 0.37 (hexanes : ethyl acetate = 4:1). 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 7.8, 
1.7 Hz, 1H), 7.87 – 7.81 (m, 2H), 7.59 – 7.51 (m, 1H), 7.42 (dd, J = 5.0, 1.9 Hz, 3H), 
7.16 – 7.07 (m, 3H), 7.02 (dd, J = 1.6, 0.8 Hz, 1H), 5.81 – 5.78 (m, 1H), 5.38 (d, J = 1.7 
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Hz, 1H), 4.71 (dt, J = 12.8, 2.1 Hz, 1H), 4.20 (d, J = 0.9 Hz, 2H), 4.16 (dt, J = 12.7, 2.1 
Hz, 1H), 1.66 (q, J = 2.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ 193.0, 156.4, 142.6, 
140.0, 136.0, 135.1, 133.7, 129.1, 127.8, 127.6, 127.5, 126.8, 126.8, 126.6, 122.4, 121.9, 
121.4, 118.0, 109.8, 108.1, 96.9, 75.6, 57.2, 13.2. IR υmax (film): 3384, 3067, 3016, 2955, 
2925, 2859, 1704, 1608, 1586, 1503, 1475, 1462, 1321, 1299, 1277, 1230, 1150, 1125, 
1103, 1067, 1052, 1029, 971, 874, 749 cm
-1
. HRMS (ESI+) m/z calculated for 
C24H20O5Na 411.1208, found 411.1192. 
301a was prepared from 3-hydroxyflavone (250 mg, 1.05 mmol, 1.0 
equiv) and furfuryl alcohol (91 µL, 1.05 mmol, 1.0 equiv) according 
to General procedure VI as a yellowish solid (330 mg, 99%).  
Rf: 0.51 (hexanes : ethyl acetate = 4:1). m.p. = 53-55 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) δ 8.29 (dd, J = 8.0, 1.8 Hz, 1 H), 7.96-8.02 (m, 4 H), 7.69 (ddd, J = 8.6, 7.0, 1.6 
Hz, 2 H), 7.53 (d, J = 8.4 Hz, 1 H), 7.39-7.47 (m, 4 H), 7.17-7.19 (m, 1 H), 6.23 (d, J = 
3.3 Hz, 1 H), 6.17 (dd, J = 3.1, 2.4 Hz, 1 H), 5.20 (s, 2 H). 
13
C NMR (100 MHz, CDCl3) 
δ 175.1, 156.6, 155.3, 150.2, 148.9, 143.1, 133.4, 130.7, 130.4, 128.7, 128.1, 125.8, 124.7, 
124.1, 118.0, 111.1, 110.2, 65.0. HRMS (ESI+) m/z calculated for C20H14O4Na 341.0790, 
found 341.0805. 
301b was prepared from 3-hydroxyflavone (250 mg, 1.05 mmol, 1.0 
equiv) and 2-thiophenemethanol (99 µL, 1.05 mmol, 1.0 equiv) 
according to General procedure VI as a yellowish solid (300 mg, 86%).  
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Rf: 0.41 (hexanes : ethyl acetate = 4:1). m.p. = 81-83 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) δ 8.30 (ddd, J = 8.2, 1.8, 0.6 Hz, 1 H), 7.98-8.03 (m, 2 H), 7.69 (ddd, J = 8.6, 7.2, 
1.8 Hz, 1 H), 7.53 (d, J = 8.4 Hz, 1 H), 7.45-7.50 (m, 3 H), 7.43 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1 H), 7.21 (dd, J = 5.1, 1.2 Hz, 1 H), 6.95 (d, J = 3.3 Hz, 1 H), 6.86 (dd, J = 5.1, 3.5 
Hz, 1 H), 5.37 (s, 2 H). 
13
C NMR (100 MHz, CDCl3) δ 175.1, 156.6, 155.3, 139.1, 138.7, 
133.5, 130.9, 130.6, 128.9, 128.3, 128.3, 126.9, 126.5, 125.7, 124.8, 124.1, 118.1, 67.6. 
IR υmax (film): 3292, 3066, 2874, 1636, 1612, 1564, 1483, 1468, 1418, 1396, 1346, 1290, 
1236, 1197, 1145, 1077, 1034, 991, 897, 757 cm
-1
. HRMS (ESI+) m/z calculated for 
C20H14O3SNa 357.0561, found 357.0560. 
301c was prepared from 3-hydroxyflavone (250 mg, 1.05 mmol, 1.0 
equiv) and 2-thiophenemethanol (90 µL, 1.05 mmol, 1.0 equiv) 
according to General procedure VI as a yellowish solid (310 mg, 93%).  
Rf: 0.69 (hexanes : ethyl acetate = 3:2). m.p. = 95-97 °C (EtOAc). 
1
H NMR (500 MHz, 
CDCl3) δ 8.29 (ddd, J = 8.0, 1.7, 0.5 Hz, 1H), 8.07-8.00 (m, 2H), 7.69 (ddd, J = 8.6, 7.1, 
1.7 Hz, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.51-7.47 (m, 3H), 7.42 (ddd, J = 8.1, 7.1, 1.1 Hz, 
1H), 7.33 (dq, J = 1.6, 0.8 Hz, 1H), 7.24 (t, J = 1.7 Hz, 1H), 6.21 (dd, J = 1.9, 0.8 Hz, 
1H), 5.09 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 175.1, 156.3, 155.1, 142.9, 141.6, 
139.3, 133.3, 130.9, 130.5, 128.7, 128.2, 125.6, 124.6, 124.0, 120.9, 117.9, 110.6, 64.8. 
IR υmax (film): 3124, 3065, 2925, 2867, 1636, 1614, 1563, 1467, 1446, 1398, 1342, 
1292,1237, 1195, 1145, 1109, 1077, 1020, 989, 899, 874, 796, 759 cm
-1
. HRMS (ESI+) 
m/z calculated for C20H14O4Na 341.0790, found 341.0790. 
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301d was prepared from 3-hydroxyflavone (250 mg, 1.05 mmol, 
1.0 equiv) and (4-methoxyphenyl)methanol (130 µL, 1.05 mmol, 
1.0 equiv) according to General procedure VI as a yellowish solid (360 mg, 96%).  
Rf: 0.43 (hexanes : ethyl acetate = 4:1). m.p. = 83-85 °C (EtOAc). 
1
H NMR (400 MHz, 
CDCl3) δ 8.30 (dd, J = 8.0, 1.8 Hz, 1 H), 7.97-8.02 (m, 2 H), 7.67 (ddd, J = 8.4, 7.0, 1.6 
Hz, 1 H), 7.52 (d, J = 8.8 Hz, 1 H), 7.43-7.49 (m, 3 H), 7.41 (ddd, J = 8.2, 7.2, 1.0 Hz, 1 
H), 7.21 (d, J = 8.6 Hz, 2 H), 6.75 (d, J = 8.8 Hz, 2 H), 5.06 (s, 2 H), 3.76 (s, 3 H). 
13
C 
NMR (100 MHz, CDCl3) δ 174.9, 159.2, 156.2, 155.0, 139.4, 133.2, 130.7, 130.3, 130.3, 
128.6, 128.4, 128.0, 125.4, 124.4, 123.8, 117.8, 113.3, 73.4, 54.9. IR υmax (film): 3070, 
2998, 2984, 2836, 1637, 1613, 1513, 1467, 1396, 1292, 1248, 1195, 1144, 1109, 1033, 
991, 822, 756 cm
-1
. HRMS (ESI+) m/z calculated for C23H18O4Na 381.1103, found 
381.1103. 
301e was prepared from 3-hydroxyflavone (250 mg, 1.05 mmol, 
1.0 equiv) and 2-thiophenemethanol (176 µL, 1.05 mmol, 1.0 
equiv) according to General procedure VI as a yellowish solid (350 mg, 93%).  
m.p. = 69-70 °C (EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 8.1 Hz, 1 H), 8.00-
8.04 (m, 2 H), 7.68 (dd, J = 8.8, 6.9 Hz, 1 H), 7.52 (d, J = 8.5 Hz, 1 H), 7.44-7.49 (m, 3 
H), 7.42 (dd, J = 7.8, 6.9 Hz, 1 H), 7.15 (t, J = 8.2 Hz, 1 H), 6.85-6.89 (m, 2 H), 6.79 (d, 
J = 8.4 Hz, 1 H), 5.14 (s, 2 H), 3.67-3.70 (m, 3 H). 
13
C NMR (100 MHz, CDCl3) δ 174.9, 
159.3, 156.1, 155.0, 139.6, 137.9, 133.3, 130.8, 130.4, 129.0, 128.7, 128.1, 125.5, 124.5, 
123.9, 120.8, 117.9, 114.2, 113.3, 73.8, 54.9. IR υmax (film): 3278, 3065, 2956, 2835, 
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1637, 1613, 1563, 1490, 1466, 1395, 1291, 1264, 1236, 1196, 1145, 1110, 1035, 993, 899, 
758 cm
-1
. HRMS (ESI+) m/z calculated for C23H18O4Na 381.1103, found 381.1109. 
General procedure X for [1,3]-rearrangement of 3-benzylic substituted flavone 
ethers. 
To a 5 mL dram vial with 4Å molecular sieves (5.0 mg, flame dried) was added a 
solution of 301a (10.0 mg, 0.03 mmol, 1.0 equiv) in DCE (0.5 mL, 0.06M) via cannula. 
La(OTf)3 (1.64 mg, 0.003 mmol, 0.10 equiv) was subsequently added in one portion. The 
reaction mixture was stirred at 40 °C for 24 h and then cooled to room temperature. The 
crude was carried on to the next step without purification. 
Following General procedure X, the reaction mixture was added 
1,2-phenylenediamine (7.5 mg, 0.07 mmol, 2.5 equiv) and stirred 
at room temperature for 2 h, before being filtered through Celite® 
and concentrated in vacuo. The crude mixture was purified by 
silica gel chromatography (5% ethyl acetate in hexanes) to yield 303d as yellow oil (8.4 
mg, 70%).  
1
H NMR (500 MHz, CDCl3) δ 8.29-8.22 (m, 2H), 8.12-8.06 (m, 1H), 7.79-7.72 (m, 2H), 
7.40 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 7.33 (dd, J = 8.3, 1.5 Hz, 2H), 7.24-7.18 (m, 3H), 
7.17-7.12 (m, 3H), 7.05 (ddd, J = 7.8, 7.2, 1.1 Hz, 1H), 6.69 (d, J = 8.7 Hz, 2H), 4.09 (d, 
J = 14.2 Hz, 1H), 3.80 (d, J = 14.3 Hz, 1H), 3.72 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 
158.1, 155.8, 151.1, 143.6, 142.1, 141.8, 141.4, 132.7, 132.5, 130.0, 129.4, 129.2, 129.2, 
128.7, 127.9, 127.3, 126.2, 125.5, 122.3, 121.3, 118.2, 112.9, 86.0, 55.1, 46.1. IR υmax 
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(film): 3062, 6013, 2930, 2835, 1607, 1556, 1512, 1491, 1460, 1347, 1246, 1177, 1109, 
1064, 1035, 953, 828, 749 cm
-1
. HRMS (ESI+) m/z calculated for C29H23O2N2 431.1760, 
found 431.1773. 
Following General procedure X with substrate 301a (10 mg, 0.03 
mmol, 1.0 equiv), the reaction mixture was added 1,2-
phenylenediamine (7.5 mg, 0.07 mmol, 2.5 equiv) and stirred at room 
temperature for 2 h. The reaction mixture was filtered through Celite® 
and concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(5% ethyl acetate in hexanes) to yield 303a as a yellow oil (11.0 mg, 90%).  
1
H NMR (500 MHz, CDCl3) δ 8.30 (dd, J = 7.8, 1.7 Hz, 1H), 8.26 – 8.19 (m, 1H), 8.16 – 
8.08 (m, 1H), 7.80 – 7.72 (m, 2H), 7.42 (dddd, J = 8.1, 7.3, 1.7, 0.7 Hz, 1H), 7.39 – 7.35 
(m, 2H), 7.25 – 7.22 (m, 1H), 7.21 – 7.12 (m, 4H), 7.08 (ddt, J = 8.1, 7.2, 1.0 Hz, 1H), 
6.16 (dt, J = 2.6, 1.1 Hz, 1H), 6.01 (dt, J = 3.2, 0.8 Hz, 1H), 4.24 (d, J = 15.4 Hz, 1H), 
3.91 (d, J = 15.4 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 155.7, 151.2, 150.7, 143.4, 
142.2, 141.4, 141.4, 141.2, 132.8, 130.1, 129.4, 129.2, 129.2, 128.0, 127.6, 126.0, 125.5, 
122.5, 121.3, 118.4, 110.1, 108.7, 85.4, 39.8. IR υmax (film): 3061, 2933, 1814, 1727, 
1607, 1586, 1557, 1493, 1461, 1443, 1348, 1247, 1110, 753 cm
-1
. HRMS (ESI+) m/z 
calculated for C26H19O2N2 391.1447, found 391.1457. 
Following General procedure X with substrate 301b (10 mg, 0.03 
mmol, 1.0 equiv), the reaction mixture was added 1,2-
phenylenediamine (7.5 mg, 0.07 mmol, 2.5 equiv) and stirred at room 
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temperature for 2 h, before filtered through Celite® and concentrated in vacuo. The crude 
mixture was purified by silica gel chromatography (5% ethyl acetate in hexanes) to yield 
303b as a yellow solid (4.5 mg, 33%).  
m.p. = 150-152 °C (EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 7.7, 1.7 Hz, 1H), 
8.28 – 8.24 (m, 1H), 8.13 – 8.09 (m, 1H), 7.81 – 7.72 (m, 2H), 7.48 – 7.40 (m, 3H), 7.29 
(dd, J = 8.3, 0.7 Hz, 1H), 7.24 – 7.13 (m, 3H), 7.09 (ddd, J = 7.8, 7.2, 1.2 Hz, 1H), 7.05 
(dd, J = 5.1, 1.2 Hz, 1H), 6.93 (dd, J = 3.5, 1.1 Hz, 1H), 6.81 (dd, J = 5.1, 3.4 Hz, 1H), 
4.45 (d, J = 15.0 Hz, 1H), 3.99 (d, J = 15.0 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
155.6, 150.4, 143.5, 142.2, 141.6, 141.4, 138.3, 132.8, 130.1, 129.3, 129.2, 128.1, 128.1, 
127.6, 126.0, 126.0, 125.5, 124.8, 122.5, 121.1, 118.2, 85.5, 41.8. IR υmax (film): 3368, 
3065, 2918, 2849, 1606, 1589, 1556, 1492, 1461, 1446, 1394, 1347, 1232, 1109, 1050, 
764, 752 cm
-1
. HRMS (ESI+) m/z calculated for C26H19OSN2 407.1218, found 407.1210. 
III. X-ray Crystallographic Data 
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Crystals of benzofuranone 8 suitable for x-ray analysis were obtained by slow 
evaporation from hexanes/ethyl acetate. 
Crystallographic data have been deposited with the Cambridge Crystallographic Data 
Centre (CCDC 916800).  
Copies of the data can be obtained free of charge on application to the CCDC, 12 Union 
Road, Cambridge CB21EZ, UK (fax: 44-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk.) 
Crystal data 
C19H14O3 Z = 2 
Mr = 290.30 F(000) = 304 
Triclinic, P1 Dx = 1.358 Mg m
-3
 
Hall symbol: -P 1 Cu Kradiation = 1.54178 Å 
a = 8.7377 (5) Å Cell parameters from 9969 reflections 
b = 8.8960 (5) Å = 4.5–66.6° 
c = 10.4794 (6) Å  = 0.74 mm-1 
 = 71.552 (2)° T = 100 K 
 = 73.334 (2)° Fragment, colorless 
= 69.603 (2)° 0.21 × 0.18 × 0.11 mm 
V = 709.85 (7) Å
3
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Data collection 
Bruker Proteum-R  
diffractometer 
2491 independent reflections 
Radiation source: rotating anode 2397 reflections with I > 2(I) 
multilayer Rint = 0.036 
& scans max = 66.7°, min = 4.5° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1996) 
h = -108 
Tmin = 0.682, Tmax = 0.753 k = -108 
13833 measured reflections l = -1211 
 
Refinement 
Refinement on F
2
 
Primary atom site location: structure-
invariant direct methods 
Least-squares matrix: full 
Secondary atom site location: difference 
Fourier map 
R[F
2
 > 2(F2)] = 0.037 
Hydrogen site location: inferred from 
neighbouring sites 
wR(F
2
) = 0.093 H-atom parameters constrained 
S = 1.04 
w = 1/[2(Fo
2
) + (0.0399P)
2
 + 0.4001P]  
where P = (Fo
2
 + 2Fc
2
)/3 
2491 reflections (/)max < 0.001 
216 parameters max = 0.23 e Å
-3
 
24 restraints min = -0.24 e Å
-3
 
  
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal symmetry. 
An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. 
planes. 
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Refinement. Refinement of F
2
 against ALL reflections. The weighted R-factor wR and 
goodness of fit S are based on F
2
, conventional R-factors R are based on F, with F set to 
zero for negative F
2
. The threshold expression of F
2
 > 2sigma(F
2
) is used only for 
calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. 
R-factors based on F
2
 are statistically about twice as large as those based on F, and R- 
factors based on ALL data will be even larger. 
Discussion: The structure exhibits a slight disorder (0.93:0.07) through a twofold axis 
passing through C5 and the C3-C12 bond, which results in two positions for C4, O1 and 
O3. The disorder was successfully refined using SHELX PART instructions. The 
PLAT366 alerts indicate that CheckCIF was unable to discern the hybridization for C12, 
and the PLAT723 alerts further indicate that CheckCIF did not detect the disorder 
refinement, since the flagged torsions involve both parts of the disorder. The real bond 
lengths and torsion angle values in each disorder component all fall within expected 
ranges. 
    
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å
2
) 
 x y z Uiso*/Ueq Occ. (<1) 
O2 0.54106 (11) 0.18324 (12) 0.44184 (10) 0.0221 (2)  
C1 0.69042 (18) 0.05861 (19) -0.05363 (15) 0.0256 (3)  
H1 0.6524 0.0642 -0.1318 0.031*  
C2 0.65717 (16) 0.20117 (17) -0.01144 (14) 0.0208 (3)  
H2 0.5960 0.3050 -0.0588 0.025*  
C3 0.71677 (15) 0.18705 (16) 0.10347 (13) 0.0165 (3)  
C5 0.79714 (16) 0.21395 (15) 0.29355 (13) 0.0161 (3)  
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C6 0.95552 (16) 0.26282 (16) 0.27084 (13) 0.0172 (3)  
C7 0.96999 (17) 0.41833 (17) 0.19500 (15) 0.0218 (3)  
H7 0.8791 0.4984 0.1572 0.026*  
C8 1.11808 (18) 0.45650 (18) 0.17449 (16) 0.0253 (3)  
H8 1.1286 0.5622 0.1214 0.030*  
C9 1.24970 (17) 0.34162 (18) 0.23086 (16) 0.0259 (3)  
H9 1.3503 0.3686 0.2171 0.031*  
C10 0.77972 (18) -0.09414 (18) 0.01785 (15) 0.0258 (3)  
H10 0.8008 -0.1902 -0.0132 0.031*  
C11 0.83794 (17) -0.10913 (17) 0.13192 (14) 0.0221 (3)  
H11 0.8984 -0.2129 0.1798 0.026*  
C12 0.80390 (15) 0.03451 (16) 0.17327 (13) 0.0174 (3)  
C13 0.68153 (16) 0.23053 (16) 0.42716 (14) 0.0181 (3)  
C14 0.44103 (18) 0.21355 (19) 0.56290 (15) 0.0258 (3)  
H14 0.3359 0.1919 0.5996 0.031*  
C15 0.51116 (18) 0.27793 (18) 0.62288 (15) 0.0247 (3)  
H15 0.4652 0.3098 0.7075 0.030*  
C16 0.66938 (17) 0.28997 (16) 0.53526 (14) 0.0210 (3)  
C17 0.7882 (2) 0.35467 (19) 0.56697 (16) 0.0295 (3)  
H17A 0.8523 0.2674 0.6320 0.044*  
H17B 0.7255 0.4493 0.6075 0.044*  
H17C 0.8645 0.3895 0.4821 0.044*  
C18 1.08855 (17) 0.14719 (17) 0.32714 (14) 0.0212 (3)  
H18 1.0790 0.0408 0.3791 0.025*  
C19 1.23508 (17) 0.18671 (18) 0.30770 (16) 0.0253 (3)  
H19 1.3254 0.1078 0.3470 0.030*  
O1A 0.84809 (18) 0.03973 (15) 0.28665 (13) 0.0178 (2) 0.932 (3) 
O3A 0.62603 (12) 0.45594 (12) 0.15358 (10) 0.0193 (3) 0.932 (3) 
C4A 0.7004 (12) 0.3093 (4) 0.1748 (7) 0.0163 (5) 0.932 (3) 
O3B 0.904 (2) -0.0951 (16) 0.3719 (16) 0.033 (5) 0.068 (3) 
C4B 0.845 (3) 0.032 (2) 0.2949 (19) 0.0178 (2) 0.068 (3) 
O1B 0.711 (12) 0.299 (3) 0.174 (7) 0.0163 (5) 0.068 (3) 
 
Atomic displacement parameters (Å
2
) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
O2 0.0179 (5) 0.0287 (5) 0.0214 (5) -0.0105 (4) -0.0008 (4) -0.0068 (4) 
C1 0.0267 (7) 0.0350 (8) 0.0212 (7) -0.0131 (6) -0.0032 (6) -0.0114 (6) 
C2 0.0181 (7) 0.0251 (7) 0.0200 (7) -0.0063 (6) -0.0048 (5) -0.0052 (5) 
C3 0.0127 (6) 0.0196 (7) 0.0182 (6) -0.0059 (5) -0.0012 (5) -0.0060 (5) 
C5 0.0161 (6) 0.0138 (6) 0.0194 (7) -0.0031 (5) -0.0048 (5) -0.0054 (5) 
C6 0.0158 (6) 0.0209 (7) 0.0176 (6) -0.0050 (5) -0.0025 (5) -0.0092 (5) 
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C7 0.0175 (7) 0.0208 (7) 0.0276 (7) -0.0047 (5) -0.0038 (5) -0.0078 (6) 
C8 0.0226 (7) 0.0227 (7) 0.0334 (8) -0.0106 (6) -0.0004 (6) -0.0106 (6) 
C9 0.0177 (7) 0.0315 (8) 0.0360 (8) -0.0098 (6) -0.0011 (6) -0.0189 (7) 
C10 0.0289 (8) 0.0243 (7) 0.0269 (7) -0.0113 (6) 0.0033 (6) -0.0134 (6) 
C11 0.0208 (7) 0.0188 (7) 0.0240 (7) -0.0054 (5) 0.0011 (5) -0.0068 (5) 
C12 0.0136 (6) 0.0217 (7) 0.0170 (6) -0.0070 (5) -0.0002 (5) -0.0052 (5) 
C13 0.0162 (6) 0.0166 (6) 0.0213 (7) -0.0047 (5) -0.0045 (5) -0.0036 (5) 
C14 0.0195 (7) 0.0317 (8) 0.0212 (7) -0.0072 (6) 0.0028 (6) -0.0056 (6) 
C15 0.0243 (7) 0.0240 (7) 0.0207 (7) -0.0020 (6) -0.0012 (6) -0.0070 (6) 
C16 0.0241 (7) 0.0170 (6) 0.0211 (7) -0.0030 (5) -0.0054 (6) -0.0058 (5) 
C17 0.0353 (8) 0.0313 (8) 0.0294 (8) -0.0116 (7) -0.0067 (6) -0.0146 (6) 
C18 0.0210 (7) 0.0227 (7) 0.0225 (7) -0.0065 (6) -0.0060 (6) -0.0071 (6) 
C19 0.0183 (7) 0.0285 (8) 0.0324 (8) -0.0021 (6) -0.0088 (6) -0.0132 (6) 
O1A 0.0195 (5) 0.0157 (5) 0.0193 (5) -0.0033 (4) -0.0064 (4) -0.0054 (4) 
O3A 0.0171 (5) 0.0164 (6) 0.0250 (6) -0.0023 (4) -0.0071 (4) -0.0058 (4) 
C4A 
0.0124 
(16) 
0.0183 (8) 0.0184 (6) -0.0056 (8) -0.0026 (7) -0.0037 (7) 
O3B 0.046 (10) 0.016 (7) 0.037 (9) -0.009 (6) -0.017 (7) 0.000 (6) 
C4B 0.0195 (5) 0.0157 (5) 0.0193 (5) -0.0033 (4) -0.0064 (4) -0.0054 (4) 
O1B 
0.0124 
(16) 
0.0183 (8) 0.0184 (6) -0.0056 (8) -0.0026 (7) -0.0037 (7) 
 
Geometric parameters (Å, º) 
 O2—C14 1.3646 (17) C9—C19 1.388 (2) 
O2—C13 1.3848 (16) C9—H9 0.9500 
C1—C2 1.383 (2) C10—C11 1.381 (2) 
C1—C10 1.403 (2) C10—H10 0.9500 
C1—H1 0.9500 C11—C12 1.3859 (19) 
C2—C3 1.3983 (19) C11—H11 0.9500 
C2—H2 0.9500 C12—O1A 1.3688 (19) 
C3—C12 1.3882 (19) C12—C4B 1.413 (18) 
C3—O1B 1.397 (18) C13—C16 1.3584 (19) 
C3—C4A 1.451 (3) C14—C15 1.339 (2) 
C5—O1A 1.4755 (18) C14—H14 0.9500 
C5—C13 1.4893 (18) C15—C16 1.442 (2) 
C5—O1B 1.501 (18) C15—H15 0.9500 
C5—C4B 1.522 (17) C16—C17 1.502 (2) 
C5—C6 1.5251 (17) C17—H17A 0.9800 
C5—C4A 1.555 (3) C17—H17B 0.9800 
C6—C7 1.3892 (19) C17—H17C 0.9800 
C6—C18 1.3904 (19) C18—C19 1.387 (2) 
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C7—C8 1.3916 (19) C18—H18 0.9500 
C7—H7 0.9500 C19—H19 0.9500 
C8—C9 1.380 (2) O3A—C4A 1.218 (3) 
C8—H8 0.9500 O3B—C4B 1.203 (16) 
C14—O2—C13 106.18 (11) C1—C10—H10 119.0 
C2—C1—C10 120.66 (13) C10—C11—C12 116.81 (13) 
C2—C1—H1 119.7 C10—C11—H11 121.6 
C10—C1—H1 119.7 C12—C11—H11 121.6 
C1—C2—C3 117.61 (13) O1A—C12—C11 123.97 (13) 
C1—C2—H2 121.2 O1A—C12—C3 113.93 (12) 
C3—C2—H2 121.2 C11—C12—C3 122.08 (12) 
C12—C3—O1B 104.9 (8) O1A—C12—C4B 3.5 (8) 
C12—C3—C2 120.80 (12) C11—C12—C4B 121.6 (7) 
O1B—C3—C2 134.3 (8) C3—C12—C4B 116.1 (7) 
C12—C3—C4A 107.85 (14) C16—C13—O2 110.44 (12) 
O1B—C3—C4A 4 (3) C16—C13—C5 137.68 (12) 
C2—C3—C4A 131.31 (14) O2—C13—C5 111.67 (11) 
O1A—C5—C13 108.61 (11) C15—C14—O2 110.79 (12) 
O1A—C5—O1B 101.5 (8) C15—C14—H14 124.6 
C13—C5—O1B 112 (4) O2—C14—H14 124.6 
O1A—C5—C4B 3.2 (8) C14—C15—C16 107.27 (13) 
C13—C5—C4B 105.5 (8) C14—C15—H15 126.4 
O1B—C5—C4B 103.5 (10) C16—C15—H15 126.4 
O1A—C5—C6 107.40 (11) C13—C16—C15 105.32 (12) 
C13—C5—C6 114.52 (11) C13—C16—C17 130.68 (13) 
O1B—C5—C6 112 (4) C15—C16—C17 123.99 (13) 
C4B—C5—C6 108.7 (8) C16—C17—H17A 109.5 
O1A—C5—C4A 104.20 (13) C16—C17—H17B 109.5 
C13—C5—C4A 109.3 (4) H17A—C17—H17B 109.5 
O1B—C5—C4A 3 (3) C16—C17—H17C 109.5 
C4B—C5—C4A 106.1 (7) H17A—C17—H17C 109.5 
C6—C5—C4A 112.2 (4) H17B—C17—H17C 109.5 
C7—C6—C18 119.69 (12) C19—C18—C6 120.22 (13) 
C7—C6—C5 121.73 (12) C19—C18—H18 119.9 
C18—C6—C5 118.58 (12) C6—C18—H18 119.9 
C6—C7—C8 119.80 (13) C18—C19—C9 119.97 (13) 
C6—C7—H7 120.1 C18—C19—H19 120.0 
C8—C7—H7 120.1 C9—C19—H19 120.0 
C9—C8—C7 120.36 (13) C12—O1A—C5 108.10 (11) 
C9—C8—H8 119.8 O3A—C4A—C3 130.0 (2) 
C7—C8—H8 119.8 O3A—C4A—C5 124.36 (18) 
C8—C9—C19 119.95 (13) C3—C4A—C5 105.62 (16) 
C8—C9—H9 120.0 O3B—C4B—C12 122.2 (16) 
C19—C9—H9 120.0 O3B—C4B—C5 134.4 (16) 
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C11—C10—C1 122.04 (13) C12—C4B—C5 103.4 (9) 
C11—C10—H10 119.0 C3—O1B—C5 111.5 (13) 
C10—C1—C2—C3 0.5 (2) C7—C6—C18—C19 0.0 (2) 
C1—C2—C3—C12 -0.94 (19) C5—C6—C18—C19 179.47 (12) 
C1—C2—C3—O1B 179 (7) C6—C18—C19—C9 -0.5 (2) 
C1—C2—C3—C4A -178.4 (6) C8—C9—C19—C18 0.3 (2) 
O1A—C5—C6—C7 141.81 (12) C11—C12—O1A—C5 177.66 (12) 
C13—C5—C6—C7 -97.49 (15) C3—C12—O1A—C5 -3.92 (16) 
O1B—C5—C6—C7 31.4 (19) C4B—C12—O1A—C5 -134 (14) 
C4B—C5—C6—C7 144.9 (7) C13—C5—O1A—C12 121.83 (12) 
C4A—C5—C6—C7 27.9 (3) O1B—C5—O1A—C12 3 (4) 
O1A—C5—C6—C18 -37.67 (16) C4B—C5—O1A—C12 133 (14) 
C13—C5—C6—C18 83.03 (15) C6—C5—O1A—C12 -113.80 (12) 
O1B—C5—C6—C18 -148.1 (19) C4A—C5—O1A—C12 5.4 (5) 
C4B—C5—C6—C18 -34.6 (7) C12—C3—C4A—O3A -175.6 (10) 
C4A—C5—C6—C18 -151.6 (2) O1B—C3—C4A—O3A 151 (72) 
C18—C6—C7—C8 0.8 (2) C2—C3—C4A—O3A 2.0 (15) 
C5—C6—C7—C8 -178.68 (12) C12—C3—C4A—C5 2.9 (7) 
C6—C7—C8—C9 -1.0 (2) O1B—C3—C4A—C5 -30 (71) 
C7—C8—C9—C19 0.4 (2) C2—C3—C4A—C5 -179.4 (2) 
C2—C1—C10—C11 -0.1 (2) O1A—C5—C4A—O3A 173.7 (9) 
C1—C10—C11—C12 0.1 (2) C13—C5—C4A—O3A 57.7 (10) 
C10—C11—C12—O1A 177.77 (13) O1B—C5—C4A—O3A -151 (71) 
C10—C11—C12—C3 -0.53 (19) C4B—C5—C4A—O3A 171.0 (12) 
C10—C11—C12—C4B 174.7 (11) C6—C5—C4A—O3A -70.5 (10) 
O1B—C3—C12—O1A 2 (5) O1A—C5—C4A—C3 -5.0 (7) 
C2—C3—C12—O1A -177.47 (12) C13—C5—C4A—C3 -121.0 (5) 
C4A—C3—C12—O1A 0.5 (5) O1B—C5—C4A—C3 30 (70) 
O1B—C3—C12—C11 -179 (5) C4B—C5—C4A—C3 -7.7 (12) 
C2—C3—C12—C11 0.99 (19) C6—C5—C4A—C3 110.8 (5) 
C4A—C3—C12—C11 178.9 (5) O1A—C12—C4B—O3B -137 (15) 
O1B—C3—C12—C4B 6 (5) C11—C12—C4B—O3B -4 (2) 
C2—C3—C12—C4B -174.5 (10) C3—C12—C4B—O3B 171.7 (14) 
C4A—C3—C12—C4B 3.5 (11) O1A—C12—C4B—C5 43 (13) 
C14—O2—C13—C16 -0.48 (15) C11—C12—C4B—C5 176.2 (5) 
C14—O2—C13—C5 -176.27 (11) C3—C12—C4B—C5 -8.3 (16) 
O1A—C5—C13—C16 126.31 (17) O1A—C5—C4B—O3B 136 (16) 
O1B—C5—C13—C16 -122 (2) C13—C5—C4B—O3B -55 (2) 
C4B—C5—C13—C16 125.7 (8) O1B—C5—C4B—O3B -173 (5) 
C6—C5—C13—C16 6.3 (2) C6—C5—C4B—O3B 68 (2) 
C4A—C5—C13—C16 -120.6 (3) C4A—C5—C4B—O3B -171 (2) 
O1A—C5—C13—O2 -59.54 (14) O1A—C5—C4B—C12 -44 (13) 
O1B—C5—C13—O2 52 (2) C13—C5—C4B—C12 125.2 (10) 
C4B—C5—C13—O2 -60.2 (7) O1B—C5—C4B—C12 7 (5) 
202 
 
 
 
C6—C5—C13—O2 -179.57 (10) C6—C5—C4B—C12 -111.5 (11) 
C4A—C5—C13—O2 53.6 (3) C4A—C5—C4B—C12 9.3 (15) 
C13—O2—C14—C15 0.51 (16) C12—C3—O1B—C5 0 (8) 
O2—C14—C15—C16 -0.36 (16) C2—C3—O1B—C5 180 (2) 
O2—C13—C16—C15 0.26 (15) C4A—C3—O1B—C5 147 (78) 
C5—C13—C16—C15 174.46 (15) O1A—C5—O1B—C3 -2 (8) 
O2—C13—C16—C17 179.53 (13) C13—C5—O1B—C3 -118 (6) 
C5—C13—C16—C17 -6.3 (3) C4B—C5—O1B—C3 -5 (8) 
C14—C15—C16—C13 0.05 (16) C6—C5—O1B—C3 112 (6) 
C14—C15—C16—C17 -179.27 (13) C4A—C5—O1B—C3 -147 (77) 
 
    
Crystals of spirodihydrofuran 11 suitable for x-ray analysis were obtained by slow 
evaporation from hexanes/ethyl acetate. 
Crystallographic data have been deposited with the Cambridge Crystallographic Data 
Centre (CCDC 916801).  
Copies of the data can be obtained free of charge on application to the CCDC, 12 Union 
Road, Cambridge CB21EZ, UK (fax: 44-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk.) 
Crystal data 
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C20H18O4 F(000) = 680 
Mr = 322.34 Dx = 1.344 Mg m
-3
 
Monoclinic, P21/n Cu K radiation,  = 1.54178 Å 
Hall symbol: -P 2yn 
Cell parameters from 9405 
reflections 
a = 7.3625 (4) Å = 6.0–65.8° 
b = 14.6288 (9) Å  = 0.76 mm-1 
c = 15.1302 (9) Å T = 114 K 
 = 102.119 (4)° Prism, colorless 
V = 1593.27 (16) Å
3
 0.07 × 0.05 × 0.04 mm 
Z = 4  
 
Data collection 
Bruker Proteum-R diffractometer 2753 independent reflections 
Radiation source: rotating anode 
2522 reflections with I > 
2(I) 
multilayer Rint = 0.031 
& scans max = 66.3°, min = 4.3° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -88 
Tmin = 0.687, Tmax = 0.753 k = -1716 
15577 measured reflections l = -1517 
   
Refinement 
Refinement on F
2
 
Primary atom site location: structure-invariant direct 
methods 
Least-squares matrix: full Secondary atom site location: difference Fourier map 
R[F
2
 > 2(F2)] = 0.029 
Hydrogen site location: inferred from neighbouring 
sites 
wR(F
2
) = 0.075 H-atom parameters constrained 
S = 1.07 
w = 1/[2(Fo
2
) + (0.0309P)
2
 + 0.5422P]  
where P = (Fo
2
 + 2Fc
2
)/3 
2753 reflections (/)max = 0.001 
219 parameters max = 0.22 e Å
-3
 
0 restraints min = -0.19 e Å
-3
 
 
Special details 
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Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal symmetry. 
An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. 
planes. 
Refinement. Refinement of F
2
 against ALL reflections. The weighted R-factor wR and 
goodness of fit S are based on F
2
, conventional R-factors R are based on F, with F set to 
zero for negative F
2
. The threshold expression of F
2
 > 2 sigma(F
2
) is used only for 
calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. 
R-factors based on F
2
 are statistically about twice as large as those based on F, and R-
factors based on ALL data will be even larger. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å
2
) 
 x y z Uiso*/Ueq 
O1 0.02332 (11) 0.88436 (6) 0.35902 (6) 0.0285 (2) 
O2 -0.18881 (10) 0.74233 (5) 0.16877 (5) 0.02168 (19) 
C1 0.24733 (17) 0.55732 (9) 0.02344 (9) 0.0332 (3) 
H1 0.3111 0.5108 -0.0017 0.040* 
C2 0.24260 (16) 0.64558 (9) -0.00960 (9) 0.0305 (3) 
H2 0.3008 0.6593 -0.0584 0.037* 
C3 0.15311 (15) 0.71442 (9) 0.02824 (8) 0.0243 (3) 
H3 0.1504 0.7750 0.0053 0.029* 
C4 0.06763 (15) 0.69458 (8) 0.09967 (8) 0.0210 (2) 
C5 -0.02016 (15) 0.76862 (7) 0.14675 (8) 0.0197 (2) 
O6 -0.04977 (10) 0.84634 (5) 0.08689 (5) 0.02092 (18) 
C7 -0.12122 (15) 0.92303 (8) 0.11959 (8) 0.0212 (2) 
C8 -0.22090 (16) 0.98283 (8) 0.05617 (9) 0.0258 (3) 
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H8 -0.2383 0.9700 -0.0066 0.031* 
C9 -0.29461 (17) 1.06147 (8) 0.08584 (9) 0.0291 (3) 
H9 -0.3635 1.1024 0.0427 0.035* 
C10 -0.26982 (16) 1.08162 (8) 0.17730 (9) 0.0294 (3) 
H10 -0.3206 1.1359 0.1967 0.035* 
C11 0.15893 (17) 0.53681 (9) 0.09326 (9) 0.0310 (3) 
H11 0.1595 0.4759 0.1150 0.037* 
C12 0.06970 (16) 0.60494 (8) 0.13145 (8) 0.0259 (3) 
H12 0.0097 0.5906 0.1795 0.031* 
C13 0.10431 (15) 0.79688 (8) 0.23872 (8) 0.0200 (2) 
C14 0.30278 (15) 0.82352 (8) 0.23410 (8) 0.0218 (3) 
C15 0.41731 (16) 0.76717 (8) 0.28690 (8) 0.0268 (3) 
H15 0.5488 0.7700 0.2959 0.032* 
C16 0.31552 (16) 0.69890 (9) 0.33047 (9) 0.0299 (3) 
H16A 0.3424 0.6360 0.3126 0.036* 
H16B 0.3502 0.7040 0.3971 0.036* 
O17 0.12271 (11) 0.72110 (5) 0.29801 (5) 0.0241 (2) 
C18 0.35196 (16) 0.90229 (8) 0.18065 (9) 0.0265 (3) 
H18A 0.4874 0.9068 0.1894 0.040* 
H18B 0.3028 0.9589 0.2011 0.040* 
H18C 0.2980 0.8928 0.1164 0.040* 
C19 0.00851 (15) 0.87607 (8) 0.27798 (8) 0.0217 (3) 
C20 -0.09492 (15) 0.94154 (8) 0.21178 (8) 0.0222 (3) 
C21 -0.17034 (16) 1.02170 (8) 0.23963 (9) 0.0265 (3) 
H21 -0.1528 1.0350 0.3023 0.032* 
C22 -0.33464 (16) 0.71900 (9) 0.09318 (9) 0.0271 (3) 
H22A -0.3679 0.7729 0.0547 0.041* 
H22B -0.4436 0.6980 0.1151 0.041* 
H22C -0.2919 0.6702 0.0581 0.041* 
 
Atomic displacement parameters (Å
2
) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
O1 0.0265 (4) 0.0380 (5) 0.0230 (5) -0.0055 (4) 0.0095 (3) -0.0049 (4) 
O2 0.0153 (4) 0.0251 (4) 0.0244 (4) -0.0027 (3) 0.0036 (3) -0.0012 (3) 
C1 0.0222 (6) 0.0366 (7) 0.0367 (8) 0.0087 (5) -0.0031 (5) -0.0159 (6) 
C2 0.0197 (6) 0.0446 (8) 0.0263 (7) 0.0038 (5) 0.0024 (5) -0.0103 (6) 
C3 0.0178 (5) 0.0302 (6) 0.0236 (6) 0.0016 (5) 0.0011 (5) -0.0027 (5) 
C4 0.0146 (5) 0.0254 (6) 0.0210 (6) 0.0006 (4) -0.0007 (4) -0.0031 (5) 
C5 0.0173 (5) 0.0203 (6) 0.0219 (6) -0.0004 (4) 0.0048 (4) 0.0020 (4) 
O6 0.0224 (4) 0.0205 (4) 0.0206 (4) 0.0034 (3) 0.0062 (3) 0.0009 (3) 
C7 0.0171 (5) 0.0197 (6) 0.0286 (6) -0.0016 (4) 0.0088 (5) -0.0011 (5) 
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C8 0.0244 (6) 0.0253 (6) 0.0288 (7) 0.0012 (5) 0.0082 (5) 0.0029 (5) 
C9 0.0231 (6) 0.0233 (6) 0.0424 (8) 0.0018 (5) 0.0105 (5) 0.0058 (5) 
C10 0.0234 (6) 0.0213 (6) 0.0472 (8) -0.0018 (5) 0.0156 (6) -0.0045 (5) 
C11 0.0243 (6) 0.0255 (6) 0.0385 (8) 0.0042 (5) -0.0041 (5) -0.0051 (5) 
C12 0.0211 (6) 0.0263 (6) 0.0280 (7) 0.0010 (5) 0.0001 (5) -0.0013 (5) 
C13 0.0179 (5) 0.0226 (6) 0.0196 (6) -0.0023 (4) 0.0044 (4) 0.0021 (4) 
C14 0.0181 (5) 0.0254 (6) 0.0225 (6) -0.0038 (5) 0.0057 (5) -0.0048 (5) 
C15 0.0183 (6) 0.0318 (7) 0.0293 (7) -0.0016 (5) 0.0024 (5) -0.0027 (5) 
C16 0.0230 (6) 0.0336 (7) 0.0297 (7) 0.0003 (5) -0.0021 (5) 0.0053 (5) 
O17 0.0211 (4) 0.0267 (4) 0.0233 (4) -0.0030 (3) 0.0021 (3) 0.0058 (3) 
C18 0.0213 (6) 0.0294 (6) 0.0303 (7) -0.0052 (5) 0.0090 (5) -0.0010 (5) 
C19 0.0169 (5) 0.0264 (6) 0.0232 (7) -0.0074 (4) 0.0073 (5) -0.0038 (5) 
C20 0.0167 (5) 0.0233 (6) 0.0281 (6) -0.0046 (4) 0.0084 (5) -0.0027 (5) 
C21 0.0221 (6) 0.0263 (6) 0.0340 (7) -0.0051 (5) 0.0124 (5) -0.0080 (5) 
C22 0.0178 (6) 0.0296 (6) 0.0310 (7) -0.0016 (5) -0.0014 (5) -0.0029 (5) 
 
Geometric parameters (Å, º) 
O1—C19 1.2141 (14) C11—C12 1.3850 (18) 
O2—C5 1.4052 (13) C11—H11 0.9500 
O2—C22 1.4358 (14) C12—H12 0.9500 
C1—C2 1.382 (2) C13—O17 1.4145 (13) 
C1—C11 1.385 (2) C13—C14 1.5280 (15) 
C1—H1 0.9500 C13—C19 1.5390 (15) 
C2—C3 1.3908 (17) C14—C15 1.3213 (17) 
C2—H2 0.9500 C14—C18 1.4953 (16) 
C3—C4 1.3906 (17) C15—C16 1.4837 (17) 
C3—H3 0.9500 C15—H15 0.9500 
C4—C12 1.3956 (17) C16—O17 1.4384 (14) 
C4—C5 1.5138 (15) C16—H16A 0.9900 
C5—O6 1.4413 (13) C16—H16B 0.9900 
C5—C13 1.5529 (16) C18—H18A 0.9800 
O6—C7 1.3745 (13) C18—H18B 0.9800 
C7—C8 1.3889 (17) C18—H18C 0.9800 
C7—C20 1.3940 (17) C19—C20 1.4766 (17) 
C8—C9 1.3864 (17) C20—C21 1.3997 (16) 
C8—H8 0.9500 C21—H21 0.9500 
C9—C10 1.3889 (19) C22—H22A 0.9800 
C9—H9 0.9500 C22—H22B 0.9800 
C10—C21 1.3798 (19) C22—H22C 0.9800 
C10—H10 0.9500   
C5—O2—C22 115.24 (9) O17—C13—C19 109.62 (9) 
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C2—C1—C11 119.87 (11) C14—C13—C19 110.23 (9) 
C2—C1—H1 120.1 O17—C13—C5 108.64 (9) 
C11—C1—H1 120.1 C14—C13—C5 114.64 (9) 
C1—C2—C3 120.37 (12) C19—C13—C5 108.31 (9) 
C1—C2—H2 119.8 C15—C14—C18 127.69 (10) 
C3—C2—H2 119.8 C15—C14—C13 107.96 (10) 
C4—C3—C2 119.98 (12) C18—C14—C13 124.32 (10) 
C4—C3—H3 120.0 C14—C15—C16 111.76 (10) 
C2—C3—H3 120.0 C14—C15—H15 124.1 
C3—C4—C12 119.33 (11) C16—C15—H15 124.1 
C3—C4—C5 121.60 (10) O17—C16—C15 104.51 (9) 
C12—C4—C5 119.02 (10) O17—C16—H16A 110.8 
O2—C5—O6 109.89 (8) C15—C16—H16A 110.8 
O2—C5—C4 113.68 (9) O17—C16—H16B 110.8 
O6—C5—C4 106.98 (9) C15—C16—H16B 110.8 
O2—C5—C13 104.18 (9) H16A—C16—H16B 108.9 
O6—C5—C13 109.63 (9) C13—O17—C16 110.48 (8) 
C4—C5—C13 112.47 (9) C14—C18—H18A 109.5 
C7—O6—C5 115.89 (8) C14—C18—H18B 109.5 
O6—C7—C8 116.88 (10) H18A—C18—H18B 109.5 
O6—C7—C20 122.37 (10) C14—C18—H18C 109.5 
C8—C7—C20 120.74 (11) H18A—C18—H18C 109.5 
C9—C8—C7 119.01 (12) H18B—C18—H18C 109.5 
C9—C8—H8 120.5 O1—C19—C20 123.00 (11) 
C7—C8—H8 120.5 O1—C19—C13 120.91 (10) 
C8—C9—C10 121.35 (12) C20—C19—C13 116.06 (9) 
C8—C9—H9 119.3 C7—C20—C21 118.91 (11) 
C10—C9—H9 119.3 C7—C20—C19 119.76 (10) 
C21—C10—C9 119.08 (11) C21—C20—C19 121.32 (11) 
C21—C10—H10 120.5 C10—C21—C20 120.91 (12) 
C9—C10—H10 120.5 C10—C21—H21 119.5 
C12—C11—C1 120.15 (12) C20—C21—H21 119.5 
C12—C11—H11 119.9 O2—C22—H22A 109.5 
C1—C11—H11 119.9 O2—C22—H22B 109.5 
C11—C12—C4 120.29 (12) H22A—C22—H22B 109.5 
C11—C12—H12 119.9 O2—C22—H22C 109.5 
C4—C12—H12 119.9 H22A—C22—H22C 109.5 
O17—C13—C14 105.29 (9) H22B—C22—H22C 109.5 
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Crystals of compound 14 suitable for x-ray analysis were obtained by slow evaporation 
from hexanes. 
Crystallographic data have been deposited with the Cambridge Crystallographic Data 
Centre (CCDC 916802).  
Copies of the data can be obtained free of charge on application to the CCDC, 12 Union 
Road, Cambridge CB21EZ, UK (fax: 44-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk.) 
Crystal data 
C19H14O4 F(000) = 1280 
Mr = 306.30 Dx = 1.370 Mg m
-3
 
Orthorhombic, Pbca Cu Kradiation,  = 1.54178 Å 
Hall symbol: -P 2ac 2ab Cell parameters from 9046 reflections 
a = 11.8949 (7) Å  = 7.3–66.5° 
b = 8.9065 (5) Å = 0.79 mm-1 
c = 28.0405 (16) Å T = 100 K 
V = 2970.7 (3) Å
3
 Prism, colorless 
Z = 8 0.15 × 0.15 × 0.14 mm 
 
  
Data collection 
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Bruker Proteum-R  
diffractometer 
2607 independent reflections 
Radiation source: rotating anode 2580 reflections with I > 2(I) 
multilayer Rint = 0.036 
&  scans max = 66.6°, min = 3.2° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1996) 
h = -1414 
Tmin = 0.718, Tmax = 0.753 k = -1010 
88094 measured reflections l = -3033 
  
Refinement 
Refinement on F
2
 
Primary atom site location: structure-
invariant direct methods 
Least-squares matrix: full 
Secondary atom site location: difference 
Fourier map 
R[F
2
 > 2(F2)] = 0.038 
Hydrogen site location: inferred from 
neighbouring sites 
wR(F
2
) = 0.090 H-atom parameters constrained 
S = 1.11 
w = 1/[2(Fo
2
) + (0.0313P)
2
 + 1.8454P]  
where P = (Fo
2
 + 2Fc
2
)/3 
2607 reflections (/)max < 0.001 
209 parameters max = 0.28 e Å
-3
 
0 restraints min = -0.19 e Å
-3
 
  
Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal 
symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
Refinement. Refinement of F
2
 against ALL reflections. The weighted R-factor wR and 
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goodness of fit S are based on F
2
, conventional R-factors R are based on F, with F set to 
zero for negative F
2
. The threshold expression of F
2
 > 2 sigma(F
2
) is used only for 
calculating R-factors(gt) etc. and is not relevant to the choice of reflections for 
refinement. R-factors based on F
2
 are statistically about twice as large as those based on 
F, and R-factors based on ALL data will be even larger. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å
2
) 
 x y z Uiso*/Ueq  
O1 0.31869 (7) 0.54623 (11) 0.37816 (3) 0.0220 (2)  
O2 0.60995 (8) 0.53403 (11) 0.33969 (4) 0.0281 (3)  
O3 0.50984 (9) 0.74696 (11) 0.31969 (4) 0.0329 (3)  
O4 0.60782 (10) 0.77098 (13) 0.40784 (4) 0.0413 (3)  
C1 0.28572 (16) 0.5824 (2) 0.50608 (6) 0.0503 (5)  
H1 0.2315 0.5592 0.5298 0.060*  
C2 0.26602 (14) 0.5410 (2) 0.45907 (5) 0.0385 (4)  
H2 0.1994 0.4888 0.4505 0.046*  
C3 0.34587 (12) 0.57757 (17) 0.42476 (5) 0.0256 (3)  
C4 0.41006 (11) 0.51475 (15) 0.34574 (5) 0.0189 (3)  
C5 0.46734 (11) 0.36740 (15) 0.35628 (4) 0.0186 (3)  
C6 0.42513 (12) 0.22771 (16) 0.36807 (5) 0.0257 (3)  
H6 0.3468 0.2129 0.3726 0.031*  
C7 0.50055 (13) 0.10916 (16) 0.37320 (5) 0.0299 (3)  
H7 0.4735 0.0124 0.3817 0.036*  
C8 0.61453 (13) 0.13100 (16) 0.36606 (5) 0.0270 (3)  
H8 0.6643 0.0483 0.3694 0.032*  
C9 0.58164 (11) 0.38674 (15) 0.34996 (5) 0.0209 (3)  
C10 0.51099 (12) 0.62519 (15) 0.34997 (5) 0.0232 (3)  
C11 0.49782 (17) 0.70655 (19) 0.27013 (6) 0.0422 (4)  
H11A 0.5688 0.6609 0.2587 0.051*  
H11B 0.4840 0.7984 0.2511 0.051*  
C12 0.40467 (15) 0.59980 (17) 0.26239 (5) 0.0345 (4)  
H12 0.3756 0.5905 0.2310 0.041*  
C13 0.35890 (12) 0.51604 (16) 0.29632 (5) 0.0254 (3)  
C14 0.44464 (12) 0.65086 (16) 0.43699 (5) 0.0274 (3)  
C15 0.46290 (15) 0.6906 (2) 0.48496 (6) 0.0393 (4)  
H15 0.5302 0.7407 0.4938 0.047*  
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C16 0.38384 (17) 0.6573 (2) 0.51886 (6) 0.0503 (5)  
H16 0.3960 0.6853 0.5511 0.060*  
C17 0.52756 (12) 0.69014 (16) 0.40054 (5) 0.0266 (3)  
C18 0.25959 (14) 0.41639 (19) 0.28796 (6) 0.0363 (4)  
H18A 0.2378 0.4214 0.2543 0.054*  
H18B 0.1967 0.4498 0.3079 0.054*  
H18C 0.2792 0.3127 0.2962 0.054*  
C19 0.65786 (12) 0.27089 (16) 0.35416 (5) 0.0255 (3)  
H19 0.7360 0.2860 0.3492 0.031*  
 
Atomic displacement parameters (Å
2
) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
O1 0.0173 (5) 0.0299 (5) 0.0189 (5) 0.0046 (4) 0.0015 (4) -0.0017 (4) 
O2 0.0216 (5) 0.0192 (5) 0.0436 (6) -0.0016 (4) 0.0104 (4) -0.0028 (4) 
O3 0.0453 (6) 0.0195 (5) 0.0340 (6) -0.0008 (5) 0.0090 (5) 0.0044 (4) 
O4 0.0381 (6) 0.0333 (6) 0.0526 (7) -0.0089 (5) -0.0048 (5) -0.0103 (5) 
C1 0.0516 (11) 0.0746 (14) 0.0247 (8) 0.0227 (10) 0.0139 (8) 0.0056 (9) 
C2 0.0319 (8) 0.0552 (11) 0.0284 (8) 0.0099 (8) 0.0070 (7) 0.0042 (7) 
C3 0.0275 (7) 0.0299 (7) 0.0195 (7) 0.0113 (6) 0.0014 (6) -0.0007 (6) 
C4 0.0188 (6) 0.0189 (6) 0.0191 (6) 0.0018 (5) 0.0030 (5) -0.0002 (5) 
C5 0.0197 (6) 0.0190 (7) 0.0170 (6) 0.0008 (5) 0.0002 (5) -0.0007 (5) 
C6 0.0236 (7) 0.0225 (7) 0.0309 (8) -0.0026 (6) 0.0015 (6) 0.0023 (6) 
C7 0.0397 (9) 0.0181 (7) 0.0320 (8) 0.0008 (6) 0.0021 (7) 0.0041 (6) 
C8 0.0329 (8) 0.0245 (7) 0.0235 (7) 0.0111 (6) -0.0026 (6) -0.0019 (6) 
C9 0.0234 (7) 0.0187 (7) 0.0207 (6) -0.0010 (5) 0.0016 (5) -0.0030 (5) 
C10 0.0233 (7) 0.0164 (6) 0.0297 (7) 0.0015 (5) 0.0057 (6) 0.0007 (6) 
C11 0.0653 (12) 0.0324 (8) 0.0288 (8) 0.0031 (8) 0.0150 (8) 0.0102 (7) 
C12 0.0537 (10) 0.0294 (8) 0.0203 (7) 0.0115 (7) 0.0010 (7) 0.0026 (6) 
C13 0.0315 (8) 0.0237 (7) 0.0209 (7) 0.0105 (6) -0.0016 (6) -0.0023 (6) 
C14 0.0316 (8) 0.0254 (7) 0.0252 (7) 0.0101 (6) -0.0039 (6) -0.0058 (6) 
C15 0.0458 (10) 0.0425 (9) 0.0295 (8) 0.0141 (8) -0.0086 (7) -0.0120 (7) 
C16 0.0610 (12) 0.0676 (13) 0.0223 (8) 0.0245 (11) -0.0046 (8) -0.0099 (8) 
C17 0.0255 (7) 0.0191 (7) 0.0352 (8) 0.0038 (6) -0.0040 (6) -0.0036 (6) 
C18 0.0322 (8) 0.0439 (9) 0.0326 (8) 0.0047 (7) -0.0105 (7) -0.0087 (7) 
C19 0.0211 (7) 0.0289 (8) 0.0264 (7) 0.0054 (6) -0.0008 (6) -0.0063 (6) 
 
Geometric parameters (Å, º) 
O1—C3 1.3748 (17) C7—H7 0.9500 
O1—C4 1.4443 (15) C8—C19 1.389 (2) 
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O2—C9 1.3846 (16) C8—H8 0.9500 
O2—C10 1.4587 (16) C9—C19 1.3785 (19) 
O3—C10 1.3774 (17) C10—C17 1.544 (2) 
O3—C11 1.442 (2) C11—C12 1.476 (3) 
O4—C17 1.2132 (18) C11—H11A 0.9900 
C1—C2 1.389 (2) C11—H11B 0.9900 
C1—C16 1.391 (3) C12—C13 1.326 (2) 
C1—H1 0.9500 C12—H12 0.9500 
C2—C3 1.391 (2) C13—C18 1.496 (2) 
C2—H2 0.9500 C14—C15 1.408 (2) 
C3—C14 1.387 (2) C14—C17 1.463 (2) 
C4—C5 1.5080 (18) C15—C16 1.370 (3) 
C4—C13 1.5135 (18) C15—H15 0.9500 
C4—C10 1.5566 (19) C16—H16 0.9500 
C5—C6 1.3817 (19) C18—H18A 0.9800 
C5—C9 1.3819 (19) C18—H18B 0.9800 
C6—C7 1.393 (2) C18—H18C 0.9800 
C6—H6 0.9500 C19—H19 0.9500 
C7—C8 1.384 (2)   
C3—O1—C4 117.43 (10) O3—C10—C4 116.29 (12) 
C9—O2—C10 106.86 (10) O2—C10—C4 104.81 (10) 
C10—O3—C11 113.48 (11) C17—C10—C4 113.90 (11) 
C2—C1—C16 120.88 (17) O3—C11—C12 112.13 (13) 
C2—C1—H1 119.6 O3—C11—H11A 109.2 
C16—C1—H1 119.6 C12—C11—H11A 109.2 
C1—C2—C3 118.64 (17) O3—C11—H11B 109.2 
C1—C2—H2 120.7 C12—C11—H11B 109.2 
C3—C2—H2 120.7 H11A—C11—H11B 107.9 
O1—C3—C14 121.99 (13) C13—C12—C11 124.41 (14) 
O1—C3—C2 116.71 (14) C13—C12—H12 117.8 
C14—C3—C2 121.18 (14) C11—C12—H12 117.8 
O1—C4—C5 112.68 (10) C12—C13—C18 123.06 (14) 
O1—C4—C13 105.80 (10) C12—C13—C4 119.74 (14) 
C5—C4—C13 111.57 (11) C18—C13—C4 117.16 (12) 
O1—C4—C10 114.19 (10) C3—C14—C15 119.03 (15) 
C5—C4—C10 100.75 (10) C3—C14—C17 120.72 (13) 
C13—C4—C10 112.03 (11) C15—C14—C17 120.23 (15) 
C6—C5—C9 120.02 (13) C16—C15—C14 120.17 (17) 
C6—C5—C4 131.79 (12) C16—C15—H15 119.9 
C9—C5—C4 108.12 (11) C14—C15—H15 119.9 
C5—C6—C7 118.25 (13) C15—C16—C1 120.08 (16) 
C5—C6—H6 120.9 C15—C16—H16 120.0 
C7—C6—H6 120.9 C1—C16—H16 120.0 
C8—C7—C6 120.61 (14) O4—C17—C14 123.68 (14) 
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C8—C7—H7 119.7 O4—C17—C10 118.54 (13) 
C6—C7—H7 119.7 C14—C17—C10 117.78 (12) 
C7—C8—C19 121.62 (13) C13—C18—H18A 109.5 
C7—C8—H8 119.2 C13—C18—H18B 109.5 
C19—C8—H8 119.2 H18A—C18—H18B 109.5 
C19—C9—C5 122.87 (13) C13—C18—H18C 109.5 
C19—C9—O2 124.54 (12) H18A—C18—H18C 109.5 
C5—C9—O2 112.58 (12) H18B—C18—H18C 109.5 
O3—C10—O2 108.93 (11) C9—C19—C8 116.61 (13) 
O3—C10—C17 105.81 (11) C9—C19—H19 121.7 
O2—C10—C17 106.67 (11) C8—C19—H19 121.7 
C16—C1—C2—C3 -0.8 (3) C13—C4—C10—O2 -93.32 (12) 
C4—O1—C3—C14 32.56 (18) O1—C4—C10—C17 30.22 (15) 
C4—O1—C3—C2 -151.51 (13) C5—C4—C10—C17 -90.82 (12) 
C1—C2—C3—O1 -174.53 (15) C13—C4—C10—C17 150.46 (11) 
C1—C2—C3—C14 1.4 (2) C10—O3—C11—C12 48.84 (18) 
C3—O1—C4—C5 69.01 (14) O3—C11—C12—C13 -18.9 (2) 
C3—O1—C4—C13 -168.83 (11) C11—C12—C13—C18 175.84 (15) 
C3—O1—C4—C10 -45.16 (15) C11—C12—C13—C4 -6.3 (2) 
O1—C4—C5—C6 42.63 (19) O1—C4—C13—C12 128.17 (14) 
C13—C4—C5—C6 -76.22 (18) C5—C4—C13—C12 -108.96 (15) 
C10—C4—C5—C6 164.73 (14) C10—C4—C13—C12 3.15 (18) 
O1—C4—C5—C9 -140.53 (11) O1—C4—C13—C18 -53.88 (15) 
C13—C4—C5—C9 100.62 (13) C5—C4—C13—C18 68.99 (15) 
C10—C4—C5—C9 -18.43 (13) C10—C4—C13—C18 -178.90 (12) 
C9—C5—C6—C7 -0.1 (2) O1—C3—C14—C15 174.74 (13) 
C4—C5—C6—C7 176.44 (13) C2—C3—C14—C15 -1.0 (2) 
C5—C6—C7—C8 -0.8 (2) O1—C3—C14—C17 -3.6 (2) 
C6—C7—C8—C19 0.7 (2) C2—C3—C14—C17 -179.39 (14) 
C6—C5—C9—C19 1.0 (2) C3—C14—C15—C16 -0.1 (2) 
C4—C5—C9—C19 -176.24 (12) C17—C14—C15—C16 178.28 (15) 
C6—C5—C9—O2 -178.21 (12) C14—C15—C16—C1 0.8 (3) 
C4—C5—C9—O2 4.51 (15) C2—C1—C16—C15 -0.3 (3) 
C10—O2—C9—C19 -166.31 (13) C3—C14—C17—O4 169.89 (14) 
C10—O2—C9—C5 12.92 (15) C15—C14—C17—O4 -8.5 (2) 
C11—O3—C10—O2 64.14 (16) C3—C14—C17—C10 -9.8 (2) 
C11—O3—C10—C17 178.50 (13) C15—C14—C17—C10 171.85 (13) 
C11—O3—C10—C4 -53.95 (16) O3—C10—C17—O4 -54.94 (17) 
C9—O2—C10—O3 -149.20 (11) O2—C10—C17—O4 60.97 (16) 
C9—O2—C10—C17 97.01 (12) C4—C10—C17—O4 176.09 (12) 
C9—O2—C10—C4 -24.10 (13) O3—C10—C17—C14 124.76 (13) 
O1—C4—C10—O3 -93.24 (14) O2—C10—C17—C14 -119.34 (13) 
C5—C4—C10—O3 145.73 (11) C4—C10—C17—C14 -4.21 (17) 
C13—C4—C10—O3 27.01 (16) C5—C9—C19—C8 -1.1 (2) 
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O1—C4—C10—O2 146.43 (10) O2—C9—C19—C8 178.10 (12) 
C5—C4—C10—O2 25.40 (12) C7—C8—C19—C9 0.2 (2) 
 
 
4.6. Select NMR spectra. 
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